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A B S T R A C T
Background
Chinese herbal medicine (CHM) has been increasingly used for atopic eczema. A previous version of this Cochrane review published
in 2004 found some evidence of a possible benefit for oral ingestion of CHM for eczema, but the results were inconclusive and the
evidence needs to be updated. We have expanded the scope of this review to include an assessment of the topical and oral effects of
CHM for eczema.
Objectives
To assess the effects of oral ingestion and topical applications of CHM for the management of eczema in children and adults.
Search methods
We searched the following databases up to September 2012: the Cochrane Skin Group Specialised Register, CENTRAL inThe Cochrane
Library (2012, Issue 8), MEDLINE (from 1946), EMBASE (from 1974), AMED (from 1985), LILACS (from 1982), and CINAHL
(from 1981). We searched the following from inception: SCOPUS, HERBMED, ProQuest, CQVIP, CNKI, and Wanfang Data. We
also searched trials registers, handsearched conference proceedings, checked the reference lists of all included and excluded studies and
review articles for further references to relevant trials, and contacted experts in Chinese medicine for unpublished studies.
Selection criteria
All randomised controlled trials (RCTs) in children and adults with eczema comparing CHM to placebo; no intervention; active
controls, including acupuncture; or conventional medicines.
Data collection and analysis
Two authors selected the RCTs, extracted data, and assessed quality independently. We contacted study authors for missing data. We
collected adverse events from the included studies.
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Main results
We included 28 studies, with a total of 2306 participants. We assessed most of the studies at high ’risk of bias’, particularly in blinding
of participants and personnel, and there was substantial inconsistency between studies, so any positive effect of CHM must be treated
with caution. We did not include the four studies from the previous version in this review, because they investigated a CHM product
that has been withdrawn from the market since 2004.
Four studies (three oral and one topical) compared CHM to placebo. Pooled data from 2 studies showed the total effectiveness rate in
the CHM group was higher (by risk ratio (RR) 2.09, 95% confidence interval (CI) 1.32 to 3.32; 2 studies; n = 85), and the itching
visual analogue score (VAS) in the CHM group was 1.53 lower (by standardised mean difference (SMD), 95% CI 2.64 to 0.41; 2
Studies; n = 94) than the placebo group, where a lower VAS score indicates reduced itch. One study of 85 participants with moderate
to severe eczema who received an oral CHM formula for 12 weeks reported a quality of life (QoL) score 2.5 lower in the CHM group
(by difference in means (MD), 95% CI 4.77 to 0.23; 1 study; n = 85) than the placebo group, where a lower score indicates better
QoL.
Twenty-two studies and 1 arm from a study with a 4-arm parallel controlled design compared CHM (5 oral, 6 topical, and 12 mixed
oral and topical) to conventional medicines. The total effectiveness rate in the CHM groups was superior (RR 1.43, 95% CI 1.27 to
1.61; 21 studies; n = 1868; very low quality evidence), and the itching VAS in the CHM groups was 0.83 lower (SMD, 95% CI 1.43
to 0.22; 7 studies; n = 465) than the comparators.
Two studies compared combined oral and topical CHM to the same oral CHM formula alone. The total effectiveness rate in 1 study
was not statistically significant (RR 1.13, 95% CI 0.78 to 1.63; 1 study; n = 20). In the other study, the itching VAS in the CHM
group was 1.05 lower (MD, 95% CI 1.75 to 0.35; 1 study; n = 23) than the control group.
With regard to side-effects, four studies did not give any report of adverse events. The other 24 studies reported minor adverse events,
which were reversed soon after stopping CHM. One participant withdrew from one trial because of exacerbation of their condition
after using the CHM intervention.
Eight studies received government funding.
Authors’ conclusions
We could not find conclusive evidence that CHM taken by mouth or applied topically to the skin could reduce the severity of eczema
in children or adults.
Well-designed, adequately powered RCTs are needed to evaluate the efficacy and safety of CHM for managing eczema.
P L A I N L A N G U A G E S U M M A R Y
Chinese herbal medicine taken by mouth or applied to the skin for atopic eczema in children and adults
Atopic eczema (eczema in short) is a common skin condition, where skin changes occur and cause redness, scaling, swelling, and skin
thickening due to chronic scratching. It is associated with loss of sleep, self-esteem, and quality of life. The frequency of eczema has
increased over the past 10 years.
A former Cochrane review published in 2004 found some evidence of a possible benefit of using oral Chinese herbal medicine (CHM)
for eczema; however, the results from only 4 included studies were inconclusive and need to be updated (those four studies have not
been included in this update as they investigated a product that has been withdrawn from the market since 2004). As well as updating
that review, we have also widened the scope of the review to assess the effects of topical CHM for eczema. We wrote a new protocol to
expand the scope of this review.
This review included 28 randomised controlled trials (RCTs), with 2306 children and adults, of which 4 compared CHM to placebo,
22 to conventional medications, and 2 to CHM taken by mouth.
Most of the included studies reported a higher number of participants who had recovered and significantly improved, with less itching
in the CHM groups than the control groups. Where CHM was compared to conventional drugs, although the total effectiveness rate
outcome was superior with CHM, it was based on very low quality evidence. One study reported that the quality of life (QoL) score
in the CHM group was better than in the placebo group after using a CHM formula taken by mouth for 12 weeks. We assessed most
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of the studies as at high ’risk of bias’ and therefore not of good quality, and there was substantial inconsistency between the studies, so
any positive effect in CHM must be treated with caution.
One study reported one severe adverse event. Minor adverse events were observed in 24 studies, including temporary elevation of
enzymes in 3 cases, which was reversed soon after stopping CHM.
Eight included studies received government funding.
We could not find conclusive evidence that CHM taken by mouth or applied to the skin was of benefit to children or adults with
eczema.
Well-designed, adequately powered RCTs are needed to evaluate the efficacy and safety of CHM for eczema.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
CHM compared to placebo for atopic eczema
Patient or population: Participants with atopic eczema
Settings: Hospital outpatients
Intervention: CHM
Comparison: Placebo
Outcomes Illustrative comparative risk* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo CHM
Total effectiveness rate
(Analysis 1.1)
Clinician’s rating
Follow up: 2 to 4 weeks
Low¹ RR 2.09
(1.32 to 3.32)
85
(2 studies)
⊕⊕©©
low²,³
2 additional studies did
not report this outcome.
A higher total effective-
ness rate indicates im-
provement of the condi-
tion
1 per 100 2 per 100
(1 to 3)
High¹
40 per 100 84 per 100
(53 to 100)
Itching VAS (Analysis
1.2)
Participant’s rating. Scale
from 1 to 10
Follow up: 4 to 12 weeks
The mean itching VAS
ranged across control
groups from
0.2 to 7.8 scores
The mean itching in VAS
in the intervention groups
was 1.53 standard devi-
ations lower (2.64 to 0.
41 lower)
94
(2 studies)
⊕⊕©©
low³,
Lower score indicates im-
provement of the condi-
tion. 2 additional studies
did not report this out-
come
Overall severity score (
Analysis 1.3)
Clinician’s rating. Scale
from 1 to 80
Follow up: 2 to 16 weeks
The mean overall severity
score ranged across con-
trol groups from
5.7 to 46.9 scores
The mean overall severity
score in the intervention
groups was 0.88 stan-
dard deviations lower (1.
67 to 0.09 lower)
239
(4 studies)
⊕©©©
very low²,³,
Lower score indicates im-
provement of the condi-
tion
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QoL (Analysis 1.5)
Participant’s rating. Scale
from 0 to 30
Follow up: 4 to 16 weeks
The mean QoL in the con-
trol groups was
10.1 scores
The mean QoL in the in-
tervention groups was 2.
5 lower (4.77 to 0.23
lower)
85
(1 study)
⊕⊕⊕©
moderate³
Lower score indicates
better quality of life. 3 ad-
ditional studies did not re-
port this outcome
Adverse events (Analysis
1.7)
Participant’s report
Follow up: 2 to 12 weeks
Low¹ RR 0.71
(0.06 to 8.67)
129
(2 studies)
⊕⊕©©
low²,³
1 additional study re-
ported numbers of ad-
verse events that were
greater than the total
participants. Data were
treated as adverse event
’count data’ rather than
participant level data,
which could not be pooled
with these 2 studies
1 per 100 1 per 100
(0 to 9)
High¹
6 per 100 4 per 100
(0 to 52)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate
¹The low and high assumed risk values are the two extreme numbers of the events taken from the control groups in the included studies.
²Unclear risk of bias in allocation concealment and high risk of bias in blinding of participants and personnel.
³Total number of events was less than 300.
Unexplained heterogeneity.
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B A C K G R O U N D
Description of the condition
Atopic eczema is a common skin condition, which affects around
one in five children in developed countries. In 2009, the Inter-
national Study of Asthma and Allergies in Childhood (ISAAC)
published data on symptoms of eczema (Odhiambo 2009). In this
study, the authors found in 6 to 7 year-old children from 143 cen-
tres in 60 countries, disease prevalence ranged from 0.9% in India
to 22.5% in Ecuador. Amongst 13 to 14 year-olds from 230 cen-
tres in 96 countries, disease prevalence was found to range from
0.2% in China to 24.6% in Colombia. Industrialised countries
have previously been reported to have higher disease prevalence
(Kerdel 2003; Schultz-Larsen 2002), although data from this most
recent ISAAC study (Odhiambo 2009) suggest that eczema is a
disease in developing countries as well, especially in Latin America
and some countries in Africa. The prevalence of atopic eczema
has increased over the last 10 years in both developed and devel-
oping countries, especially in those aged 6 to 7 years (Williams
2008), for reasons that are unclear. The causes of atopic eczema
are still not fully understood, but probably involve an interaction
between genetic factors that determine the integrity of the skin
barrier and immune responses, and environmental factors, such as
early-life gut bacteria; humidity; irritation from soaps; microbes,
such as Staphylococcus aureus; and allergens, such as house dust
mites. Most children with atopic eczema improve with time, but
around 40% persist with the condition into adulthood (Williams
2000).
There was no such terminology as ’atopic eczema’ in the classi-
cal literature of ancient Chinese medicine. The definition of ’Si
Wan Feng’ (wind of the four fossae) in Chinese medicine how-
ever correlates to atopic eczema in conventional medicine based
on the comparison of Chinese medical literature records and the
descriptions of clinical features in conventional medicine. ’Si Wan
Feng’ in Chinese medicine was officially defined as atopic eczema
in the Criteria of Diagnosis and Therapeutic Effect of Disease and
Syndromes in Traditional Chinese Medicine published by the State
Administration of Traditional ChineseMedicine, China (SATCM
1994). Although the term ’atopic’ eczema is frequently used, not
all people with typical atopic eczema are truly atopic; that is, they
do not demonstrate specific immunoglobulin E (IgE) antibod-
ies to common environmental allergens, such as house dust mite,
pollens, grass, and foods (Flohr 2008). In accordance with the
World Allergy Organisation recommendations on nomenclature
(Johansson 2004), we used the term ’eczema’ throughout this re-
view.
Eczema is characterised by poorly demarcated redness of the skin
and associated surface changes, such as scaling, swelling (oedema),
accentuation of the hair follicles, and skin thickening (lichenifi-
cation) as a result of chronic scratching. Eczema is an itchy skin
condition, which can result in sleep loss for the child and family
members. The stigma of a visible skin disease can affect a person’s
self-esteem, and severe disease is associated with a poor quality of
life (QoL) (Schmid-Ott 2003).
Description of the intervention
Current treatment for eczema has limitations. Topical administra-
tion of corticosteroids, as one of the standard first-line therapies
for the management of inflammatory episodes of eczema, can be
associated with certain adverse events, such as skin thinning, if
used for too long or in a too-strong concentration for sensitive
sites, such as the face where the skin is naturally thinner. Long-
term application of steroids has been a great concern to those us-
ing them and to healthcare professionals (Hanifin 2004). A study
showed up to 72.5% of people who were using steroids (or their
guardians) were concerned about the application of corticosteroids
for the treatment of eczema (Charman 2000). New drugs for the
treatment of eczema, such as tacrolimus and pimecrolimus (these
two drugs are categorised as topical immunomodulators (TIMs) or
calcineurin inhibitors), have been developed as second-line thera-
pies. However, issues regarding the long-term safety of these new
drugs, particularly the potential link between TIMs and cancer,
have been raised (CDER 2005). Therefore, many eczema suffer-
ers have chosen to use complementary and alternative medicine,
including Chinese herbal medicine (CHM), for the management
of eczema (Hon 2005).
How the intervention might work
In Chinese medicine, those with eczema are recognised as hav-
ing a specific constitution that leads to internal dampness-heat
accumulated because of the reduced function of the spleen. Ex-
posure to wind, dampness, and heat pathogens can trigger symp-
toms (Zhao 1983). Clinically, eczema is classified into the follow-
ing patterns from a Chinese medicine viewpoint: accumulation
of internal dampness, excess of dampness with spleen deficiency,
or Yin deficiency with dryness of blood (Chen 1991). Chinese
herbal medicine is one of the important components in Chinese
medicine for prevention and treatment of diseases. Botanical re-
sources, such as barks, seeds, flowers, roots, or animal or mineral
substances, are prescribed and administered in the form of decoc-
tions (liquids from extraction of herbs by boiling), pills, washing
lotions, or ointments for conditions diagnosed by practitioners
qualified to practice Chinese medicine or Oriental medicine. Chi-
nese herbalmedicines may be neither Chinese nor herbal; the term
CHM in this review is used loosely to refer to any medicinal sub-
stances used within the paradigm of Chinese medicine practice.
Chinese herbal medicines have been employed for the treatment
of eczema for many years. They may be administered orally or
topically or by a combination of oral ingestion and topical applica-
tion (Chen 2001). Oral ingestion of CHM is under the guidance
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of the Chinese medicine pattern differentiation method, known
as ’individualised treatment’, whilst topical administrations have
been devised with little or no consideration of pattern differenti-
ation (Guo 2007; Zhou 2008).
Why it is important to do this review
The Cochrane systematic review on oral ingestion of CHM for
eczemawas published in 2004 (Zhang 2004). It is timely to update
this review to take into account new evidence that has emerged
in relation to oral ingestion of herbal interventions. Furthermore,
there has been no systematic evaluation of the effectiveness and
safety of the topical application of CHM for eczema.
We decided it would be best to review both oral ingestion and
topical CHM since people with eczema are likely to be interested
in both types of treatment. We therefore wrote a new protocol to
plan for the expanded scope of this review.
O B J E C T I V E S
To assess the effects of oral ingestion and topical applications of
CHM for the management of eczema in children and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled clinical trials (RCTs) with or without
blinding, regardless of language.
Types of participants
We included adults or children (from1month to 16 years old)with
eczema. We accepted diagnostic criteria, such as the Hanifin and
Rajka definition (Hanifin 1980) or the UK refinement (Williams
1994), when using the terms ’atopic eczema’ or ’atopic dermatitis’.
In the absence of explicit diagnostic criteria, we excluded adults
diagnosedwith ’eczema’ or ’chronic eczema’, but accepted children
diagnosed with ’eczema’ by physicians or dermatologists.
Types of interventions
Oral ingestion and topical applications of a single Chinese medic-
inal herb or formula, manufactured or clinician self-designed Chi-
nese medicinal formulae (a clinician self-designed formula is usu-
ally composed of different types of Chinese herbs prescribed by
a Chinese medicine practitioner who determines the selection of
herbs based on a person’s condition), compared to the following
control interventions: placebo, no intervention, and active con-
trols, including acupuncture or conventional medicines.
We also included trials with a combination of oral ingestion and
topical interventions.
We excluded interventions based on individualised treatment un-
less there were appropriate control interventions.
Types of outcome measures
Primary outcomes
1. Percentage of trial participants with at least good or
excellent improvement in terms of investigator global score. We
included both short-term (within six weeks) and long-term
(more than six weeks) improvement.
2. Percentage of trial participants with at least good or
excellent improvement in terms of participants’ or parents’ global
score. We included both short-term (within six weeks) and long-
term (more than six weeks) improvement.
Secondary outcomes
1. Changes in participant- or parent-rated global improvement
in EASI (Eczema Area and Severity Index), SCORAD (Severity
Scoring of Atopic Dermatitis), POEM (Patient-oriented Eczema
Measure), or SASSAD (Six Area, Six Sign Atopic Dermatitis)
(Schmitt 2007) as stated in each of the trials in both the short-
term (within six weeks) and the long-term (more than six weeks).
2. Changes in participant- or parent-rated global
improvement in quality of life, such as CDLQI (Children’s
Dermatology Life Quality Index) or DLQI (Dermatology Life
Quality Index) in both the short-term (within six weeks) and the
long-term (more than six weeks).
3. Adverse events.
Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
We searched the following databases up to 11 September 2012:
• the Cochrane Skin Group Specialised Register using the
following terms: ((Chinese and (herb* or medicin* or traditional
or plant*)) or “traditional medicin*” or “traditional therap*” or
((orient* or herbal) and (medicin* or therap*)) or phytotherapy
or phytopharmaceutic* or (plant and (medicin* or extract*)))
AND (dermatitis OR (besnier* AND prurigo) OR eczema);
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• the Cochrane Central Register of Controlled Trials
(CENTRAL), issue 8, 2012, in The Cochrane Library using the
search strategy in Appendix 1;
• MEDLINE via OVID (from 1946) using the strategy in
Appendix 2;
• EMBASE via OVID (from 1974) using the strategy in
Appendix 3;
• AMED via OVID (Allied and Complementary Medicine,
from 1985) using the strategy in Appendix 4;
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 5; and
• CINAHL via EBSCO (Cumulative Index to Nursing and
Allied Health Literature, from 1981) using the search strategy in
Appendix 6.
A final prepublication search for this review was undertaken on
6 June 2013. Although it has not been possible to incorporate
RCTs identified through this search within this review, we listed
relevant references under Studies awaiting classification. We will
incorporate them into the next update of the review.
We searched the following databases up to 13 September 2012:
• Scopus (from 1996) using the terms (eczema or dermatitis)
AND (Chinese) AND (random$);
• HerbMed® (from 1998) using the terms (eczema or
dermatitis) AND (Chinese) AND (random$); and
• ProQuest (from 1938) using the terms (atopic eczema or
atopic dermatitis) AND (Chinese medicine) AND (random$).
We also searched the following databases in the Chinese language
up to 13 September 2012:
• CQVIP (Chongqing VIP Information Co., Ltd,) Chinese
Scientific Journals Fulltext Database (from 1989) using the
strategy in Appendix 7 in Chinese;
• CNKI (China National Knowledge Infrastructure) (from
1979) using the strategy in Appendix 8 in Chinese;
• Wanfang Data (from 1982) using the strategy in Appendix
9 in Chinese;
• Chinese Scientific Journal Net (from 1994) (the database
has been merged into CQVIP); and
• China Proceedings of Conference Database (from 1994)
(the database has been merged into CQVIP).
Trials Registers
We searched for reports of trials in the following trials databases
up to 13 September 2012:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).
• The Ongoing Skin Trials Register (www.nottingham.ac.uk/
ongoingskintrials).
Searching other resources
Handsearching
We handsearched the conference proceedings - relevant to eczema
- of the First World Congress of Chinese Medicine from 2003
onwards. We also handsearched conference proceedings of the
Conference of Skin Diseases: Integrating Chinese and Western
Medicine 2007, and the 1st International Dermatology Academic
Symposium of TCM and Integrated TCM-WM (traditional Chi-
nese medicine and Western medicine) 2009.
Reference lists
We checked the reference lists of all identified RCTs and review
articles for further references to relevant trials.
Adverse effects
We did not perform a separate search for adverse effects of the
target interventions.However, we examined data on adverse effects
from the included studies we identified.
Correspondence
On 13 December 2011, 18 September 2012, and 17 June 2013,
we contacted the clinicians, dermatologists, and experts in tradi-
tional Chinese medicine listed in Appendix 10 and requested in-
formation on any unpublished RCTs on our topic.
Data collection and analysis
If the data on the number of participants with each outcome mea-
sure were not available in the published paper, we contacted the
study author for further information. We also contacted all study
authors of included trials for their raw data where they had not
reported the outcomes in such a way that meta-analysis was pos-
sible.
Selection of studies
Two authors (SG and AWY) selected the trials or studies inde-
pendently according to the inclusion criteria. We screened papers
through reading the titles and abstracts and retrieved full texts of
the potential included studies for further assessment. We resolved
discrepancies of the assessments by discussion between SG and
AWY. The other two team members, HCW and WZ, provided
arbitrating advice when we could not achieve a consensus.
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Data extraction and management
Two authors (SG and AWY) independently extracted the data
from the included studies onto a data extraction form developed
by the Cochrane Skin Group, which we modified to suit this re-
view. We extracted characteristics of participants, interventions,
and outcome measures. Data from each selected study consisted
of the number of events (n) and participants (N) for dichotomous
data; and number of participants (N), and mean and standard de-
viations (SD) for continuous data.
We resolved discrepancies in data extraction by discussion between
SG and AWY or through other arbitrating team members, HCW
and WZ, when we could not achieve a consensus.
Assessment of risk of bias in included studies
We adopted The Cochrane Collaboration’s domain-based evalu-
ation for assessing risk of bias, which included the following do-
mains:
(a) sequence generation;
(b) allocation concealment;
(c) blinding of participants, personnel, and outcome assessors;
(d) incomplete outcomedata (missingdatawere analysed byworst-
case scenarios. The funnel plot analysis was tested for potential
publication bias); and
(e) selective outcome reporting and other sources of bias.
We presented the risk of bias for each included study as part of
its Characteristics of included studies table in the review, as rec-
ommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
We set an additional quality criterion of whether the study used
published and validated scoring systems (i.e. EASI, SCORAD,
POEM, or SASSAD) under the heading of “use of published vali-
dated scoring systems” to record the severity of the disease (Schmitt
2007).
Measures of treatment effect
The total effectiveness rate and the number of adverse events were
dichotomous data. As the included studies compared the events
in 2 groups, we expressed dichotomous data as risk ratios (RR)
with 95% confidence intervals (CI). A higher total effectiveness
rate indicates better improvement of the condition. We planned
to express dichotomous data as number needed to treat (NNT).
We planned to express NNTB (number needed to treat for an ad-
ditional beneficial outcome) for beneficial outcome and NNTH
(number needed to treat for an additional harmful outcome) for
harmful events as recommended by theCochraneHandbook for Sys-
tematic Reviews of Interventions (Higgins 2011). The baseline event
rate includes the control event rate (CER) and the experimental
event rate (EER) for calculation of NNT. We planned to use a
plausible range of CERs from the individual trials. An NNTB
range of two to four should indicate that the interventions are
effective, which should imply a beneficial outcome.
The scores of itching VAS, global symptom improvement scores,
and QoL were continuous data. We expressed them as difference
in means (MD) with 95% CI. As outcome scales used in the
included studies were various, we also expressed the continuous
data as standardised mean differences (SMD) with 95%CI, where
different outcome scales were pooled.
Studies with multiple treatment groups
For studies with more than two interventions, we selected the
comparison group that met the inclusion criteria.
Unit of analysis issues
We considered unit of analysis issues if a study involved measure-
ments on different body parts, such as comparison of a site on one
arm versus another site on the other arm for topical interventions.
In this case, we treated the study as a ’within-patient trial’, and we
performed a separate meta-analysis as appropriate.
For cross-over trials where participants were given different treat-
ments in random sequence, we planned to undertake a separate
meta-analysis. The results from the first phase could be combined
with those from the parallel trials if data were available.
We planned to combine the data from included parallel studies
and the first period of included cross-over studies in the meta-
analysis. We planned to include cross-over studies only if their
methods were appropriate as suggested in the Cochrane Handbook
for Systematic Reviews of Interventions.
Dealing with missing data
We contacted the trial author of a study for more information if
there were any missing data in the trial. We applied intention-to-
treat (ITT) analysis to the included studies in which there were
missing individuals.
Assessment of heterogeneity
We assessed heterogeneity (inconsistency) in included studies by
using the I² statistic, which describes the percentage of variation
across studies due to heterogeneity rather than by chance.
Assessment of reporting biases
We tested funnel plot asymmetry where there were more than 10
trials included in the meta-analysis.
Data synthesis
We anticipated that the nature of the interventions would be quite
diverse, and it was therefore unlikely that they would all estimate
the same treatment effect. It was in fact that the studies in our re-
view estimated different, yet related, intervention effects, and for
this reason, we conducted a random-effects model when attempt-
ing to pool data from several studies. We performed the meta-
9Chinese herbal medicine for atopic eczema (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
analyses irrespective of the level of heterogeneity for the purpose
of explanation of potential inconsistency across the included stud-
ies. When substantial heterogeneity was found (I² statistic greater
than 50%), then we explored the sources of such heterogeneity by
rechecking the data, and by subgroup analysis based on clinical
and methodological diversity factors.
We performedmeta-analysis by using the inverse-variance method
inReviewManager 5 (RevMan), as outlined in theCochraneHand-
book for Systematic Reviews of Interventions, for effect estimates
from the collected data.
We reported studies relating to adverse events quantitatively.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses under the heading
of “children (16 years old or under) with eczema versus adults
with eczema”, and “application of intervention based on Chinese
medicine syndrome differentiation versus non-individualisation
formula” where there were at least moderate levels of heterogeneity
across the included studies. We investigated the sources of hetero-
geneity including participant factors (e.g. age, diagnosis, sex, race,
comorbidity), treatment factors (e.g. dosage, formulation), study
factors (e.g. concordance rates, quality of reporting), and quality
control for the Chinese herbal preparations (e.g. source, purity,
preparation facilities) to explain such differences.
Sensitivity analysis
We planned to perform sensitivity analyses of the primary out-
comes by excluding studies of low methodological quality. Where
substantial heterogeneity existed between studies for the primary
outcome (I² statistic > 50%), we were to seek sources for such
heterogeneity, such as quality of disease definition or composition
or dose of the herbal medication, and explore them in sensitivity
analyses. However, we were unable to carry out these analyses due
to the lack of data.
R E S U L T S
Description of studies
Results of the search
We identified a total of 1740 records through thorough searches.
We excluded 1674 records after screening the titles and abstracts.
Of the remaining 66 records, we found that 3were registered trials,
and we classified them as ’ongoing studies’. We retrieved full texts
of the remaining 63 records. Of these, we excluded 20 as they
were not randomised controlled trials. We excluded another four
studies because their comparison interventions did not meet the
inclusion criteria of this review (see Excluded studies). We need
further information about nine studies in order for us to make
a decision about their inclusion or exclusion. We listed these in
the ’Characteristics of studies awaiting classification’ tables while
we wait for further details from the trial investigators. Of the
remaining 30 records, we found 1 was a protocol for a study that
has been completed, but no final report has been published, andwe
added this to the 3 records we found that were ongoing trials. We
listed details of these four registered trials in the ’Characteristics
of ongoing studies’ tables and hope that these can be included in a
future revision of this review once the trial reports are published.
We included 28 studies (from 29 records; 1 study was reported
twice, and we have included the 2 identical trials under the same
study ID: Hon 2007). We summarised the screening process in
our ’Study selection flow diagram’ (Figure 1).
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Figure 1. Study selection flow diagram
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Included studies
We included 28 studies, with a total of 2306 participants.
Design
All 28 included studieswere randomised controlled parallel clinical
studies with oral ingestion or topical applications of CHM for
eczema, except the Lin 2010 study, which used CHM topically on
a randomised selected arm or leg of the participant for comparison
with the other non-treatment site on the same participant.
None of the included studies were cross-over trials, but one study
(Lin 2010) was a within-patient trial, and we treated data as if they
were obtained from the first phase of a cross-over trial (Higgins
2011).
The sample sizes of the studies ranged from 25 to 220, with a total
of 2306 participants aged from 12 days to 65 years.
We listed details of the included studies in the ’Characteristics of
included studies’ tables.
Setting
All of the included studies were conducted in public hospitals
(most of them were in Chinese medicine teaching hospitals) in
mainlandChina,HongKong, or Taiwan, where Chinesemedicine
has a long history of practice and widespread applications in the
healthcare system. The majority of the included studies were pub-
lished in Chinese. Two studies were printed in English (Cheng
2010; Hon 2007).
Treatment duration
Treatment duration ranged from 5 days to 16 weeks in the in-
cluded studies. Among the 28 included studies, 13 studies reported
follow-up, and the follow-up periods ranged from 4 to 52 weeks
after treatment stopped.
Funding
Eight studies reported receiving funding or support from govern-
ments (Cheng 2010; Gong 2010;Hon 2007;Ma 2010; Sun 2009;
Xue 2011; Yang 2007; Yu 1999).
Interventions
All of the studies used a combination of CHM originated from
plants or animal or mineral products as an active intervention.
1. CHM versus placebo
We found four studies that compared CHM to placebo (Chao
2003; Cheng 2010; Hon 2007; Sun 2009). Three studies used
oral ingestion of interventions (Cheng 2010; Hon 2007; Sun
2009), and one study administered the interventions via topical
application (Chao 2003).
The Chao 2003 study was a four-arm parallel randomised con-
trolled trial. It treated 120 children aged from 1 to 38 months
(mean = 7 months) with 5% (1st arm) or 10% (2nd arm) of
Huangbai ZicaoDiyu cream, econazole nitrate cream (Pevisone®)
(3rd arm), or placebo (petroleum jelly) (4th arm), respectively, for
2 to 3 weeks.We did not use data from the 1st arm as the 2nd arm
showed a higher effectiveness rate than the 1st arm. We analysed
data from the 2nd arm compared to the 4th arm (CHM versus
placebo) and the 2nd arm compared to the 3rd arm (CHM versus
conventional medicines) in the Effects of interventions section.
The Cheng 2010 study randomised 71 participants with a mean
age of 13 in a ratio of 2:1 who were treated with Chinese herbal
decoction of Xiao-Feng-San granules or placebo for 8 weeks. Fol-
low-up assessment was done after an eight-week treatment period.
TheHon 2007 study recruited a total of 85 participants aged from
5 to 21 years (mean = 11 years) with moderate-to-severe eczema
(objective SCORAD>15). Chinese herbalmedicine capsules con-
taining 5Chinese herbs or placebowere used for 12 weeks, and the
study conducted follow-up at week 16 of the trial period. The Sun
2009 study prescribed Jianpi Shenshi granules with 10 Chinese
herbs or placebo to 25 participants aged from 3 to 20 years old
(mean = 9 years) for 4 weeks. Follow-up assessment was conducted
at 24 weeks after the treatment period. All four studies allowed
other medicines in both groups.
2. CHM versus conventional medicines (drugs)
We found 22 studies plus the Chao 2003 study where one of its 4
arms compared the effects of CHM to drugs.
a) Oral ingestion (five studies)
There were 62 participants aged from 10 to 52 years old, with
a mean age of 20 years, randomly assigned to the treatment or
control group in the Jin 2007 study. Jianpi Zhiyang granules with
12 CHMs or loratadine tablet (an antihistamine medication) were
given to the participants for 4 weeks.
The Luo 2010 study recruited 62 children with a mean age of 9,
who they treatedwithXiao-Feng-Sandecoction and individualised
modifications, loratadine, or another antihistamine drug for 16
weeks.
The Yang 2009 study used a formula containing 9 herbs and re-
cruited 60 children or adults aged from 4 to 27 years, with a mean
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age of 16, for 4 weeks of treatment. The Yang 2009 study also
used the loratadine tablet as the control intervention.
The Yu 1999 study had the largest sample size (220 participants)
among the 28 included studies. PiyanXiaojingyin granules II com-
posed of more than 5 herbs were given to participants aged from
5 to 53 years old (mean = 13 years). The loratadine tablet was the
control intervention, and both groups were supplied with saline
or zinc oxide cream for 12 weeks. The study conducted follow-up
assessment at 52 weeks after the treatment period.
The Zhang 2011 study reported that they used a clinician self-
designed CHM formula with modifications based on individual
cases or levocetirizine dihydrochloride tablets (an antihistamine
medication) for treatment of 56 children aged from 2.5 to 14 years
old (with a mean age of 7 years) for 8 weeks. The study conducted
follow-up assessment at 24 weeks after the 8-week treatment pe-
riod.
b) Topical application (six studies)
The Chao 2003 study compared the effects of CHM to econazole
nitrate cream (Pevisone®), which was composed of 1% of econa-
zole nitrate (antifungal medication) and 0.1% of triamcinolone
acetonide (corticosteroid) in its 3rd arm.
The Chen 2011 study randomly entered 100 children (aged from
58 days to 2 years old) into the treatment or control groups, and
they were treated with Huanglian Qingdai cream made from 6
herbs or mometasone furoate cream (a corticosteroid) for 2 weeks.
There were 65 boys and girls aged from 12 days to 11 months
(mean = 5 months) in the Wang 2008 study, which used Chushi
Zhiyang ointment, a manufactured CHM product made up of 13
Chinese herbs, topically for 1 week. The study employed vitamin
B cream (a moisturising agent) as the control intervention.
The Huang 2010 study recruited 195 participants aged from 3
months to 22 years old, with a mean age of 12 years, who were
treatedwithChushi Zhiyang ointment, whichwas the sameCHM
product used in the Wang 2008 study, or clobetasol propionate
ointment (a corticosteroid) for 2 weeks. The study performed
follow-up assessment at 12 weeks after the treatment period.
The Zhou 2011 study treated 176 children aged 3 to 38 months
old (mean = 10 months) with Cang Er Kushen lotion, which
had 13 Chinese herbs, or calamine lotion (an anti-itching agent),
which they used topically as the control intervention for 2 weeks.
The study conducted follow-up assessment 24 weeks after the
treatment period.
The Zou 2011 study randomised 50 children aged from 3 to 36
months, with a mean age of 16 months. Moist dressing with a
CHM lotion composed of nine herbs and topical application with
the same herbal powder mixed with sesame oil were used for two
weeks. Boric acid solution (an antiseptic agent) and zinc oxide
cream (a moisturising agent) served as control interventions.
c) Combination of oral ingestion and topical application
(twelve studies)
The included studies in this group used CHM by oral ingestion
and topical application in their treatment groups for comparison
of the effect to the control groups.
The Cao 2009 study treated 56 children aged from 2 to 16 years
(mean = 8 years) with Zhuling Jianpi Huashi decoction (which
could bemodified when the condition of an individual participant
changed) or with oral ingestion of cetirizine hydrochloride drops
(an antihistamine medication) for 1 to 4 weeks. There were 12
herbs in the Zhuling Jianpi Huashi decoction used in this study.
The Zhang 2005 study also evaluated the same CHM decoction
(although the name of the formula was changed).
The Gong 2010 study randomised 56 adults aged from 16 to 65
years old (mean = 37 years) into the treatment or control group
and treated them with Liangxue Xiaofeng decoction composed
of 13 herbs or oral ingestion of desloratidine (an antihistamine
medication) for 4 weeks.
The Lang 2007 study used Shengui decoction with 8 herbs and
Shidu ointment for the treatment group for 4 weeks, and oral in-
gestion of loratadine tablets and 1% hydrocortisone cream (a cor-
ticosteroid) topically as control interventions for 72 participants
aged from 3 to 34 years old (mean = 17 years).
The Liu 2005 study recruited 184 children and adults aged from
3 months to 42 years old (mean not provided) for 4 to 8 weeks
of treatment. The participants were treated with oral ingestion of
Cangyi decoction with individualised modifications and Qingdai
ointment andHuangbai lotion topically in the treatment group, or
they were treated with terfenadine tablet (an antihistamine med-
ication) and 0.025% dexamethasone cream (a corticosteroid) as
control interventions. There were 12 herbs in the Cangyi decoc-
tion, and the ingredients of the topically used CHM interventions
were unknown in this study.
The Ma 2010 study treated 82 children and adults aged from 7
to 33 years old (mean = 18 years) with loratadine tablet or Jianpi
Runfu decoction containing 11 herbs. The oral ingestion of CHM
could bemodified based on the individual’s condition in the study,
and Zicao oil or butyl flufenamate cream (an anti-inflammatory
medication) was also used topically in the treatment group or
control group, respectively, for four weeks.
The Tian 2005 study treated 100 participants (did not report the
range of age) with oral ingestion of Fuyang granules composed of
5 herbs and used the same formula for topical application or oral
ingestion of cyproheptadine tablet (an antihistamine medication)
plus 3% sulphur cream (an antiseptic agent) externally for only 5
days.
The Xiao 2008 study used oral ingestion and external application
of Machixian decoction as a basic formula, which was modified
according to an individual’s condition. The control interventions
were chlorphenamine tablet (an antihistamine medication) and
3% boric acid solution. There were a total of 52 participants aged
from 3 to 23 years old (mean = 13 years) in this study, and treat-
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ment duration was 8 weeks with follow-up assessment at 12 weeks
after the treatment period.
The Xiao 2011 study recruited 60 participants aged from 2 to 60
years old (mean = 12 years) and provided 4 weeks of treatment
with Huailian decoction composed of 12 herbs, and loratadine
tablet was the control oral ingestion intervention. External use of
nitrofurazone, calamine, menthol, and CHM ointment were also
provided to both groups.
The Xue 2011 study used Shengxue Runfu decoction composed
of 15 herbs. The formula could be modified depending upon an
individual’s condition, and loratadine was the control oral inges-
tion intervention for an 8-week treatment. There were 63 boys
and girls ranged from 2 to 12 years old (mean = 7 years) in this
study. Topical application of CHM ointment and emollients were
employed for both groups.
The Yang 2007 study used the same oral ingestion of CHM inter-
vention as the Jin 2007 study. The two studies were conducted at
the same department of a Chinese medicine hospital in Shenzhen,
China. The Yang 2007 study however also used CHM ointment
topically with a total of 64 participants from 5 to 25 years old
(mean = 7 years) who were treated with Chinese herbs or oral in-
gestion of loratadine tablet and 1% hydrocortisone butyrate cream
(a corticosteroid) for 4 weeks.
The Zhang 2005 study recruited 45 children under 16 years old
(mean = 8 years) and compared the efficacy of aCHMdecoction to
chlorpheniramine tablet for 12 weeks in 3 groups of participants.
In this study, CHM lotion or CHM ointment were also used
topically according to an individual’s condition in all the groups.
Finally, the Zhang 2009 study treated 61 children aged from 2 to
12 years old (mean not provided) with Xiao’er Huashi decoction
(composed of 13 herbs) or loratadine granules for 4 weeks. Exter-
nal use of CHM lotion and CHM cream were provided to both
groups.
3. Combination of oral and topical CHM interventions
versus same oral CHM alone
We found two studies comparing the effects of a combination of
oral and topical CHM to the same oral CHM formula alone (Lin
2010; Rao 2010). The Lin 2010 study used Runfu Xiaoyan lotion
composed of 4 herbs applied externally on a randomly selected
site of the limb (which had received no previous treatment with
regard to the topical intervention) of 23 participants aged from
11 months to 27 years old (mean = 10 years) for 2 weeks. The Lin
2010 study also used oral ingestion of Qingxin Peitu decoction
for moderate and severe cases.
The Rao 2010 study was a 3-arm parallel controlled design of 12
weeks’ treatment duration, which recruited 30 participants aged
from 7 to 25 years old (mean = 15 years). The treatment group
(the first arm) received Qingxin Peitu decoction with individu-
alised modifications plus external use of Qingxin Peitu lotion. The
second-arm group was treated with the same oral ingestion of the
intervention but no topical intervention, and the third-arm group
used oral ingestion of placebo plus oral ingestion of cetirizine hy-
drochloride tablet and topical application of mometasone furoate
cream. We did not use data from the third-arm group in this re-
view as there was no appropriate comparator for this group.
Outcomes
With regard to our first primary outcome, the trial investigators
in most of the included studies converted the measure score into
effectiveness rate without reporting the actual score. Thus, we ac-
cepted that a ’recovery’ was where there was > 90% reduction of
the investigator global score, and a ’significant improvement’ was
> 70% reduction of the score as stated by the trial investigator(s).
A total effectiveness rate was a sum of effectiveness rates expressed
as ’recovery’ and ’significant’ by the trial investigator(s) of the in-
cluded studies. A higher total effectiveness rate indicates better
improvement of the condition.
With regard to our second primary outcome, most of the included
studies measured severity of itching score and expressed this as a
participant-rated visual analogue score (VAS). Thereafter, we ex-
tracted continuous data in mean values, standard deviations (SD),
and total numbers of events assessed at the end point of the trial
as one of the primary outcome measures to replace the percentage
of trial participants that we planned.
With regard to our third secondary outcome, we extracted adverse
events in a data extraction form for all included studies. A severe
adverse event was an adverse effect that led a participant to with-
draw from the study. A minor adverse event was one reported by
the participant or clinician but that was not serious and the person
still completed the treatment.
With regard to short-term or long-term improvement of a relevant
outcome, the short-term improvement was an outcome measured
within six weeks in the follow-up period after stopping the treat-
ment. The long-term improvement was an outcome measured
more than six weeks into the follow-up period after stopping the
treatment.
Excluded studies
We excluded four studies because their comparison interventions
did not meet the inclusion criteria of this review. Please see the
’Characteristics of excluded studies’ tables.
Risk of bias in included studies
Two authors (SG and AWY) independently assessed the risk of
bias in the included studies and resolved discrepancies of the as-
sessments by discussion. The other two teammembers, HCW and
WZ, provided arbitrating advice when a consensus could not be
achieved.We assessed risk of bias and provided a brief rationale for
our judgment for each study (see the ’Risk of bias’ tables, which
are an extension of the ’Characteristics of included studies’ tables).
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Overall, the risk of bias in the included studies was high for blind-
ing of participants and research personnel and unclear for the other
domains. Our judgements according to the published data about
each ’Risk of bias’ item presented as percentages across all included
studies are shown in Figure 2. We summarised our judgements,
which we based on The Cochrane Collaboration’s domain-based
evaluation for “assessing risk of bias” about each ’Risk of bias’ item
for each included study, in Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Allocation
Almost half of the included studies (13/28) did not state how
they generated allocation sequences (Chao 2003; Chen 2011;
Jin 2007; Liu 2005; Sun 2009; Tian 2005; Wang 2008; Xiao
2008; Xue 2011; Yang 2007; Yu 1999; Zhang 2005; Zhang 2009).
Of the 28 included studies, only 2 studies explicitly explained
the procedures for allocation concealment of randomised codes
for avoiding potential selection bias (Cheng 2010; Hon 2007).
Both studies used an independent party to provide randomised
codes, which were generated by a computer program. The Cheng
2010 study placed the random codes in an envelope. In the Hon
2007 study, the trial investigator did not break the codes of any
participant until the trial was completed.
Blinding
Blinding of participants and personnel involved in direct contact
with the participants is important for minimising bias from sub-
jective outcome measures (Tal 2011).
One of the most common quoted subjective outcome measures in
eczema was VAS for itching severity. About 89% of the included
studies (25/28) did not use blinding either on the participants or
on the trial investigators, which implied the highest risk of bias
within the assessed domains. Although the Sun2009 study claimed
that the trial was a double-blind design, there was only one author
in the published paper with absence of acknowledgment of other
personnel. We were not sure how the blinding was implemented
in this study. Only two studies employed the double-blind design
and provided clear description of blinding methods (Cheng 2010;
Hon 2007).
Blinding of the outcome assessors was another overall weakness of
methodology in the included studies. Most of the included stud-
ies (82%; 23/28) did not state whether they had used blinding in
assessments of outcomes. In many situations, the appearance and
administration of the two compared interventions were different
in the trial, e.g. Chinese herbal decoction versus Western medica-
tions, which made blinding impossible even though the study did
not particularly state that it did not use blinding. The Cao 2009
and Luo 2010 studies declared that they did not require blinding.
Only three studies appropriately blinded the chief investigators
of the trials from awareness of the interventions used, when they
performed outcome assessments or used a third party to carry out
such assessments (Cheng 2010; Hon 2007; Rao 2010).
Incomplete outcome data
There was unclear risk of bias among the included studies as the
numbers of participants randomised and analysed were identical
in 75% of the included studies, and it seems that there were no
incomplete outcome data in those studies. High risk of attrition
bias (a bias associated with withdrawal or dropout of participants
in a study) existed as there were withdrawals or dropouts in the
studies of Chao 2003; Lang 2007; Lin 2010; and Xue 2011, and
these studies did not use ITT. The Cheng 2010; Hon 2007; and
Ma 2010 studies reported data for withdrawals and dropouts, and
they used the ITT principle in the final statistical calculations.
Therefore, we considered the risk of bias at a low level.
Selective reporting
In the Huang 2010 study, the trial investigators claimed full blood
counts (they performed liver and renal function tests after the
two-week treatment period), but we could not find the results of
those tests in their study. We were unable to assess the outcome
reporting bias because of insufficient information in the rest of the
27 included studies.
Other potential sources of bias
We set “use of published validated scoring systems” to assess po-
tential sources of bias and found that more than 64% (18/28) of
the included studies used published and validated scoring systems,
including EASI, SAASAD, or SCORAD, as outcome measures.
Five included studies did not use any published and validated
scoring system, and we considered these studies at a high risk of
bias (Liu 2005; Tian 2005; Wang 2008; Zhou 2011; Zou 2011).
Four studies used a scoring system developed by the trial investi-
gator(s) for measurement of outcomes (Chao 2003; Chen 2011;
Yang 2009; Yu 1999). We were not able to assess the validation of
those trial investigators’ self-developed scoring systems; thus, we
classed the risk of bias as unclear. The Cheng 2010 study claimed
to use a “standardised scoring system”; again, we were unable to
assess whether the system had been validated, although the scoring
system had been previously used and published in other trials, so
we classed the risk of bias as unclear in this study, too.
None of the included studies used POEM for scoring the severity
of the condition.
Effects of interventions
See: Summary of findings for the main comparison CHM
compared to placebo; Summary of findings 2CHMcompared to
drugs; Summary of findings 3 Combination of oral and topical
CHM compared to same oral CHM
I. CHM versus placebo
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1. Primary outcomes
a) Total effectiveness rate
The Chao 2003 study showed that there was a statistically signif-
icant increase in total effectiveness rate (those participants with
’recovery’ or ’significant improvement’) in the CHM group treated
with 10% strength CHM cream compared to those in the con-
trol group using petroleum jelly (Vaseline) at the end of the 3-
week treatment period. We decided to include the full strength
(10%) CHM cream for analysis in this review. The Sun 2009
study recorded no effect in the sum of ’recovery’ and ’significant
improvement’ events in both groups at the end of the four-week
treatment period.
We pooled data from these 2 studies using the statistical method
of inverse-variance with the random-effects analysis model and
expressed an estimate of their overall effects as RR with 95% CI,
which showed a statistically significant effect of the CHM inter-
vention (RR 2.09, 95% CI 1.32 to 3.32; see Analysis 1.1).
The Chao 2003 study did not report short-term or long-term im-
provement. The Sun 2009 study reported long-term improvement
(24 weeks after stopping the treatment) assessed with ’Recurrence
rate’. We did not perform further analysis of the data as the ’Re-
currence rate’ was not a prespecified outcome of this review.
The Cheng 2010 and Hon 2007 studies did not report the out-
comes as ’effectiveness rate’.
b) Severity of itching score measured by VAS
The Cheng 2010 study reported the improvement of itching in
scores (scale from 0 to 4). The score was expressed as least-squares
mean ± the standard error (SE) change from baseline for each in-
tervention group following the eight-week treatment period. The
Cheng 2010 study also provided data of baseline median (in-
terquartile range (IQ)) per group.We did not use the SEs provided
as theywere too narrow.We pooled the data by using an alternative
SD estimated from the baseline data (calculation from baseline
IQ range: SD = IQ/1.35) to ensure the least-squares means did
not receive too much weight in the meta-analysis (Higgins 2011).
The Sun 2009 study also used VAS (scale unknown) to assess the
severity of itching at the end of the four-week treatment period but
did not report scale. We pooled the data and expressed as SMD
with 95% CI due to different outcome scales being used in these
2 studies (SMD -1.53, 95% CI -2.64 to -0.41; see Analysis 1.2).
As the Cheng 2010 study reported improvement of VAS without
the actual score and the Sun 2009 study recorded decrease of VAS
at end point, we multiplied the mean in the Cheng 2010 study
by -1 to ensure the 2 outcomes were in the same direction (Deeks
2011). Both studies showed favourable results towards the CHM
groups.
The Cheng 2010 study reported short-term improvement (four
weeks after stopping the treatment) and stated that better scores
of itching were seen in the CHM group, but it did not provide
details of data.
We found no record of severity of itching score in the Chao 2003
and Hon 2007 studies.
2. Secondary outcomes
a) Overall severity score measured by the scoring system (e.g.
EASI, SAASAD, or SCORAD)
The Chao 2003 study used a self-developed scoring system and
recorded the score at end point in the CHM group (2nd arm)
and control group (4th arm). The Cheng 2010 study reported
improvement in clinical lesion scores, which were expressed as
least-squares means ± SE at the end of the eight-week treatment
period.We analysed the data by using an alternative SD as outlined
above. The Hon 2007 study reported the SCORAD score at the
end of the 12-week treatment period in both groups and stated
that there was no significant difference between the 2 groups. The
Sun 2009 study also used SCORAD to measure the outcomes
and claimed that a significant difference in the treatment and
control groups at the end of the treatment period was observed,
and the effect in theCHMgroupwas superior to the control group.
We pooled data from those 4 studies and recorded a significant
difference (SMD -0.88, 95% CI -1.67 to -0.09; see Analysis 1.3).
The Cheng 2010 study reported short-term improvement (four
weeks after stopping the treatment) and stated that improved clin-
ical lesion scores were seen in the CHM group; however, no data
were provided. The Hon 2007 study reported that no short-term
improvement was observed as there was no difference between the
2 groups 4 weeks after stopping the treatment (MD 3.40, 95% CI
-5.70 to 12.50; see Analysis 1.4). The Chao 2003 and Sun 2009
studies did not report short-term or long-term improvement in
overall severity score.
b) QoL index
The Hon 2007 study reported improvement in CDLQI score
in the CHM group at the end of the 12-week treatment period
(MD -2.50, 95% CI -4.77 to -0.23; see Analysis 1.5). The Hon
2007 study also stated that there was a short-term improvement
in CDLQI 4 weeks after stopping the treatment, but this claim
was not supported by the statistical analysis (MD -1.30, 95% CI
-3.51 to 0.91; see Analysis 1.6).
The Chao 2003; Cheng 2010; and Sun 2009 studies did not use
a QoL index to measure the outcomes.
c) Adverse events
There were two minor adverse events in the CHM group in the
Chao 2003 study. TheCheng 2010 study reported that one partic-
ipant had transient elevation of aspartate aminotransferase (AST);
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the trial investigators did not state in which group the participant
was assessed. There were two participants in the treatment group
who complained of gastrointestinal upset in the first week of the
treatment, but the participants were able to complete the whole
trial (Cheng 2010). The Sun 2009 study stated that none of the
trial participants reported adverse events.
We pooled data from the Chao 2003 and Cheng 2010 studies
about minor adverse events; no significant difference was seen be-
tween the treatment and control groups (RR 0.71, 95%CI 0.06 to
8.67; 2 studies, n = 129; see Analysis 1.7). There were a total of 82
minor adverse events reported by participants in the CHM group
and 47 minor adverse events reported by participants in the con-
trol group in the Hon 2007 study. The trial investigators claimed
that there was no significant difference in terms of frequency of
minor adverse events in the two groups. We treated the frequency
of those adverse events as ’count data’ and converted to risk ratio
(Deeks 2011). It showed a statistically significant difference in the
minor adverse events between the 2 groups, and the CHM group
had a higher rate in the incident of the events (RR 1.77, 95% CI
1.24 to 2.53; see Analysis 1.8).
Subgroup analysis and investigation of heterogeneity
We found substantial heterogeneity (I² statistic = 87%, see Figure
4) across the 4 studies in the outcome ’overall severity score’. We
planned to perform subgroup analyses of “children (16 years old
or under) with eczema versus adults with eczema” and “application
of interventions based on Chinese medicine syndrome differen-
tiation versus non-individualisation formula” where there were at
least moderate levels of heterogeneity across the included studies.
However, only the Chao 2003 study recruited children aged from
1 to 38 months; the other 3 studies mixed children with adults,
and these 3 studies used non-individualised formulae. Thus, we
did not conduct subgroup analyses.
Figure 4. Forest plot of comparison: 1 CHM versus placebo, outcome: 1.3 Overall severity score
We could not explain such differences by further analysis of the
sources of heterogeneity, which included the following:
• participant factors, e.g. age (children versus adults, because
we were not able to identify the difference for the reasons stated
above), diagnosis (infantile eczema in the Chao 2003 study
versus atopic eczema in the Cheng 2010; Hon 2007; and Sun
2009 studies), sex (mixed gender in all four studies), race (all
Asians), and comorbidity (not able to identify because of
insufficient data);
• treatment factors, e.g. dosage (various CHM dosages
applied across the four studies) and formulation (four different
CHM formulae used in four studies); and
• study factors, e.g. concordance rates (all four studies
reported high compliance rates), quality of reporting (this was
overcome by assessment of risk of bias in this review), and
quality control for the Chinese herbal preparations, e.g. source,
purity, and preparation facilities (all four studies reported quality
control for the CHM interventions).
Sensitivity analysis
We planned to perform sensitivity analyses of the primary out-
comes by excluding studies of low methodological quality. We
found substantial heterogeneity (I² statistic = 74%; see Analysis
1.2) in the 2 studies that measured 1 of the primary outcomes,
the severity of itching, by VAS. We could not perform sensitivity
analysis as there were only two studies in the meta-analysis.
II. CHM versus no treatment
None of the included studies compared CHM with no treatment.
III. CHM versus acupuncture
None of the included studies compared CHM with acupuncture
treatment.
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IV. CHM versus conventional medicines (drugs)
1. Primary outcomes
a) Total effectiveness rate
A total of 20 included studies employed total effectiveness rate as
the outcome measure. In addition, we included one arm of the
Chao 2003 study, which was a four-arm design where CHM was
used topically (second arm) compared to steroid cream (third arm)
in the current category. We pooled data from the 21 included
studies using the statistical method of inverse-variance with the
random-effects analysis model and expressed an estimate of their
overall effects as RR with 95% CI. The forest plot of comparison
showed that application of CHM significantly improved the con-
dition compared to control interventions (RR 1.43, 95% CI 1.27
to 1.61; see Analysis 2.1).
The Cao 2009; Chao 2003; Chen 2011; Lang 2007; Ma 2010;
Tian 2005; Wang 2008; Xue 2011; Yang 2007; Yang 2009; and
Zhang 2005 studies did not report short-term or long-term im-
provement. The Zhang 2009 study reported short-term improve-
ment assessed with ’Recurrence rate’. The Huang 2010; Liu 2005;
Xiao 2011; Zhang 2011; Zhou 2011; and Zou 2011 studies also
used ’Recurrence rate’ to report long-term improvement. All of
them stated that the CHM groups had a lower recurrence rate
than their comparators. The Luo 2010 study reported long-term
improvement, but provided no data. TheGong 2010 and Yu 1999
studies reported long-term improvement and stated that CHM
groups had a higher effectiveness rate than the control groups (RR
1.52, 95% CI 1.11 to 2.08; see Analysis 2.2).
b) Severity of itching score measured by VAS
Seven included studies reported continuous VAS data to measure
the severity of itching score. The scale was 0 to 10 in all studies
except the Chen 2011 study where the scale of VAS was 0 to 3.We
expressed the data as SMD with 95% CI as the included studies
used different outcome scales. The forest plot figure showed that
there was a statistically significant difference between the CHM
group and control group in terms of reduction of the severity of
itching, and overall effects were favourable to the CHM groups
(SMD -0.83, 95% CI -1.43 to -0.22; see Analysis 2.3).
None of the seven included studies reported short-term or long-
term improvement in terms of itching score (Chen 2011; Jin 2007;
Lang 2007; Ma 2010; Xue 2011; Yang 2007; Zhang 2005).
2. Secondary outcomes
a) Overall severity score measured by the scoring system (e.g.
EASI, SAASAD, or SCORAD)
The Liu 2005; Tian 2005; Wang 2008; Zhou 2011; and Zou
2011 studies did not report measurement of overall severity of the
condition. The Yang 2009; Yu 1999; and Zhang 2009 studies did
not provide data for the scores. We pooled data collected from the
remaining 15 included studies and expressed them as SMD with
95% CI as the studies used different outcome scales. The Cao
2009; Luo 2010; and Zhang 2005 studies reported data measured
at the end point as percentage of reduction of total SASSAD score
and expressed the data as ’numbers ±’. We assumed unlabelled
data in these three studies were ’mean and SD’. We multiplied the
mean by -1 to ensure all scales were in the same direction in the
meta-analysis. The forest plot figure showed that application of
CHMsignificantly reduced the severity of skin lesionsmeasured by
various scoring systems when compared to Western medications
(SMD -0.97, 95% CI -1.23 to -0.71; see Analysis 2.4).
Cao 2009; Chao 2003; Chen 2011; Jin 2007; Lang 2007; Ma
2010; Xue 2011; Yang 2007; and Zhang 2005 reported no short-
term or long-term improvement. The Gong 2010; Huang 2010;
Luo 2010; Xiao 2008; Xiao 2011; and Zhang 2011 studies re-
ported long-term improvement. Only the Xiao 2008 study pro-
vided data to support a long-term improvement observed in the
CHM group (MD -8.50, 95% CI -13.40 to -3.60; see Analysis
2.5).
b) QoL index
No studies in this group employedQoLquestionnaires as outcome
measures.
c) Adverse events
The Jin 2007;Xue 2011;Zhang 2009; andZhang 2011 studies did
not report adverse events. The Cao 2009; Luo 2010; Zhou 2011;
and Zou 2011 studies stated that no adverse events were reported
during the trial period. None of the studies reported withdrawals
of participants due to any adverse event. When combined, the 15
studies indicated there were significantly less minor adverse events
in the CHM than the control groups (RR 0.44, 95% CI 0.32 to
0.61; see Analysis 2.6).
Subgroup analysis and investigation of heterogeneity
Therewas substantial heterogeneity (I² statistic = 65%; seeAnalysis
2.1 and Figure 5) across the 21 included studies with the outcome
measured by total effectiveness rate. We planned to conduct a
subgroup analysis of the studies of “children (16 years old or under)
with eczema versus adults with eczema” and identified 12 studies
in which the participants were 16 years old or under. The other
nine studies however recruited participants with a mix of children
and adults; therefore, wewere unable to conduct subgroup analysis
under this heading.
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Figure 5. Forest plot of comparison: 2 CHM versus drugs, outcome: 2.1 Total effectiveness rate (number of
participants recovered and significantly improved) with subgroup analysis
We also compared the difference in the total effectiveness rate
between two groups where application of CHM was based on
Chinese medicine syndrome differentiation or non-individualised
formula. There was low inconsistency (I² statistic = 22%) within
the 7 subgrouped studies, which applied CHM based on Chinese
medicine syndrome differentiation (individualised modifications)
and showed that CHMwas more effective than theWestern med-
ications (RR 1.50, 95% CI 1.30 to 1.74; see analysis 2.1.1 in
Analysis 2.1). There were no subgroup differences (I² statistic =
0) when comparing the individualised treatment subgroup to the
non-individualised subgroup. Where non-individualised formu-
lae were used, there was a high level of heterogeneity between the
studies in this subgroup (I² statistic = 71%; see analysis 2.1.2 in
Figure 5).
We performed a posthoc subgroup analysis of ’CHM versus topi-
cal steroid’, ’CHMversus antihistamines’, and ’CHMversus other
agents’ as the different types of comparators could be a possible
reason for heterogeneity in the studies. We found substantial het-
erogeneity in the subgroup of topical steroid (I² statistic = 72%).
Although there were no inconsistencies in the subgroups of an-
tihistamines or other agents, the total subgroup differences were
statistically significant (P = 0.02; I² statistic = 74.4%; see Analysis
2.7).
We were unable to further investigate the sources of the hetero-
geneity in this group from participant factors (e.g. age, diagnosis,
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sex, race, comorbidity), treatment factors (e.g. dosage, formula-
tion), study factors (e.g. concordance rates, quality of reporting),
and quality control for the Chinese herbal preparations as no data
were available for appropriate comparisons.
Sensitivity analysis
We could not perform sensitivity analyses of the primary outcomes
by further excluding studies of low methodological quality as all
studies in this category had similar methodological weaknesses
(e.g. high risk of bias in blinding of participants and research
personnel).
Assessment of reporting bias
We generated a funnel plot (Figure 6) to inspect visually for evi-
dence of potential reporting bias including publication bias across
15 included studies, which compared effects of CHM and West-
ern medications (Cao 2009; Chao 2003; Chen 2011; Gong 2010;
Huang 2010; Jin 2007; Lang 2007; Luo 2010; Ma 2010; Xiao
2008; Xiao 2011; Xue 2011; Yang 2007; Zhang 2005; Zhang
2011).We further assessed for any bias captured in the funnel plot
with the test proposed by Egger 1997. The results of the assess-
ment indicated that there were no statistically asymmetrical dis-
tributions among those 15 studies (Egger test P = 0.2021).
Figure 6. Funnel plot of comparison: 2 CHM vs drugs, outcome: 2.4 Overall severity score
V. Combination of oral and topical CHM
interventions versus same oral CHM alone
1. Primary outcomes
a) Total effectiveness rate
The Lin 2010 study did not express the outcomes as ’effectiveness
rate’. The Rao 2010 study reported no difference in the effects
between the first arm (CHMused orally and topically) and second
arm (CHM was used by oral ingestion only, but there was no
topical intervention) at the end of the 12-week treatment period
(RR 1.13, 95% CI 0.78 to 1.63; see Analysis 3.1).
The Lin 2010 study did not report short-term or long-term im-
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provement. TheRao 2010 study reported long-term improvement
(24 weeks after stopping the treatment), but no difference was
observed between the 2 groups (RR 1.00, 95% CI 0.75 to 1.34;
see Analysis 3.2).
b) Severity of itching score measured by VAS
The Lin 2010 study reported that there was statistically significant
improvement in terms of itching relief (scale from 0 to 10) in
the treatment site compared to the control site of the limb at the
end of 2 weeks of treatment (MD -1.05, 95% CI -1.75 to -0.35;
see Analysis 3.3). The Lin 2010 study did not report short-term
or long-term improvement. The Rao 2010 study did not report
severity of itching score.
2. Secondary outcomes
a) Overall severity score measured by the scoring system (e.g.
EASI, SAASAD, or SCORAD)
The Lin 2010 study used a self-developed scale (scale 0 to 24)
for scoring the severity of skin lesions and reported a statistically
significant improvement in terms of skin lesions at the treatment
site of the limb compared to the control site, at the end of the 2-
week treatment period (MD -1.59, 95% CI -2.92 to -0.26; see
Analysis 3.4). We did not pool the score of SCORAD in the Lin
2010 study as the data provided were recorded at the baseline and
the end of the treatment period rather than the treatment site
and control site. The Rao 2010 study stated no difference in the
reduction of SCORAD between the treatment group and control
group at the end of the 12-week treatment period (MD -3.43,
95% CI -7.01 to 0.15; see Analysis 3.5). We did not pool the data
from the two studies for meta-analysis as the Lin 2010 study was
a within-patient trial.
The two studies did not report short-term or long-term improve-
ment.
b) QoL index
The Lin 2010 study did not use a QoL index for measurement
of outcomes. The Rao 2010 study used CDLQI as the secondary
outcome measure and recorded the scores at the end of the 12-
week treatment period, which indicated no difference between the
2 groups (MD 0.90, 95% CI -2.89 to 4.69; see Analysis 3.6).
The Rao 2010 study also used CDLQI scores for measuring long-
term improvement in 24 weeks after stopping the treatment, but
provided no data.
c) Adverse events
There was one participant withdrawal (a severe adverse event)
from the Lin 2010 study due to exacerbation of the skin condition
after using the Chinese herbs for two days, and three participants
complained of mild to moderate burning and pain sensations, but
they still completed the two-week treatment. The Rao 2010 study
stated that there was 1 participant with increased serum alanine
transaminase (ALT) each in the treatment and control group (RR
1.00, 95% CI 0.07 to 13.87; see Analysis 3.7).
We did not perform subgroup or sensitivity analyses for this com-
parison.
Number needed to treat (NNT) or number needed to
benefit (NNTB)
Because of high risk of bias in most of the included studies, we
decided not to express dichotomous data as NNT or continuous
data as NNTB as these additional variations may have induced
unnecessary misleading implications.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
CHM compared to drugs for atopic eczema
Patient or population: Participants with atopic eczema
Settings: Hospital outpatients
Intervention: CHM
Comparison: Drugs
Outcomes Illustrative comparative risk* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Drugs CHM
Total effectiveness rate
(Analysis 2.1)
Clinician’s rating
Follow up: 2 to 52 weeks
Low¹ RR 1.43
(1.27 to 1.61)
1868
(21 studies)
⊕©©©
very low²,³, ,
A higher total effective-
ness rate indicates im-
provement of the condi-
tion
20 per 100 29 per 100
(25 to 32)
High¹
90 per 100 100 per 100
(100 to 100)
Total effectiveness rate
with subgroup analysis -
individualised treatment
Clinician’s rating
Follow up: 4 to 8 weeks
Low¹ RR 1.50
(1.30 to 1.74)
567
(7 studies)
⊕⊕©©
low²,³,
20 per 100 30 per 100
(26 to 35)
High¹
70 per 100 100 per 100
(91 to 100)
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Total effectiveness rate
with subgroup analysis -
non-individualised treat-
ment
Clinician’s rating
Follow up: 2 to 52 weeks
Low¹ RR 1.37
(1.17 to 1.60)
1301
(14 studies)
⊕©©©
very low²,³, ,
20 per 100 27 per 100
(23 to 32)
High¹
90 per 100 100 per 100
(100 to 100)
Itching VAS (Analysis
2.3)
Participant’s rating. Scale
from 0 to 10
Follow up: 2 to 12 weeks
The mean itching VAS
ranged across control
groups from
0.3 to 5.75 scores
The mean itching VAS
in the intervention groups
was 0.83 standard devi-
ations lower (1.43 to 0.
22 lower)
465
(7 studies)
⊕⊕©©
low²,³,
Lower score indicates im-
provement of the condi-
tion. 16 additional stud-
ies did not report this out-
come
Overall severity score (
Analysis 2.4)
Clinician’s rating. Scale
from 0 to 103
Follow up: 2 to 12 weeks
The mean overall severity
score ranged across con-
trol groups from
0.3 to 70.82 scores
The mean overall severity
score in the intervention
groups was 0.97 stan-
dard deviations lower (1.
23 to 0.71 lower)
1062
(15 studies)
⊕⊕©©
low²,³,
Lower score indicates im-
provement of the condi-
tion. 8 additional studies
did not report this out-
come
Adverse events (Analysis
2.6)
Participant’s reports
Follow up: 2 to 52 weeks
Low¹ RR 0.44
(0.32 to 0.61)
1396
(15 studies)
⊕⊕©©
low²,³,
4 additional studies did
not report this outcome
1 per 100 0 per 100
(0 to 1)
High¹
60 per 100 26 per 100
(19 to 37)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate
¹The low and high assumed risk values are the two extreme numbers of the events taken from the control groups in the included studies.
²Unclear risk of bias in allocation concealment and high risk of bias in blinding participants and personnel.
³High risk of bias in blinding of outcome assessment.
High risk of bias in other potential sources of bias.
Unexplained heterogeneity.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Combination of oral and topical CHM compared to same oral CHM for atopic eczema
Patient or population: Participants with atopic eczema
Settings: Hospital outpatients
Intervention: Combination of oral and topical CHM
Comparison: Same oral CHM
Outcomes Illustrative comparative risk* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
CHM (oral) CHM (combination of
oral and topical)
Total effectiveness rate
(Analysis 3.1)
Clinician’s rating
Follow up: 4 to 24 weeks
Moderate RR 1.13
(0.78 to 1.63)
20
(1 study)
⊕⊕©©
low¹,²
1 additional study did not
report this outcome. A
higher total effectiveness
rate indicates improve-
ment of the condition
80 per 100 90 per 100
(62 to 100)
Overall severity score (
Analysis 3.5)
Clinician’s rating. Scale
from 0 to 103
Follow up: 4 to 24 weeks
The mean overall sever-
ity score in the control
groups was
21.02 scores
The mean overall sever-
ity score in the inter-
vention groups was 3.43
lower (7.01 lower to 0.15
higher)
20
(1 study)
⊕⊕©©
low¹,²
Lower score indicates im-
provement of the condi-
tion. 1 additional study
was a within-patient de-
sign; data were analysed
separately
QoL (Analysis 3.6)
Participant’s rating. Scale
from 0 to 30
Follow up: 4 to 24 weeks
The mean QoL in the con-
trol groups was
5.8 scores
The mean QoL in the in-
tervention groups was 0.
9 higher (2.89 lower to 4.
69 higher)
20
(1 study)
⊕⊕©©
low¹,²
Lower score indicates
better quality of life. 1 ad-
ditional study did not re-
port this outcome
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Adverse events (Analysis
3.7)
Participant’s report
Follow up: 4 to 12 weeks
Moderate RR 1
(0.07 to 13.87)
20
(1 study)
⊕⊕©©
low¹,²
1 additional study was a
within-patient study, and
data on adverse events
were analysed separately
in this review
10 per 100 10 per 100
(1 to 100)
Itching VAS (Analysis
3.3)
Participant’s rating. Scale
from 0 to 10
Follow up: 1 to 2 weeks
The mean itching VAS in
the control groups was
5.76 scores
The mean itching VAS
in the intervention groups
was 1.05 lower (1.75 to
0.35 lower)
22
(1 study)
⊕⊕©©
low¹,²,³
Lower score indicates im-
provement of the condi-
tion. This was a within-
patient study
Skin lesion score (
Analysis 3.4)
Clinician’s rating. Scale
from 0 to 24
Follow up: 1 to 2 weeks
The mean skin lesion
score in the control
groups was
9.05 scores
The mean skin lesion
score in the intervention
groups was 1.59 lower
(2.92 to 0.26 lower)
22
(1 study)
⊕⊕©©
low¹,²,³
Lower score indicates im-
provement of the condi-
tion. This was a within-
patient study
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate
¹Unclear risk of bias in allocation concealment and high risk of bias in blinding of participants and personnel.
²Total number of events was less than 300.
³High risk of bias in incomplete outcome data.
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D I S C U S S I O N
Summary of main results
This review is an updated version with a new team of authors and
a newly published protocol. We did not include the four studies
that were included in the previous version of this review as they all
investigated a Chinese herbal medicine (CHM) product, Zema-
phyte, which themanufacturer withdrew from themarket in 2004
(Zhang 2004). And we think it would skew the significance of sys-
tematically produced evidence-based medicine if we incorporated
data that is not linked to current clinical practice or research.
This review included 28 studies, with a total of 2306 participants.
Chinese herbal medicines and comparators were taken orally or
applied topically by children and adults with eczema. Four studies
compared CHM to placebo. Two studies compared a combination
of oral and topical CHM to the same oral CHM formula alone,
and 22 studies and 1 arm of theChao 2003 study compared CHM
to Western medications.
We found evidence from one 12-week study of moderate to se-
vere eczema, comparing an oral CHM to placebo, of a statistically
significant difference between the 2 groups with respect to QoL
score (MD -2.50, 95% CI -4.77 to -0.23; see Analysis 1.5) (Hon
2007). The mean QoL score in the CHM groups was 2.5 lower
than that in the placebo groups, which indicated that oral inges-
tion of CHM could improve QoL. Although the overall effect in
the outcomes of ’total effectiveness rate’, ’severity of itching score’,
and ’overall severity score’ showed a statistically significant differ-
ence between the groups in favour of CHM, these findings were
inconclusive because of the high risk of bias with regard to blind-
ing of participants and research personnel, incomplete outcomes,
or other unclear risk of bias that existed across these four studies
(see Summary of findings for the main comparison). Unexplained
high heterogeneity (I² statistic = 87%; see Figure 4) among the 4
studies in the outcome measured by ’overall severity score’ further
weakened the strength of the positive estimates.
The majority of the included studies (22 studies and 1 arm of the
Chao 2003 study) used conventional medicines (Western med-
ications) as comparators, which included oral ingestion of anti-
histamine tablets; topical use of corticosteroid cream; and other
agents, such as antifungals, antiseptics, or emollients. Twenty-one
studies expressed their primary outcome as ’total effectiveness rate’,
and all reported that effectiveness of CHM interventions was su-
perior to the comparators except the Chao 2003 and Chen 2011
studies, which used corticosteroid cream as the control interven-
tion. In addition to these two studies, our meta-analyses showed
no statistically significant difference between the CHM and con-
ventional medicine groups observed in the studies of Gong 2010;
Huang 2010; Lang 2007; Tian 2005;Wang 2008; Xiao 2011; and
Zhang 2009, although the overall effects of the 21 included stud-
ies favoured the CHM groups (RR 1.43, 95% CI 1.27 to 1.61;
see Analysis 2.1).
The claim of positive effects with CHM intervention needs to be
interpreted with caution because of substantial heterogeneity (I²
statistic = 65%; see Figure 5) across the studies. The result from
a posthoc subgroup analysis (subgroup differences I² statistic =
74.4%) also confirmed there was unexplained heterogeneity. We
also found there was high risk of bias in the domains for blind-
ing of participants and research personnel and blinding of out-
come assessment, as well as other potential sources of bias (absence
of usage of published and validated scoring systems for outcome
measures) in this group of studies (see Summary of findings 2).
All included studies in this group were associated with several ma-
jor methodological weaknesses. For example, although all studies
used randomisation for grouping of participants, none of them
provided information of the procedure for allocation concealment
(see Figure 3). Inadequate randomisation could give rise to an in-
vestigator’s bias for grouping of participants, which consequently
affects the outcomes (Liu 2006).
Two studies reported a statistically significant difference in out-
comes of ’total effectiveness rate’ or ’severity of itching score mea-
sured by VAS’, respectively, and overall effects in the combination
of oral and topical CHM groups were always superior to the oral
CHM control groups (Lin 2010; Rao 2010).We did not pool data
from the two studies as the Lin 2010 study was a within-patient
study. The Lin 2010 study had a high risk of performance bias
and attrition bias. The Rao 2010 study had a high risk of bias in
the domain of blinding of the participants and research personnel,
and both studies had small sample sizes (a total of 42 participants
in 2 studies evaluated). Their claims that overall effects in CHM
groups were superior to the control groups were in doubt (see
Summary of findings 3).
It is worth pointing out that nearly half of the included studies
did not use published and validated scoring systems for measuring
the severity of the condition. Some studies used the scoring sys-
tem but did not provide continuous data for the scores. The ab-
sence of these data made quantifiable data analysis impossible and
downgraded the credibility of the results (Eichenfield 2003). We
were unable to further estimate if CHM has potential for short-
term or long-term improvement of eczema because of limited data
provided by the included studies.
Chinese herbal medicines’ possible association with hepatotoxi-
city (liver toxicity) was discussed when 11 cases of liver damage
following oral ingestion of some raw Chinese herbal mixtures for
skin conditions were reported in the UK between 1991 to 1993
(Perharic 1995). The reporters indicated that the mechanism of
toxicity was not clear. The adverse effects of those CHMmixtures
seemed to not be dose-related and were probably idiosyncratic.
The safety issue of oral ingestion of CHM has been a concern of
healthcare professionals and the public (Chitturi 2000). In this
review, we evaluated both beneficial effects and adverse effects of
interventions from the included studies. We found only a quarter
(7/28) of the included studies had monitored the liver and renal
function of the participants during the period of the trial (Cheng
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2010; Hon 2007; Luo 2010; Rao 2010; Xiao 2008; Xiao 2011;
Zou 2011).
With regard to adverse events including liver or kidney dysfunc-
tion, there was one withdrawal due to aggravation of the condition
(a severe adverse event) after using CHM (Lin 2010), no severe
adverse events were reported in 23 studies, and the remaining 4
studies did not report adverse events (Jin 2007; Xue 2011; Zhang
2009; Zhang 2011). Twenty-four studies reported minor adverse
events; 2 studies observed transient elevation of aspartate amino-
transferase or alanine transaminase in the trial participants (Cheng
2010; Rao 2010). Apart from theHon 2007 study, which recorded
a statistically significant difference in minor adverse events with a
higher incidence in the CHM group, pooled data from other in-
cluded studies demonstrated significantly lessminor adverse events
with CHM interventions than their comparators. Nevertheless,
the quality of evidence was low.
There were eight included studies (Cheng 2010; Gong 2010;Hon
2007; Ma 2010; Sun 2009; Xue 2011; Yang 2007; Yu 1999) that
were funded by governments. In addition, 75% of the included
studies, all conducted inmainland China, reported identical num-
bers of participants randomised and analysed. These studies re-
ported no incomplete outcome data. We were not able to find
out the underlying reasons for such unusually high compliance in
RCTs.
Overall completeness and applicability of
evidence
We included studies with CHM interventions administered orally
or applied topically, or a combination of both, for children or
adults diagnosed with eczema. All 28 included studies specifi-
cally focused on management of eczema with CHM. Based on
a Chinese medicine description, the selected Chinese herbs in
the included studies were under categories of “exterior-releasing”,
“heat-clearing”, “purgative”, “wind-damp-dispelling”, “damp-re-
solving”, “damp-draining”, “interior-warming”, “Qi-regulating”,
“digestant”, “haemostatic”, “blood-activating and stasis-resolv-
ing”, “liver-pacifying wind-extinguishing”, “resuscitative”, “toni-
fying”, “astringent”, and “externally applied and miscellaneous”
(Li 2008). The top seven most commonly used herbs were Gan-
cao (Radix glycyrrhizae) (16 studies), Cangzhu (Rhizoma atracty-
lodis) (13 studies), Danggui (Radix angelicae sinensis) (11 stud-
ies), Baizhu (Rhizoma atractylodis macrocephalae) (9 studies), Baix-
ianpi (Cortex dictamni) (9 studies), Fuling (Poria) (9 studies), and
Shengdihuang (Radix rehmanniae) (9 studies). We also included
studies in which the CHM formulae were modified based on Chi-
nese medicine syndrome differentiation, as well as the studies that
only recruited people with eczemawho had a prespecified Chinese
medicine syndrome.Many of the included studies were conducted
in Chinese medicine teaching hospitals or general medical teach-
ing hospitals, which are expected to have standardised facilities and
qualified personnel and represent the standard of clinical practice
of the profession (MEPRC 1992). The results have reflected the
up-to-date management of eczema with CHM. The findings of
this review could provide a crucial reference for current evidence-
based Chinese medical practice and research.
Quality of the evidence
We used the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) system, recommended by the
Cochrane Handbook for Systematic Reviews of Interventions, to as-
sess the level of evidence on outcome measures reported by the
included studies (Schünemann 2011). Overall, the quality of the
included studies was poor except the Hon 2007 study where the
level of quality of the evidence was ’moderate’ in the outcome
measured by QoL. The majority of the included studies showed
unclear risk of bias for allocation concealment and high risk of bias
due to lack of blinding; thus, we had to downgrade the strength
of evidence of those studies into ’low level’ because of serious lim-
itations in their design and implementation (absence of alloca-
tion concealment and blinding). The 2306 participants within
the 28 included studies were diverse, with their ages ranging from
newborn babies to 65 years, and most of the studies had mixed
children with adults. There were heterogeneous Chinese herbs or
formulae with regard to the ingredients, dosage, and administra-
tion in the included studies. This contributed to a high level of
inconsistency of the outcomes across the studies although such
underlying sources of heterogeneity have not been confirmed by
statistical analyses because of insufficiency of data.
Potential biases in the review process
The randomised controlled trial is a gold standard to test efficacy
of an intervention for a defined condition within a population
(Kane 2004). It is debatable however whether results from RCTs
can really reflect the intrinsic effect obtained from an individu-
alised treatment, which is one of the essential features of Chi-
nese medicine practice. For this reason, we scrupulously aimed
to include studies using individualised treatments or studies only
recruiting people with eczema who had a specific type of Chi-
nese medicine syndrome as far as there was an appropriate control
group, i.e. with balanced numbers of randomised participants, in
the study. We further performed subgroup analysis in those in-
cluded studies with individualised treatment. We tried our best to
search for any studies that matched the inclusion criteria, but it
could still be possible that we overlooked some papers, in partic-
ular those published in Chinese. This is because we had limited
access to the printed Chinese medical journals that were not cov-
ered by the Chinese databases we had searched.We were unable to
rule out the possibility of potential language bias in this review as
Chinese medicine is also popularly used in other Asian countries,
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such as Japan, Vietnam, and Korea. We were not able to search
databases developed by these countries.
The funnel plot in Figure 6 andEgger test did not show statistically
asymmetrical distributions among those 15 studies that compared
the effects of CHM andWestern medications. However, we could
not exclude reporting bias including publication bias in those 15
studies because of the relatively low power of the Egger test (Sterne
2011).
Agreements and disagreements with other
studies or reviews
The first Cochrane systematic review of CHM for eczema was
published in 2004 (Zhang 2004); it included only 4 studies with
oral ingestion of a CHM product, which is no longer available
on the market. We did not include these studies in this updated
review. Poor trial quality and “small study effect” were found across
the included studies in both the version published in 2004 and
this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We could not find conclusive evidence that oral ingestion of
other Chinese herbs or Chinese herbal formulae used in the in-
cluded studies could improve the condition. Furthermore, we
could not find convincing evidence that topical application of
CHM, whether used alone or in conjunction with oral ingestion
of Chinese herbal formulae, could reduce the severity of eczema in
children or adults. Even though in the included studies there were
statistically significant differences in the outcome measures where
CHM treatment groups were compared to those in the control
groups, because of a low strength of evidence and high risk of bias,
these claims cannot be regarded as reliable.
Implications for research
There is evidence that CHM has been increasingly used for the
management of eczema since the publication of the first Cochrane
systematic review in this area, and many included studies were
government-funded research projects (almost one third of the in-
cluded studies received funding). The following are our sugges-
tions for conducting a randomised controlled trial of CHM for
eczema in the future.
• Recruitment of participants with similar ages or severity of
their condition is needed to minimise heterogeneous outcomes
within the study. Stratified randomisation is recommended if the
study recruits both children and adults.
• Sample size in the intervention group and control group
should be balanced. Characteristics of participants in the two
groups should be comparable. Methods for randomisation must
be clearly described on the published paper.
• Blinding should always be used, because in most cases,
outcome measures for eczema are subjective. An open-label
design study could lead to risk of bias for outcome assessment.
• Application of the intervention should be used alone, i.e.
oral ingestion or topical application with appropriate comparator
unless efficacy of the oral ingestion or topical application of the
intervention has been confirmed respectively. Quality control,
including appropriate toxicology studies and quality assurance of
Chinese herbs to be investigated, should be performed prior to
the conduct of clinical trials as contamination of any non-CHM
components detracts from the high standards and tradition of
Chinese medicine.
• Assessment of effectiveness of the intervention should rely
on data from both objective and subjective outcome measures
assessed at baseline and at the end point of the trial. Using
published and validated scoring systems, such as EASI, SASSAD,
or SCORAD as a primary outcome measure may help to achieve
this, and continuous data should always be reported or provided
upon request.
• Adverse events should be adequately reported. Liver and
renal function tests should be used as one of the safety
parameters in a randomised controlled trial.
In summary, well-designed, adequately powered, randomised
placebo-controlled clinical trials are required to evaluate the effi-
cacy and safety of CHM for managing eczema.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cao 2009
Methods This was a randomised, non-blinded, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of a university
teaching hospital in Nanjing, China
2. Age: from 2 to 16 years of age
3. Sex (men/women): 32/24
4. Number of participants randomised: 56
5. T/C: 32/24
Interventions I. Treatment group
1. Zhuling Jianpi Huashi decoction with individualised modifications
1.1 Ingredients and dosage
• Fuling (Poria) 6 g
• Cangzhu (Rhizoma atractylodis) 6 g
• Baizhu (Rhizoma atractylodis macrocephalae) 6 g
• Chenpi (Pericarpium citri reticulatae) 3 g
• Zexie (Rhizoma alismatis) 6 g
• Baixianpi (Cortex dictamni) 6 g
• Maiya (Fructus hordei germinatus) 15 g
• Huashi (Talcum) 6 g
• Gancao(Radix glycyrrhizae) 4 g
1.2 Administration
• 1 package per day, drink the decoction twice daily
1.3 Duration of treatment
• 1 to 4 weeks
1.4 Follow up
• Did not state
II. Control group
a. oral ingestion
2. Cetirizine hydrochloride drops
2.1 Ingredients and dosage
• 0.5 ml for 2- to 6-year-old participants, 1.0 ml for 7- to 16-year-old participants
2.2 Administration
• Once daily
2.3 Duration of treatment
• 1 to 4 weeks
2.4 Follow up
• Did not state
- CHM lotion and cream (external use) were applied in both groups
Outcomes 1. Percentage of reduction of total SASSAD score
2. Effectiveness rate
3. Adverse events
All assessmentswere conducted at baseline, week 4, and at the endof the 8-week treatment
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period, respectively
Notes 1. The trial investigator claimed they included only those who were diagnosed with
AD and identified as “spleen deficiency with accumulation of dampness” in Chinese
medicine
2. Effectiveness rate = ((pre-treatment score of SASSAD - post-treatment score of SAS-
SAD)/pre-treatment score of SASSAD) * 100%
3. The treatment intervention used was the same as the 1 orally used in Zhang 2005
4. The SASSAD scores were expressed as ’numbers ±’ without labels, and we assumed
they meant mean ± SD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...used SPSS software for randomi-
sation...”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “...no blinding was required”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “...no blinding was required”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Those who were not compliant
with the treatment were excluded”
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SASSAD
Chao 2003
Methods This was a randomised, controlled, 4-arm parallel clinical trial
Participants 1. Setting: The trial recruited participants from the outpatient dermatology department
of hospitals in Qingdao, China
2. Age: from 1 to 38 months
3. Sex (men/women): 58/62
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4. Number of participants randomised: 120
5. T/T/C/C: 30/30/30/30
Interventions I. Treatment group (A) (1st arm)
1.Huangbai ZicaoDiyu cream (5%).Data from this groupwere not used for comparison
in this review as the trial investigator reported that the total effectiveness rate of the 2nd
arm (group B) was superior to that in the 1st arm (group A)
1.1 Ingredients and dosage
• Huangbai (Cortex phellodendri) 50 g
• Zicao (Radix arnebiae) 50 g
• Diyu (Radix sanguisorbae) 100 g
1.2 Administration
• Twice daily topically
1.3 Duration of treatment
• 2 to 3 weeks
1.4 Follow up
• Did not state
II. Treatment group (B) (2nd arm)
• This group used Huangbai Zicao Diyu cream 10%
III. Control group (C) (3rd arm)
2. Compound Econazole nitrate cream (Pevisone)
2.1 Ingredients and dosage
• Econazole nitrate and triamcinolone acetonide (dosage not provided)
2.2 Administration
1. Twice daily topically
2.3 Duration of treatment
• 2 to 3 weeks
2.4 Follow up
• Did not state
IV. Control group (D) (4th arm)
2. Placebo
2.1 Ingredients and dosage
• Petroleum jelly (Vaseline) (dosage not provided)
2.2 Administration
• Twice daily topically
2.3 Duration of treatment
• 2 to 3 weeks
2.4 Follow up
• Did not state
- CHM lotion (external use) for washing the skin lesion was applied in all groups
Outcomes 1. Skin lesion score. The trial investigators developed the scoring system. The trial
investigators expressed data as “mean ±”, and we assumed the “±” was SD
2. Effectiveness rate
3. Adverse events
4. Bacteriologic eradication rate on the skin lesions
All assessments were conducted at baseline, weeks 1 and 2, and at the end of the 3-week
treatment period, respectively
39Chinese herbal medicine for atopic eczema (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance of the treat-
ment intervention and placebo were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Those who did not use the creams
on time, or did not turn up for re-assess-
ment or drop out were excluded”
Quote: “We recruited 132 participants and
excluded 12 patients due to non compli-
ance with the trial”
Comment: The trial did not use ITT anal-
ysis
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Unclear risk The trial used a scoring system developed
by the trial investigators
Chen 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of a Chinese
medicine hospital in Changshu, China
2. Age: from 58 days to 2 years of age
3. Sex (men/women): 59/41
4. Number of participants randomised: 100
5. T/C: 50/50
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Interventions I. Treatment group
1. Huanglian Qingdai ointment
1.1 Ingredients and dosage
• Huanglian powder (Rhizoma coptidis) 0.6 g
• Qingdai (Indigo naturalis) 0.3 g
• Huangbai powder (Cortex phellodendri) 0.3 g
• Mingfan (Alum) 0.3 g
• Bingpian (Borneolum syntheticum) (dosage not provided)
• Niaoshuang (Urea cream) 40 g
1.2 Administration
• Topical use 2 to 3 times daily
1.3 Duration of treatment
• 2 weeks
1.4 Follow up
• Did not state
II. Control group
2. Mometasone furoate cream
2.1 Ingredients and dosage
• Mometasone furoate cream 5 g/tube
2.2 Administration
• Topical use once daily
2.3 Duration of treatment
• 2 weeks
2.4 Follow up
• Did not state
Outcomes 1. Severity of itching score (measured by participant-rated score, scale 0 to 3)
2. Skin lesion (erythema and papule) score (measured by clinician-rated score). The trial
investigators developed the scoring system
3. Skin lesion area score (measured by clinician-rated score). The trial investigators
developed the scoring system
4. Effectiveness rate (the trial investigator developed the rating)
5. Adverse events
All assessments were conducted at baseline and at the end of the 2-week treatment period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
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ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
The numbers of participants randomised
and analysed were equivalent. It seems that
there were no withdrawals/dropouts in this
study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Unclear risk The trial used a scoring system developed
by the trial investigators
Cheng 2010
Methods This was a randomised, double-blind, placebo-controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from the department of Integration of Tradi-
tional Chinese and Western Medicine, in a university hospital in Taiwan
2. Age: from 8 to 23 years of age
3. Sex (men/women): 37/34
4. Number of participants randomised: 71
5. T/C: 47/24
Interventions I. Treatment group
1. Xiao-Feng-San (XFS)
1.1 Ingredients and dosage
• Fangfeng(Radix saposhnikovia) 2.5 mg
• Jingjie(Herba schizonepetae) 2.5 mg
• Danggui (Radix angelicae sinensis) 2.5 mg
• Shengdihuang (Radix rehmanniae) 2.5 mg
• Kushen(Radix sophorae flavescentis) 2.5 mg
• Cangzhu(Rhizoma atractylodis) 2.5 mg
• Chantui(Periostracum cicdae) 2.5 mg
• Yamazi(Linum usitatissimum) 2.5 mg
• Zhimu(Rhizoma anemarrhenae) 2.5 mg
• Shigao(Gypsum fibrosum) 2.5 mg
• Chuanmutong (Caulis clematidis armandii) 1.25 mg
• Gancao(Radix glycyrrhizae) 1.25 mg
• Niubangzi(Fructus arctii) 2.5 mg
1.2 Administration
• 3 times daily orally, 1 sachet of granules for 3 to 7 year-olds, 2 sachets for 8 to 12
year-olds, and 3 sachets for those aged 13 and over. There were 3 grams of XFS
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concentrated particles in each sachet
1.3 Duration of treatment
• 8 weeks
1.4 Follow up
• 4 weeks after the 8-week treatment period
II. Control group
2. Placebo
2.1 Ingredients and dosage
• Placebo was made of caramel, lactose, and starch - at a ratio of 2:1:1 - and put
into identical-appearing 3 g packs. The placebo mixture has no known benefit in
atopic dermatitis but has a similar appearance and taste to the active treatment
2.2 Administration
• Same as at 1.2
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• 4 weeks after the 8-week treatment period
Outcomes 1. Improvement of clinical lesion score from baseline (the sum of erythema score and
surface damage score measured by clinician-rated score)
2. Improvement of itching relief score from baseline (measured by participant-rated
score)
3. Improvement of sleep score from baseline (measured by participant-rated score)
4. Adverse events
5. Full blood count, serum bilirubin, aspartate aminotransferase, alkaline phosphatase,
albumin, urea and electrolytes, creatinine, calcium, phosphate, glucose, creatine phos-
phokinase and immunologic markers (IgE, eosinophil count, eosinophil cationic pro-
tein, IL-5, IL-13)
All assessments were conducted at baseline and weeks 4, 8, and 12 of the trial
Notes 1. Outcomes 1 to 3 were expressed as least-squares means ± SE at end points
2. There was a total of 15 withdrawals/dropouts. 69 participants (T/C: 46/23) were
included in the ITT analysis
3. The final number of participants completing the entire trial was 56 (T/C: 35/21)
4. Ingredients of the treatment intervention were also used by Luo 2010
5. The trial was supported by the Department of Health, Committee on Chinese
Medicine and Pharmacy, Taiwan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients were randomized
at a ratio of 2:1 to receive XFS or placebo
for an 8-week treatment period”
Allocation concealment (selection bias) Low risk Quote: “The computer generated ran-
domisation list was drawn up by an inde-
pendent statistician and placed in an enve-
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lope until the study was completed”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both participants and evaluating
physicians were unaware [of ] the interven-
tions used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Both participants and evaluating
physicians were unaware [of ] the interven-
tions used”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data and ITT analysis
were addressed
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Unclear risk Quote: “...using a standardised scoring sys-
tem”
Comment: We found no evidence that the
scoring system had been validated
Gong 2010
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient and inpatient department
of a Chinese medicine hospital in Changsha, China
2. Age: from 16 to 65 years of age
3. Sex (men/women): 31/25
4. Number of participants randomised: 56
5. T/C: 28/28
Interventions I. Treatment group
1. Liangxue Xiaofeng decoction
1.1 Ingredients and dosage
• Fangfeng(Radix saposhnikovia) 10 g
• Jingjie(Herba schizonepetae) 10 g
• Danggui (Radix angelicae sinensis) 10 g
• Shengdihuang (Radix rehmanniae) 15 g
• Kushen(Radix sophorae flavescentis) 10 g
• Cangzhu(Rhizoma atractylodis) 6 g
• Chantui(Periostracum cicdae) 6 g
• Zhimu(Rhizoma anemarrhenae) 10 g
• Gancao(Radix glycyrrhizae) 5 g
• Niubangzi(Fructus arctii) 10 g
• Zicao (Radix arnebiae)10 g
• Chishao (Radix paeoniae rubra) 10 g
• Mudanpi (Cortex moutan) 10 g
1.2 Administration
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• 1 pack of herbs cooked with water and the decoction drank twice daily
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• 12 weeks after the 4-week treatment period
II. Control group
2. Desloratadine tablet
2.1 Ingredients and dosage
• Desloratadine 5 mg
2.2 Administration
• Once daily, oral ingestion
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• 12 weeks after 4-week treatment period
- CHM lotion (external use) for washing the skin lesion was applied 3 times daily in
both groups
Outcomes 1. SCORAD score
2. Effectiveness rate
3. Adverse events
All assessments were conducted at baseline, at the end of the 4-week treatment period,
and 12 weeks after the 4-week treatment period
Notes The trial was funded by the Department of Science and Technology, Hunan Province,
China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...random number table was used
for stratified randomisation”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
The numbers of participants randomised
and analysed were equivalent. It seems that
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there were no withdrawals/dropouts in this
study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Hon 2007
Methods This was a randomised, double-blind placebo-controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from the paediatric dermatology outpatient
of a university teaching hospital in Hong Kong, China
2. Age: from 5 to 21 years of age
3. Sex (men/women): 46/39
4. Number of participants randomised: 85
5. T/C: 42/43
Interventions I. Treatment group
1. TCHM capsules
1.1 Ingredients and dosage
• Jinyinhua (Flos lonicerae) 2 g
• Bohe (Herba menthae) 1 g
• Mudanpi (Cortex moutan) 2 g
• Cangzhu (Rhizoma atractylodis) 2 g
• Huangbai (Cortex phellodendri) 2 g
• (a total 9 g of raw herbs)
1.2 Administration
• 3 capsules twice daily
1.3 Duration of treatment
• 12 weeks
1.4 Follow up
• 4 weeks after the 12-week treatment period
II. Control group
2. Placebo
2.1 Ingredients and dosage
• Capsule shell, corn starch (pharmaceutical grade), and caramel (food grade)
2.2 Administration
• 3 capsules twice daily
2.3 Duration of treatment
• 12 weeks
2.4 Follow up
• 4 weeks after the 12-week treatment period
Outcomes 1. SCORAD score
2. CDLQI score
3. Adverse events
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4. Record of the usage of trial medications and primary Western medications
All assessments were conducted at baseline, every 4 weeks during the trial period, and at
the end of the 12-week course (visit 4)
5. Complete blood counts; eosinophil counts; total IgE levels; liver and renal function
were obtained before treatment (visit 1) and at the end of the 12-week course (visit 4)
Notes 1. There were 2 non-compliant participants in the control group
2. The trial was reported again in February 2011
3. The trial was supported by the Health and Health Services Research Fund, Food and
Health Bureau, Hong Kong SAR Government
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The Institute of ChineseMedicine
(ICM) of the Chinese University of Hong
Kong allocated TCHM or placebo treat-
ment by using a computer generated ran-
domization code”
Allocation concealment (selection bias) Low risk Quote: “The investigators were not allowed
to break the code for any patient until the
trial was completed”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The trial medications were sup-
plied in containers labelled with the ran-
domisation codes. The drugs were allo-
cated to patients in strict numerical se-
quence. TCHMandplacebowere provided
in matching capsules”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Statistical analysis of the clinical
and laboratory data was performed inde-
pendently by a statistician not involved in
the clinical trial”
Quote: “...counting and weighing of un-
used trial medications and primary medi-
cations were performed by the research as-
sistant and such information was blinded
from the principal investigator”
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis was performed
Selective reporting (reporting bias) Unclear risk There was insufficient information
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Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Huang 2010
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from the a hospital in Mianyang, China
2. Age: from 3 months to 22 years of age
3. Sex (men/women): 96/99
4. Number of participants randomised: 195
5. T/C: 98/97
Interventions I. Treatment group
1. Chushi Zhiyang ointment (a CHM product manufactured by a pharmaceutical com-
pany)
1.1 Ingredients and dosage
• Baixianpi (Cortex dictamni)
• Shechuangzi (Fructus cnidii)
• Huanglian (Rhizoma coptidis)
• Huangbai (Cortex phellodendri)
• Kushen (Radix sophorae flavescentis)
• Huzhang (Rhizoma polygoni cuspidati)
• Zihuadiding (Herba violae)
• Bianxu (Herba polygoni avicularis)
• Yinchen (Herba artemisiae scopariae)
• Cangzhu (Rhizoma atractylodis)
• Huajiao (Pericarpium zanthoxyli)
• Bingpian (Borneolum syntheticum), etc
• Did not provide dosage of the ingredients
1.2 Administration
• 3 times daily, topically
1.3 Duration of treatment
• 2 weeks
1.4 Follow up
• 12 weeks after 2-week treatment period
II. Control group
2. Clobetasol propionate ointment
2.1 Ingredients and dosage
• Clobetasol propionate (dosage not provided)
2.2 Administration
• 3 times daily, topically
2.3 Duration of treatment
• 2 weeks
2.4 Follow up
• 12 weeks after 2-week treatment period
- Oral ingestion of phenergan syrup and moist dressing with 3% boric acid solution and
infrared rays therapy for acute and subacute cases in both groups
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Outcomes 1. EASI score
2. Effectiveness rate
3. Adverse events (asessments were conducted at baseline, every week during the trial
period, respectively, and follow-up 3 months after the 2-week treatment)
4. Full blood counts, liver and renal function tests
Conducted after a 2-week treatment period
Notes The treatment intervention Chushi Zhiyang ointment was also used in Wang 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...random number table was used”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
The numbers of participants randomised
and analysed were equivalent. It seems that
there were no withdrawals/dropouts in this
study
Selective reporting (reporting bias) High risk Quote: “...full blood counts, liver and renal
function testswere performed after 2-weeks
treatment”
Comment: The proposed outcomes were
not reported
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used EASI
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Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine hospital in Shenzhen, China
2. Age: from 10 to 52 years of age
3. Sex (men/women): 40/22
4. Number of participants randomised: 62
5. T/C: 32/30
Interventions I. Treatment group
1. Jianpi Zhiyang granules
1.1 Ingredients and dosage
• Huangqi (Radix astragali)
• Baizhu (Rhizoma atractylodis macrocephalae)
• Danggui (Radix angelicae sinensis)
• Heshouwu (Radix polygoni)
• Shengdihuang (Radix rehmanniae)
• Baishao (Radix paeoniae alba)
• Chuangxiong (Rhizoma chuanxiong)
• Fangfeng(Radix saposhnikovia)
• Jingjie(Herba schizonepetae)
• Baijili (Fructus tribuli terrestris)
• Gouteng (Ramulus uncariae cum uncis)
• Gancao(Radix glycyrrhizae)
• Did not provide dosage of the ingredients
1.2 Administration
• 10 g 3 times daily, oral ingestion
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
II. Control group
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg/tablet
2.2 Administration
• 1 tablet daily, oral ingestion
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
Outcomes 1. SCORAD score
2. Severity of itching score (measured by patient-rated VAS, scale 0 to 10)
3. Serum IgE level and eosinophil count
All assessments were conducted at baseline and at the end of the 4-week treatment period
Notes 1. The trial did not report adverse events
2. The treatment intervention was the same as that orally ingested in the Yang 2007
study
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Those who did not completed the
trial were excluded”
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Lang 2007
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from the dermatology department of aChinese
medicine hospital in Beijing, China
2. Age: from 3 to 34 years of age
3. Sex (men/women): 31/33 plus 8 dropouts without statement of gender
4. Number of participants randomised: 72
5. T/C: 36/36
Interventions I. Treatment group
a. Oral ingestion
1. Shengui decoction
1.1 Ingredients and dosage
• Danggui (Radix angelicae sinensis) 10 g
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• Fuling (Poria) 10 g
• Xuanshen (Radix scrophulariae) 10 g
• Shengdihuang (Radix rehmanniae) 10 g
• Shudihuang (Radix rehmanniae preparata) 10 g
• Shouwuteng (Caulis polygoni) 15 g
• Baixianpi (Cortex dictamni) 15 g
• Baijili (Fructus tribuli terrestris) 8 g
1.2 Administration
• 50 ml for children or under 30 kg body weight, and 100 ml for adults or body
weight over 30 kg twice daily, oral ingestion
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
b. Topical application
1. Shidu ointment
1.1 Ingredients and dosage
• Qingdai (Indigo naturalis)
• Huangbai (Cortex phellodendri)
• Did not provide dosage
1.2 Administration
• Once daily topically
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
II. Control group
a. Oral ingestion
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine: body weight < 30 kg = 5 mg, body weight > 30 kg = 10 mg
2.2 Administration
• Once daily orally
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
b. Topical application
2. Hydrocortisone cream
2.1 Ingredients and dosage
• 1% Hydrocortisone cream
2.2 Administration
• Once daily topically
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
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Outcomes 1. EASI score
2. Severity of itching score (measured by participant-rated score, scale 0 to 3)
3. Effectiveness rate
4. Adverse events
All measurements were performed at baseline and at the end of the 4-week treatment
period
Notes The final number of participants evaluated was 64 (T/C: 33/31)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...random number table was used”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk There were 8 dropouts/withdrawals (3 in
the treatment group and 5 in the control
group). The investigators did not report
reasons for dropouts/withdrawals, and ITT
analysis was not used
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used EASI
Lin 2010
Methods This was a randomised, controlled, within-patient trial
Participants 1. Setting: The trial recruited participants from the dermatology department of aChinese
medicine teaching hospital in Guangzhou, China
2. Age: from 11 months to 27 years of age
3. Sex (men/women): 13/10
4. Number of participants randomised: 23
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Interventions I. Treatment group
1. Runfu Xiaoyan lotion
1.1 Ingredients and dosage
• Jinyinhua (Flos lonicerae) 10 g
• Bohe (Herba menthae) 5 g
• Huangjing (Rhizoma polygonati) 10 g
• Gancao (Radix glycyrrhizae) 3 g
1.2 Administration
• 2 to 3 times daily, washing or moist dressing externally
1.3 Duration of treatment
• 2 weeks
1.4 Follow up
• Did not state
II. Control group
2. No external CHM lotion was used
- Basic moisturising cream was used topically for both groups and oral ingestion of
Qingxin Peitu decoction for moderate and severe cases
Outcomes 1. Skin lesion score (measured by clinician-rated score)
2. Severity of itching score (measured by participant-rated VAS, scale 0 to 10)
3. SCORAD
4. Adverse events
All assessmentswere conducted at baseline, week 1, and at the endof the 2-week treatment
period
Notes 1. This was a within-patient trial. CHM was topically used on a randomised selected
arm or leg of the participant for comparison with the other non-treatment site of the
same participant
2. There was 1 dropout due to exacerbation of the condition after using the intervention.
The final number of participants evaluated was 22
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...computer generated random
number table was used for selection of the
involved site of the patients”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: It is unlikely that a blinding
method was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
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Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Five cases did not come back for
assessment but last observation carried for-
ward (LOCF) was performed”
Comment: There was another 1 dropout,
but ITT analysis was not used
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Liu 2005
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of a Chinese
medicine teaching hospital in Changsha and a specialty outpatient department of a
teaching hospital in Hong Kong, China
2. Age: from 3 months to 42 years of age
3. Sex (men/women): 98/86
4. Number of randomised: 184
5. T/C: 92/92
Interventions I. Treatment group
a. Oral ingestion
1. Cangyi decoction with individualised modifications
1.1 Ingredients and dosage
• Cangzhu(Rhizoma atractylodis) 15 g
• Yiyiren (Semen coicis) 40 g
• Baixianpi (Cortex dictamni) 20 g
• Baijili (Fructus tribuli terrestris) 30 g
• Huangqin (Radix scutellariae) 15 g
• Difuzi (Fructus kochiae) 20 g
• Baimaogen (Rhizoma imperatae) 30 g
• Zicao (Radix arnebiae) 30 g
• Chishao (Radix paeoniae rubra) 9 g
• Rendongteng (Caulis lonicerae) 30 g
• Kushen(Radix sophorae flavescentis) 20 g
• Gancao(Radix glycyrrhizae) 6 g
1.2 Administration
• 1 package of herbs daily, oral ingestion
1.3 Duration of treatment
• 4 to 8 weeks
1.4 Follow up
• 24 weeks after the treatment period
b. Topical application
1. Qingdai ointment and Huangbai lotion
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1.1 Ingredients and dosage
• Did not state
1.2 Administration
• 3 times daily topically
1.3 Duration of treatment
• 4 to 8 weeks
1.4 Follow up
• 24 weeks after the treatment period
II. Control group
a. Oral ingestion
2. Terfenadine tablet
2.1 Ingredients and dosage
• Terfenadine
2.2 Administration
• 30 mg for children or 60 mg for adults twice daily, oral ingestion
2.3 Duration of treatment
• 4 to 8 weeks
2.4 Follow up
• 24 weeks after the treatment
b. Topical application
2. Dexamethasone cream
2.1 Ingredients and dosage
• 0.025% Dexamethasone cream
2.2 Administration
• 3 times daily
2.3 Duration of treatment
• 4 to 8 weeks
2.4 Follow up
• 24 weeks after the treatment period
Outcomes 1. Effectiveness rate
2. Adverse events
Assessments were measured at baseline and at the end of the 4- to 8-week treatment
period
3. Recurrence rate
Conducted at 24 weeks after the treatment period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
High risk The trial did not use a published validated
scoring system
Luo 2010
Methods This was a randomised, non-blind, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from the departments of Chinese medicine
and dermatology in a teaching hospital in Taiwan
2. Age: from 7 to 14 years of age
3. Sex (men/women): 36/26
4. Number of participants randomised: 62
5. T/C: 34/28
Interventions I. Treatment group
1. Xiao-Feng-San with individualised modifications
1.1 Ingredients and dosage
• Fangfeng(Radix saposhnikovia) 3 g
• Jingjie(Herba schizonepetae) 3 g
• Danggui (Radix angelicae sinensis) 3 g
• Shengdihuang (Radix rehmanniae) 3 g
• Kushen(Radix sophorae flavescentis) 3 g
• Cangzhu(Rhizoma atractylodis) 3 g
• Chantui(Periostracum cicdae) 3 g
• Humaren (Semen sesami nigrum) 3 g
• Zhimu(Rhizoma anemarrhenae) 3 g
• Shigao(Gypsum fibrosum) 3 g
• Niubangzi(Fructus arctii) 3 g
• Chuangmutong (Caulis clematidis armandii) 1.5 g
• Gancao(Radix glycyrrhizae) 1.5 g
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1.2 Administration
• 1 package of the herbs daily, oral ingestion
1.3 Duration of treatment
• 16 weeks
1.4 Follow up
• 12 weeks after the 4-week treatment period
II. Control group
2. Loratadine tablet and antihistamine tablet
2.1 Ingredients and dosage
• Loratadine: 5 mg for body weight < 30 kg, 10 mg for body weight > 30 kg
• Did not provide ingredient and dosage of antihistamine
2.2 Administration
• Once daily oral ingestion
2.3 Duration of treatment
• 16 weeks
2.4 Follow up
• 12 weeks after the 4-week treatment period
Outcomes 1. Percentage of reduction of total SASSAD score
2. Effectiveness rate
3. Adverse events
Assessments were conducted at baseline and weeks 4, 8, 14, and 16 of the treatment
period
4. Full counts of blood, routine tests of urine and stool
5. Electrocardiogram, liver and renal function tests
Assessment time points were not stated
Notes 1. The trial investigator claimed that they included only those who were diagnosed with
AD and identified as “spleen deficiency with accumulation of dampness” in acute stage
with wind, heat, or dampness in Chinese medicine
2. Effectiveness rate = ((pre-treatment score of SASSAD - post-treatment score of SAS-
SAD)/pre-treatment score of SASSAD) * 100%
3. Ingredients of the treatment intervention were also used by Cheng 2010
4. The SASSAD scores were expressed as ’numbers ±’ without labelled by the trial
investigators, and we assumed they were mean ± SD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...used SPSS software for randomi-
sation”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “No blinding was required”
58Chinese herbal medicine for atopic eczema (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Luo 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “No blinding was required”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SASSAD
Ma 2010
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient and inpatient department
of dermatology in a Chinese medicine teaching hospital in Beijing, China
2. Age: from 7 to 33 years of age
3. Sex (men/women): 42/40
4. Number of participants randomised: 82
5. T/C: 42/40
Interventions I. Treatment group
a. Oral ingestion
1. Jianpi Runfu decoction with individualised modifications
1.1 Ingredients and dosage
• Danggui (Radix angelicae sinensis) 10 g
• Fuling (Poria) 10 g
• Shengdihuang (Radix rehmanniae) 10 g
• Cangzhu(Rhizoma atractylodis) 10 g
• Baizhu (Rhizoma atractylodis macrocephalae) 10 g
• Chenpi (Pericarpium citri reticulatae) 10 g
• Dangshen (Radix salviae miltiorrhizae) 10 g
• Jixueteng (Radix et Caulis jixueteng) 10 g
• Chishao (Radix paeoniae rubra) 10 g
• Baishao (Radix paeoniae alba) 10 g
1.2 Administration
• 1 package, the decoction drank twice daily, half dosage for children under 14
years of age
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
b. Topical application
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1. Gancao oil
1.1 Ingredients and dosage
• Gancao(Radix glycyrrhizae)
• Did not provide dosage
1.2 Administration
• Twice daily topically
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
II. Control group
a. Oral ingestion
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine: 5 mg for children under 14 years of age, 10 mg for participants > 14
years of age
2.2 Administration
• Once daily, oral ingestion
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
b. Topical application
2. Butyl flufenamate cream
2.1 Ingredients and dosage
• Butyl flufenamate
• Did not provide dosage
2.2 Administration
• Twice daily topically
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
Outcomes 1. EASI score
2. Severity of itching score (measured by participant-rated VAS, scale 0 to 10)
3. Adverse events
All measurements were conducted at baseline and at the end of the 4-week treatment
period
Notes 1. The trial investigator claimed they included only those who were diagnosed with AD
and identified as “spleen deficiency with dryness of blood” in Chinese medicine
2. The trial was funded by the 51510 Science and technology project of Chinese
medicine, Beijing (“the 11th of five-year planning”) and Zhao Bingnan renown expert
research laboratory, passing on the heritage of Chinese medicine 3+3 project, Beijing,
China
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...random number table was used”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “...one in treatment group and
two in control group dropouts which were
treated as no effects”
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used EASI
Rao 2010
Methods This was a randomised, placebo-controlled, 3-arm parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine teaching hospital in Nanjing, China
2. Age: from 7 to 25 years of age
3. Sex (men/women): 20/10
4. Number of participants randomised: 30
5. T/C/C: 10/10/10
Interventions I. Treatment group
a. Oral ingestion
1. Qingxin Peitu decoction with individualised modifications
1.1 Ingredients and dosage
• Taizishen (Radix pseudostellariae)
• Lianqiao (Fructus forsythiae)
• Danzhuye (Herba lophatheri)
• Shanyao (Rhizoma dioscoreae), etc
• Did not provide other ingredients and dosage
1.2 Administration
• 1 package of the herbs per day, the decoction drank twice daily, 1 dosage for body
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weight < 40 kg, 2 dosages for body weight > 40 kg
1.3 Duration of treatment
• 12 weeks
1.4 Follow up
• 24 weeks after the 12-week treatment period
b. Topical application
1. Qingxin Peitu lotion
1.1 Ingredients and dosage
• Jinyinhua (Flos lonicerae)
• Gancao (Radix glycyrrhizae), etc
• Did not provide other ingredients and dosage
1.2 Administration
• Once or twice daily, washing or moist dressing
1.3 Duration of treatment
• 12 weeks
1.4 Follow up
• 24 weeks after the 12-week treatment period
II. Control group A
• Used the same oral ingestion intervention as that in the treatment group only
• No topical application of CHM was used
III. Control group B (Data of this group were not used for comparison in this
review)
a. Oral ingestion
2. Placebo plus cetirizine hydrochloride tablet
2.1 Ingredients and dosage
• Did provide ingredients of placebo
• Cetirizine 5 to 10 mg
2.2 Administration
• Once daily, oral ingestion
2.3 Duration of treatment
• 12 weeks
2.4 Follow up
• 24 weeks after the 12-week treatment period
b. Topical application
2. Mometasone furoate cream
2.1 Ingredients and dosage
• Mometasone furoate
• Did not provide dosage
2.2 Administration
• Once daily topically
2.3 Duration of treatment
• 12 weeks
2.4 Follow up
• 24 weeks after the 12-week treatment period
Outcomes 1. SCORAD score
2. Investigators’ Global Assessment score (IGA)
3. Effectiveness rate
Assessments were conducted at baseline, every 4 weeks during the trial period, at the end
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of the 12-week treatment period, and 24 weeks after the 12-week treatment period
4. Participant’s self experience
Assessment was conducted at baseline, every 2 weeks during the trial period, and at the
end of the 12-week treatment period
5. CDLQI or DLQI score
Assessment was conducted at baseline, at the end of the 12-week treatment period, and
24 weeks after the 12-week treatment period
6. Full counts of blood, routine tests of urine and stool
7. Electrocardiogram, liver and renal function
8. Adverse events
Assessments were conducted at baseline and at the end of the 12-week treatment period
Notes The interventions used in control group B were not comparable to other groups; thus,
the outcome of this group was not included for evaluation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...used SPSS17.0 software for ran-
domisation”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “...no blinding was required”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “...outcomes were evaluated by the
third party person”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
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Methods This was a randomised, double-blind, placebo-controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine teaching hospital in Guangzhou, China
2. Age: from 3 to 20 years of age
3. Sex (men/women): 12/13
4. Number of participants randomised: 25
5. T/C: 14/11
Interventions I. Treatment group
1. Jianpi Shenshi granules
1.1 Ingredients and dosage
• Dangshen (Radix codonopsis)
• Zexie (Rhizoma alismatis)
• Fuling (Poria)
• Yiyiren (Semen coicis)
• Baizhu (Rhizoma atractylodis macrocephalae)
• Dazao (Fructus jujubae)
• Shanyao (Rhizoma dioscoreae)
• Chenpi (Pericarpium citri reticulatae)
• Baibiandou (Semen lablab album)
• Jiegen (Radix platycodi)
• Did not provide dosage of the ingredients
1.2 Administration
• 6 grams for 3 to 11 year-olds, 12 grams for 12 to 20 year-olds, dissolved the
granules with boiling water, oral ingestion 3 times daily
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• 24 weeks after the 4-week treatment period
II. Control group
2. Placebo
2.1 Ingredients and dosage
• Did not provide ingredients and dosage
2.2 Administration
• 5 grams for 3 to 11 year-olds, 15 grams for 12 to 20 year-olds, dissolved the
granules with boiling water, oral ingestion 3 times daily
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• 24 weeks after the 4-week treatment period
- Both groups applied non-medicinal moisturising cream topically and oral ingestion of
cyproheptadine tablets for cases with severe itchiness
Outcomes 1. SCORAD score
2. Severity of itching score (measured by participant-rated score, scale unknown)
3. Sleeping disturbance rate
4. Skin lesion area
5. Severity of skin lesion
6. Effectiveness rate
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7. Adverse events
All assessments were conducted at baseline and at the end of the 4-week treatment period
8. Recurrence rate
Conducted at 24 weeks after the 4-week treatment period
Notes 1. The trial investigator claimed that they included only those who were diagnosed with
AD and identified as “spleen deficiency” in Chinese medicine
2. The trial was funded by Department of Science and Technology, Guangdong
Provience, China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “...double-blind controlled trial”
Comment:Nodetails of blindingwere pro-
vided, and the paper was published by only
1 author without acknowledgment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Tian 2005
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a hospital in Yingkou, China
2. Age: children (age not stated)
3. Sex (men/women): 71/29
4. Number of participants randomised: 100
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5. T/C: 58/42
Interventions I. Treatment group
a. Oral ingestion
1. Fuyang granules
1.1 Ingredients and dosage
• Cangerzi (Fructus xanthii)
• Difuzi (Fructus kochiae)
• Chuangxiong (Rhizoma chuanxiong)
• Honghua (Flos carthami)
• Baiying (Herba solani lyrati)
• Did not provide dosage of the ingredients
1.2 Administration
• Oral ingestion 2.25 to 3 g of the granules, twice daily
1.3 Duration of treatment
• 5 days
1.4 Follow up
• Did not state
b. Topical application
• Used the remaining solution of the oral ingestion intervention for external
application
II. Control group
a. Oral ingestion
2. Cyproheptadine tablet
2.1 Ingredients and dosage
• Cyproheptadine 0.25 mg
2.2 Administration
• 3 times daily oral ingestion
2.3 Duration of treatment
• 5 days
2.4 Follow up
• Did not state
b. Topical application
2. Sulphur cream
2.1 Ingredients and dosage
• 3% sulphur cream
2.2 Administration
• Applied the cream topically, did not state how often it was applied
2.3 Duration of treatment
• 5 days
2.4 Follow up
• Did not state
Outcomes 1. Effectiveness rate developed by the trial investigators
2. Adverse events
Assessments were measured at baseline and at the end of the 5-day treatment period
Notes -
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
High risk The trial did not use a published validated
scoring system
Wang 2008
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department in a teaching
hospital in Yichang, China
2. Age: from 12 days to 11 months
3. Sex (men/women): 22/43
4. Number of participants randomised: 65
5. T/C: 35/30
Interventions I. Treatment group
1. Chushi Zhiyang ointment (a CHM product manufactured by a pharmaceutical com-
pany)
1.1 Ingredients and dosage
• Baixianpi (Cortex dictamni)
• Shechuangzi (Fructus cnidii)
• Huanglian (Rhizoma coptidis)
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• Huangbai (Cortex phellodendri)
• Kushen (Radix sophorae flavescentis)
• Huzhang (Rhizoma polygoni cuspidati)
• Zihuadiding (Herba violae)
• Bianxu (Herba polygoni avicularis)
• Yinchen (Herba artemisiae scopariae)
• Cangzhu (Rhizoma atractylodis)
• Huajiao (Pericarpium zanthoxyli)
• Bingpian (Borneolum syntheticum), etc
• Did not provide dosage of the ingredients
1.2 Administration
• External use twice daily
1.3 Duration of treatment
• 1 week
1.4 Follow up
• Did not state
II. Control group
2. Vitamin B cream
2.1 Ingredients and dosage
• Vitamin B
(dosage not provided)
2.2 Administration
• Twice daily topically
2.3 Duration of treatment
• 1 week
2.4 Follow up
• Did not state
Outcomes 1. Effectiveness rate developed by the trial investigators
2. Adverse events
Assessments were measured at baseline and at the end of the 1-week treatment period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The 2 interventions were made
by the 2 pharmaceutical companies, so it is
unlikely that a blinding method was used
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
High risk The trial did not use a published validated
scoring system
Xiao 2008
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient and inpatient department
of dermatology in a Chinese medicine teaching hospital in Chengdu, China
2. Age: from 3 to 23 years of age
3. Sex (men/women): 29/23
4. Number of participants randomised: 52
5. T/C: 26/26
Interventions I. Treatment group
a. Oral ingestion
1. Machixian decoction with individualised modifications
1.1 Ingredients and dosage
• Machixian (Herba portulacae)
• Tufuling (Rhizoma smilacis glabrae)
• Yuxingcao (Herba houttuyniae)
• Fuling (Poria)
• Mudanpi (Cortex moutan)
• Zijingpi (Cortex cercis chinensis)
• Longgu (Os draconis)
• Jiangcan (Bombyx batryticatus)
• Gancao(Radix glycyrrhizae), etc
• Did not provide dosage of the ingredients
1.2 Administration
• Oral ingestion 3 times daily, 30 ml of decoction for children below 12 years of
age, 100 ml for 12 to 23 year-olds
1.3 Duration of treatment
• 8 weeks
1.4 Follow up
• 12 weeks after the 8-week treatment period
b. Topical application
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• Used the same oral ingestion intervention for external moist dressing 3 times daily
II. Control group
a. Oral ingestion
2. Chlorphenamine tablet
2.1 Ingredients and dosage
• Chlorphenamine 0.35 mg per kg of body weight per day
2.2 Administration
• Oral ingestion
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• 12 weeks after the 8-week treatment
b. Topical application
2. Boric acid solution
2.1 Ingredients and dosage
• 3% boric acid solution
2.2 Administration
• 3 times daily topically
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• 12 weeks after the 8-week treatment period
- Sesame oil was used for cases with dry skin twice daily for both groups
Outcomes 1. SCORAD score
2. Adverse events
Assessments were conducted at baseline and at the end of the 8-week treatment period
3. Full counts of blood, routine tests of urine and stool, liver and renal function tests,
serum IgE level
Assessments were conducted at baseline and at the end of the 8-week treatment period
4. Recurrence rate
Assessment was conducted at 12 weeks after the treatment period
Notes The trial investigator claimed that they included only those who were diagnosed with
AD and identified as “dampness-heat” in Chinese medicine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
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was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Xiao 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine teaching hospital in Guangzhou, China
2. Age: from 2 to 60 years of age
3. Sex: did not state
4. Number of participants randomised: 60
5. T/C: 30/30
Interventions I. Treatment group
1. Huailian decoction
1.1 Ingredients and dosage
• Maidong (Radix ophiopogonis) 15 g
• Beishashen (Radix glehniae) 15 g
• Yuzhu (Rhizoma polygonati odorati) 15 g
• Tianhuafen (Radix trichosanthis) 15 g
• Shanyao (Rhizoma dioscoreae) 30 g
• Heye (Lolium nelumbinis) 15 g
• Huanglian powder (Rhizoma coptidis) 6 g
• Ejiao (Gelatinum asini) 10 g
• Jinyinhua (Flos lonicerae) 15 g
• Danzhuye (Herba lophatheri) 10 g
• Fuling (Poria) 30 g
• Gancao(Radix glycyrrhizae) 6 g
1.2 Administration
• Oral ingestion of 1 full dosage of the decoction for body weight over 45 kg, 2/3 of
the full dosage for body weight at 25 to 45 kg and 1/3 for < 25 kg
1.3 Duration of treatment
• 4 weeks
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1.4 Follow up
• 24 weeks after the 4-week treatment period
II. Control group
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg/tablet
2.2 Administration
• Oral ingestion, 10 mg once daily for > 12 year-olds or 2 to 12 year-olds with body
weight > 30 kg, 5 mg once daily for 2 to 12 year-olds with body weight < 30 kg
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• 24 weeks after the 4-week treatment period
- External use of nitrofurazone, calamine, menthol, and CHM ointment for both groups
Outcomes 1. SCORAD score
2. Effectiveness rate
3. Adverse events
Assessments were conducted at baseline, week 2, and at the end of the 4-week treatment
period
4. Full counts of blood, routine tests of urine and stool, liver and renal function tests
Asssesments were conducted at baseline and after the 4-week treatment period
5. Recurrence rate
Conducted at 24 weeks after the 4-week treatment period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...computer generated random
numbers were used”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
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It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Xue 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from aChinesemedicine hospital in Jiangmen,
China
2. Age: from 2 to 12 years of age
3. Sex (men/women): 37/26
4. Number of participants randomised: 63
5. T/C: 33/30
Interventions I. Treatment group
1. Shengxue Runfu decoction with individualised modifications
1.1 Ingredients and dosage
• Danggui(Radix angelicae sinensis) 6 g
• Ejiao (Gelatinum asini) 6 g
• Baizhu (Rhizoma atractylodis macrocephalae) 6 g
• Tiandong (Radix asparagi) 6 g
• Maidong (Radix ophiopogonis) 6 g
• Taoren (Semen persicae) 6 g
• Mudanpi (Cortex moutan) 6 g
• Shudihuang(Radix rehmanniae preparata) 10 g
• Huangqi (Radix astragali) 10 g
• Fuling (Poria) 10 g
• Baixianpi (Cortex dictamni) 10 g
• Honghua (Flos carthami) 10 g
• Huangqin (Radix scutellariae) 10 g
• Gancao(Radix glycyrrhizae) 3 g
• Shengma (Rhizoma cimicifugae) 3 g
1.2 Administration
• Oral ingestion of the decoction 2 to 3 times daily
1.3 Duration of treatment
• 8 weeks
1.4 Follow up
• Did not state
II. Control group
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg/tablet
2.2 Administration
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• Oral ingestion 10 mg for body weight ≥ 30 kg once daily, 5 mg for body weight <
30 kg once daily
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• Did not state
- Topical application of CHM ointment and emollients for both groups
Outcomes 1. SCORAD score
2. Severity of itching score (measured by participant-rated score, scale 0 to 10)
3. Skin lesion area score
4. Severity of skin lesion score
5. Effectiveness rate
6. Chinese medicine clinical syndrome score
All assessmentswere conducted at baseline, week 4, and at the endof the 8-week treatment
period
Notes 1. The trial investigators claimed that they included only those who were diagnosed with
AD and identified as “blood deficiency with wind-dryness” in Chinese medicine
2. Did not report adverse event
3. The trial was funded by Guangdong Bureau of Chinese Medicine, China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “...only those who took the herbal
decoction for 20 days or more at week 4 of
the trial were included for statistic analysis”
Comment: ITTwas not used for those who
took herbal decoction for less than 20 days
Selective reporting (reporting bias) Unclear risk There was insufficient information
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Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Yang 2007
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
of a Chinese medicine teaching hospital in Shenzhen, China
2. Age: from 5 to 25 years of age
3. Sex (men/women): 35/29
4. Number of participants randomised: 64
5. T/C: 32/32
Interventions I. Treatment group
a. Oral ingestion
1. Jianpi Zhiyang granules
1.1 Ingredients and dosage
• Huangqi (Radix astragali)
• Baizhu (Rhizoma atractylodis macrocephalae)
• Danggui (Radix angelicae sinensis)
• Sheshouwu (Radix polygoni)
• Shengdihuang (Radix rehmanniae)
• Baishao (Radix paeoniae alba)
• Chuangxiong (Rhizoma chuanxiong)
• Fangfeng(Radix saposhnikovia)
• Jingjie(Herba schizonepetae)
• Baijili (Fructus tribuli terrestris)
• Gouteng (Ramulus uncariae cum uncis)
• Gancao(Radix glycyrrhizae)
• Did not provide dosage of the ingredients
1.2 Administration
• 10 grams 3 times daily, half dosage for children < 6 years of age
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
b. Topical application
1. Pibao Xiaoyan Xuanshi ointment
1.1 Ingredients and dosage
• Shengyaodi (Hydrargyrum oxydatum crudum bottom)
• Shenghualiu (Sublimed Sulfur)
• Shechuangzi (Fructus cnidii)
• Zhangnao (Camphora)
• Bingpian (Borneolum syntheticum), etc
• Did not provide dosage of the ingredients
1.2 Administration
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• Twice daily topically
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
II. Control group
a. Oral ingestion
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg/tablet
2.2 Administration
• 10 mg oral ingestion daily for adults and children 2 to 12 years old with body
weight > 30 kg, 5 mg daily for body weight < 30 kg
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
b. Topical application
2. Hydrocortisone butyrate cream
2.1 Ingredients and dosage
• 1% hydrocortisone butyrate
2.2 Administration
• Twice daily topically
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
Outcomes 1. SCORAD score
2. Severity of itching score (measured by participant-rated VAS, scale 0 to 10)
3. Effectiveness rate
4. Adverse events
5. Serum IgE level and eosinophil count
All assessments were conducted at baseline and at the end of the 4-week treatment period
Notes 1. The oral ingestion treatment intervention was the same as that used in Jin 2007
2. The trial was funded by Shenzhen Science and Technology Planning Project, China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 4 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insuficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Yang 2009
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of a Chinese
medicine teaching hospital and dermatology and venereology outpatient department of
a teaching hospital in Kunming, China
2. Age: from 4 to 27 years of age
3. Sex (men/women): 33/27
4. Number of participants randomised: 60
5. T/C: 30/30
Interventions I. Treatment group
1. Jianpi Yangxue Qufeng decoction with individualised modifications
1.1 Ingredients and dosage
• Huangqi (Radix astragali) 30 g
• Baizhu (Rhizoma atractylodis macrocephalae) 15 g
• Danggui (Radix angelicae sinensis) 15 g
• Heshouwu (Radix polygoni) 30 g
• Fangfeng(Radix saposhnikovia) 20 g
• Baijili (Fructus tribuli terrestris) 30 g
• Wugong (Scolopendra) 10 g
1.2 Administration
• Oral ingestion of the decoction, did not state other details
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
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• Did not state
II. Control group
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg
2.2 Administration
• Oral ingestion, 10 mg once daily
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
Outcomes 1. Skin lesion area score (measured by clinician-rated score)
2. Skin lesion severity score (measured by clinician-rated score)
3. Severity of itching score (measured by participant-rated VAS, scale 0 to 3)
4. Erythema score (measured by clinician-rated score)
5. Transepidermal water loss, skin oil, and skin elasticity (measured by a multifunctional
skin testing equipment)
6. Effectiveness rate
7. Adverse events
All assessments were conducted at baseline and at the end of the 4-week treatment period
Notes 1. The trial investigator claimed that they included only those who were diagnosed with
AD and identified as “spleen deficiency with dryness of blood” in Chinese medicine
2. 30 healthy volunteers were also recruited for assessment of transepidermal water loss,
skin oil, and skin elasticity
3. The paper did not provide continuous data of outcomes 1 to 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...random number table was used”
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
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randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Unclear risk The trial used a scoring system developed
by the trial investigators
Yu 1999
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient and inpatient department
in 3 hospitals in Shanghai and Hangzhou, China
2. Age: from 5 to 53 years of age
3. Sex (men/women): 112/108
4. Number of participants randomised: 220
5. T/C: 120/100
Interventions I. Treatment group
1. Piyan Xiaojingyin granules II
1.1 Ingredients and dosage
• Cangzhu(Rhizoma atractylodis)
• Danggui (Radix angelicae sinensis)
• Hanfangji (Radix stephaniae tetrandrae)
• Huangqin (Radix scutellariae)
• Chaihu (Radix bupleuri), etc
• Did not provide dosage of the ingredients
1.2 Administration
• Oral ingestion, 10 g for 5 to 9 year-olds, 15 g for 10 to 14 year-olds, 20 g for
participants aged 14 and above, 3 times daily
1.3 Duration of treatment
• 12 weeks
1.4 Follow up
• 52 weeks after the 12-week treatment period
II. Control group
2. Loratadine (Clarityne) tablet
2.1 Ingredients and dosage
• Loratadine
• Did not provide dosage
2.2 Administration
• Oral ingestion, did not state other details
2.3 Duration of treatment
• 12 weeks
2.4 Follow up
• 52 weeks after the 12-week treatment period
- Topical application of saline or zinc oxide cream for both groups
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Outcomes 1. Skin lesion severity score (measured by clinician-rated score)
2. Skin lesion area score (measured by clinician-rated score)
3. Severity of itching score (measured by participant-rated VAS, scale 0 to 3)
4. Effectiveness rate
5. Adverse events
Assessments were conducted at baseline, at the end of the 12-week treatment period,
and 52 weeks after the 12-week treatment period
6. Serum CD4/CD8 ratio and IgE level
Assessments were conducted at baseline and at the end of the 12-week treatment period
Notes 1. The trial investigator claimed they only included those who were diagnosed with AD
and identified as “spleen deficiency with dryness of blood” in Chinese medicine
2. The trial did not provide continuous data of outcomes 1 to 3
3. The trial was funded and registered in the State Administration of Traditional Chinese
Medicine, China
4. The trial passed the evaluation at the Ministerial level on 18 August 1998
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Unclear risk The trial used a scoring system developed
by the trial investigators
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Methods This was a randomised, controlled, 3-arm parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine teaching hospital in Nanjing, China
2. Age: below or at 16 years of age
3. Sex (men/women): did not state
4. Number of participants randomised: 45
5. T/C/C: 15/15/15
Interventions I. Treatment group
1. Jianpi Huashi decoction
1.1 Ingredients and dosage
• Fuling(Poria) 6 g
• Cangzhu(Rhizoma atractylodis) 6 g
• Baizhu (Rhizoma atractylodis macrocephalae) 6 g
• Chenpi (Pericarpium citri reticulatae) 3 g
• Zexie(Rhizoma alismatis) 6 g
• Baixianpi (Cortex dictamni) 6 g
• Maiya (Fructus hordei germinatus) 15 g
• Huashi(Talcum) 6 g
• Gancao(Radix glycyrrhizae) 4 g
1.2 Administration
• 1 package per day, oral ingestion of the decoction twice daily, half dosage for
children aged 10 or below
1.3 Duration of treatment
• 12 weeks
1.4 Follow up
• Did not state
II. Control group A
2. Chlorpheniramine tablet
2.1 Ingredients and dosage
• Chlorpheniramine
2.2 Administration
• Oral ingestion 0.30 mg per kg of the body weight daily
2.3 Duration of treatment
• 12 weeks
2.4 Follow up
• Did not state
III. Control group B
• No oral ingestion of medications. Data from this group were not used for
comparison in this review
- Topical application of CHM lotion or CHM ointment according to the condition of
an individual in all groups
Outcomes 1. Percentage of reduction of total SASSAD score
2. Severity of itching score from baseline (measured by participant-rated VAS, scale 0 to
10)
3. IgE and EOS level
4. Effectiveness rate
5. Adverse events
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All measurements were conducted at baseline, 4 weeks, and at the end of the 12-week
treatment period
Notes The SASSAD scores were expressed as ’numbers ±’ without labels, and we assumed they
meant mean ± SD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the interventions were different,
so it is unlikely that a blinding method was
used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SASSAD
Zhang 2009
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine teaching hospital in Jinan, China
2. Age: from 2 to 12 years of age
3. Sex (men/women): did not state
4. Number of participants randomised: 61
5. T/C: 36/25
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Interventions I. Treatment group
1. Xiao’er Huashi decoction
1.1 Ingredients and dosage
• Cangzhu(Rhizoma atractylodis) 6 g
• Baizhu (Rhizoma atractylodis macrocephalae) 6 g
• Chenpi (Pericarpium citri reticulatae) 3 g
• Zexie (Rhizoma alismatis) 6 g
• Fuling(Poria) 9 g
• Baixianpi (Cortex dictamni) 6 g
• Maiya (Fructus hordei germinatus) 15 g
• Huashi (Talcum) 12 g
• Gancao(Radix glycyrrhizae) 6 g
• Laifuzi (Semen raphani) 9 g
• Binglang (Semen arecae) 9 g
• Jineijin (Endothelium corneum gigeriae galli) 9 g
• Shengdihuang (Radix rehmanniae) 6 g
• Mudanpi (Cortex moutan) 6 g
• Huangqin (Radix scutellariae) 9 g
1.2 Administration
• 1 package per day, oral ingestion of the decoction 3 to 4 times daily
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• 4 weeks after the 4-week treatment period
II. Control group
2. Loratadine granules
2.1 Ingredients and dosage
• Loratadine 10 mg
2.2 Administration
• Oral ingestion 10 mg daily for children age 2 to 12 years old with body weight >
30 kg, or 5 mg per night for body weight ≤ 30 kg
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• 4 weeks after the 4-week treatment period
- External use of CHM lotion and CHM cream for both groups
Outcomes 1. EASI score
2. Effectiveness rate
Assessments were conducted at baseline and at the end of the 4-week treatment period
3. Recurrence rate
Conducted at 4 weeks after the 4-week treatment period
Notes 1. The trial did not report adverse events
2. The trial did not provide continuous data of EASI score
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not stated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used EASI
Zhang 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine teaching hospital in Tianjin, China
2. Age: 2.5 to 14 years of age
3. Sex (men/women): 31/25
4. Number of randomised: 56
5. T/C: 30/26
Interventions I. Treatment group
1. Self-designed CHM decoction with individualised modifications
1.1 Ingredients and dosage
• Shengdihuang (Radix rehmanniae) 15 g
• Danggui (Radix angelicae sinensis) 10 g
• Xuanshen (Radix scrophulariae) 15 g
• Shengdihuang (Radix rehmanniae) 10 g
• Shouwuteng(Caulis polygoni) 15 g
• Chishao (Radix paeoniae rubra) 15 g
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• Digupi (Cortex lycii) 15 g
• Tianhuafen(Radix trichosanthis) 15 g
• Huangqin (Radix scutellariae) 10 g
• Zhimu(Rhizoma anemarrhenae) 10 g
• Maidong (Radix ophiopogonis) 15 g
• Beishashen(Radix glehniae) 10 g
• Mugua (Fructus chaenomelis) 10 g
• Lingxiaohua (Flos campsis) 15 g
• Dangshen (Radix salviae miltiorrhizae) 10 g
• Jixueteng (Radix et Caulis jixueteng) 15 g
• Gancao(Radix glycyrrhizae) 10 g
1.2 Administration
• 1 package per day, oral ingestion of the decoction twice daily, half dosage for
participants aged 10 years old or below or body weight < 30 kg
1.3 Duration of treatment
• 8 weeks
1.4 Follow up
• 24 weeks after the 8-week treatment period
II. Control group
2. Levocetirizine dihydrochloride tablets
2.1 Ingredients and dosage
• Levocetirizine dihydrochloride
2.2 Administration
• Oral ingestion 5 mg once daily for 6 year-olds or above, 2.5 mg for 2 to 6 year-
olds once daily
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• 24 weeks after the 8-week treatment period
Outcomes 1. SCORAD score
2. Effectiveness rate
Assessments were conducted at baseline and at the end of the 8-week treatment period
3. Recurrence rate
Conducted at 24 weeks after the 8-week treatment period
Notes The trial did not report adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...random number table was used”
Allocation concealment (selection bias) Unclear risk This was not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
Low risk The trial used SCORAD
Zhou 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in Jiangyong country Chinese medicine hospital in Hunan, China
2. Age: 3 to 38 months old
3. Sex (men/women): 95/81
4. Number of participants randomised: 176
5. T/C: 89/87
Interventions I. Treatment group
1. Cang Er Kushen lotion
1.1 Ingredients and dosage
• Cangerzi (Fructus xanthii) 30 g
• Kushen(Radix sophorae flavescentis) 30 g
• Tufuling (Rhizoma smilacis glabrae) 25 g
• Shechuangzi (Fructus cnidii) 15 g
• Cangzhu (Rhizoma atractylodis) 15 g
• Jingjie(Herba schizonepetae) 15 g
• Zicao (Radix arnebiae) 15 g
• Huangbai (Cortex phellodendri) 15 g
1.2 Administration
• Moist dressing with the lotion 3 to 4 times daily
1.3 Duration of treatment
• 2 weeks
1.4 Follow up
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• 24 weeks after the 2-week treatment period
II. Control group
2. Calamine lotion
2.1 Ingredients and dosage
• Calamine
• Did not provide dosage
2.2 Adminstration
• Topical use 3 times daily
2.3 Duration of treatment
• 2 weeks
2.4 Follow up
• 24 weeks after the 2-week treatment period
Outcomes 1. Effectiveness rate
2. Adverse events
Assessments were conducted at baseline and at the end of the treatment period
3. Recurrence rate
Conducted at 24 weeks after the 2-week treatment period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised into
treatment or control group at a ratio of 1:
1”
Comment: The paper did not state how
random sequence was generated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
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Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
High risk The trial did not use a published validated
scoring system
Zou 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of dermatology
in a Chinese medicine teaching hospital and another teaching hospital in Nanchang,
China
2. Age: 3 to 36 months old
3. Sex (men/women): 27/23
4. Number of participants randomised: 50
5. T/C: 30/20
Interventions I. Treatment group
1. Fufang Sanhuang lotion and oil
1.1 Ingredients and dosage
• Dahuang(Radix et rhizoma rhei) 15 g
• Zicao(Radix arnebiae) 15 g
• Huangbai (Cortex phellodendri) 15 g
• Huangqin (Radix scutellariae) 15 g
• Diyu (Radix sanguisorbae) 15 g
• Shechuangzi(Fructus cnidii) 15 g
• Wubeizi (Galla chinensis) 20 g
• Qingdai (Indigo naturalis) 10 g
• Mingfan (Alum) 6 g
1.2 Administration
• Moist dressing with the lotion 3 to 4 times daily and topical application with the
same herbal powder mixed with sesame oil
1.3 Duration of treatment
• 2 weeks
1.4 Follow up
• 12 weeks after the 2-week treatment period
II. Control group
2. Boric acid solution and zinc oxide cream
2.1 Ingredients and dosage
• 3% Boric acid solution, zinc oxide cream (dosage not provided)
2.2 Administration
• Topical use 3 to 4 times daily
2.3 Duration of treatment
• 2 weeks
2.4 Follow-up
• 12 weeks after the 2-week treatment period
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Outcomes 1. Effectiveness rate
2. Serum IgE, EOS, liver and renal function tests
3. Adverse events
Assessments were conducted at baseline and at the end of the 2-week treatment period
4. Recurrence rate
Conducted at 12 weeks after the 2-week treatment period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised into
treatment or control group at a ratio of 3:
2 according to the proportion principle of
ratio not less than 2:1”
Comment: The paper did not state how
random sequence was generated
Allocation concealment (selection bias) Unclear risk This was not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not stated
Comment: The appearance and adminis-
tration of the 2 interventions were differ-
ent, so it is unlikely that a blinding method
was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was not stated
Comment: The numbers of participants
randomised and analysed were equivalent.
It seems that there were no withdrawals/
dropouts in this study
Selective reporting (reporting bias) Unclear risk There was insufficient information
Other potential sources of bias (use of pub-
lished validated scoring system )
High risk The trial did not use a published validated
scoring system
CDLQI: Children’s Dermatology Life Quality Index
CHM: Chinese herbal medicine
DLQI: Dermatology Life Quality Index
EASI: Eczema Area and Severity Index
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ITT: Intention-to-treat
POEM: Patient-oriented Eczema Measure
SASSAD: Six Area, Six Sign Atopic Dermatitis severity score
SCORAD: Severity Scoring of Atopic Dermatitis
T/C: Treatment group/Control group
VAS: Visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Li 2006 The trial used inappropriate comparator interventions
Udompataikul 2011 The trial used inappropriate treatment interventions
Zhang 2010 The trial used inappropriate comparator interventions
Zhao 2008 The trial used inappropriate comparator outcome measures
Characteristics of studies awaiting assessment [ordered by study ID]
Cai 2012
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient dermatology department of a Chinese medicine hospital
in Zhangzhou, China
2. Age: from 1.5 to 13 years of age
3. Sex (men/women): 49/35
4. Number of participants randomised: 84
5. T/C: 43/41
Interventions I. Treatment group
1. Shenling Baizhu decoction with individualised modifications
1.1 Ingredients and dosage
• Dangshen (Radix salviae miltiorrhizae) 10 g
• Baizhu (Rhizoma atractylodis macrocephalae) 10 g
• Fuling (Poria) 15 g
• Baixianpi (Cortex dictamni) 10 g
• Yiyiren (Semen coicis) 15 g
• Shanyao (Rhizoma dioscoreae) 12 g
• Jiegen (Radix platycodi) 10 g
• Tufuling (Rhizoma smilacis glabrae) 12 g
• Mohanlian (Herba ecliptae) 15 g
• Nuzhenzi (Fructus ligustri lucidi) 10 g
• Gancao(Radix glycyrrhizae) 6 g
1.2 Administration
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• Oral ingestion of the decoction 2 times daily
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
II. Control group
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg/tablet
2.2 Administration
• Oral ingestion 10 mg once daily
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
- Topical application of triamcinolone acetonide acetate cream and vitamin B cream were provided for both groups
Outcomes 1. Effectiveness rate
2. Adverse events
Assessed at the end of the 4-week treatment period
Notes 1. The trial investigator claimed that they included only those who were diagnosed with AD and identified as “spleen
deficiency with dryness of blood” in Chinese medicine
2. We contacted the corresponding trial investigator for further information (such as the randomisation method,
whether the study was a prospective design, etc). We received no reply
Chi 2012
Methods This was a randomised, controlled, parallel, multicentre clinical trial
Participants 1. Setting: The trial recruited participants from 2 Chinese medicine teaching hospitals and 3 teaching hospitals in
Beijing, Changsha, and Shanghai, China
2. Age: from 7 to 60 years of age
3. Sex (men/women): 89/103
4. Number of participants randomised: 201
5. T/C: 96/96
Interventions I. Treatment group
a. Oral ingestion
1. No. 1 Longmu formula for subgroups with “retention of wind dampness on the skin”
1.1 Ingredients and dosage
No. 1 Longmu formula:
• Longgu (Os draconis) 30 g
• Muli (Concha ostreae) 30 g
• Fuling (Poria) 30 g
• Danzhuye (Herba lophatheri) 15 g
No. 2 Longmu formula for subgroups with “blood deficiency with dryness wind”:
• Longgu (Os draconis) 30 g
91Chinese herbal medicine for atopic eczema (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chi 2012 (Continued)
• Muli (Concha ostreae) 30 g
• Gushuibu (Rhizoma drynariae) 10 g
• Difuzi (Fructus kochiae) 30 g
1.2 Administration
• The decocted formula produced 150 ml of herbal liquid. Oral ingestion of the herbal liquid was twice daily.
Half dosage for participants aged 7 to 12 years
1.3 Duration of treatment
• 8 weeks
1.4 Follow up
• 12 weeks after the 8-week treatment period
b. Topical application
• Decocted the above formula for the second time, external use of the herbal liquid twice daily
II. Control group
a. Oral ingestion
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg
2.2 Administration
• Once daily
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• 12 weeks after the 8-week treatment period
b. Topical application
2. Hydrocortisone butyrate cream
2.1 Ingredients and dosage
• 0.1% Hydrocortisone butyrate cream (dosage not provided)
2.2 Administration
• Twice daily
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• 12 weeks after the 8-week treatment period
Outcomes 1. Effectiveness rate
2. SCORAD
3. CDLQI or DLQI
4. Adverse events
Assessments were conducted at baseline; weeks 1, 2, and 4; and at the end of the 8-week treatment period
5.Complete blood cell count (CBC), urine analysis, liver and kidney function, serumeosinophil count, IgE, eosinophil
cationic protein (ECP)
Assessments were conducted at baseline and at the end of the 8-week treatment period
6. Recurrence rate
Conducted at 12 weeks after the 8-week treatment period
Notes 1. There were 9 dropouts in the treatment group and 9 dropouts in the control group; 2 were excluded from the
control group because of non-compliance
2. The trial investigators claimed they included only those who were diagnosed with AD and identified as “retention
of wind dampness on the skin” or “blood deficiency with dryness wind” in Chinese medicine
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3. The corresponding trial investigator was contacted for further information, such as whether the trial was the same
one in Zhao 2011 (as both trials were under the same funding and used the same interventions). We received no
reply
4. The trial was funded by Science and Technology National Suppport Scheme - Research on Chinese medicine for
common diseases, China
Dong 2012
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from the outpatient dermatology department of a general hospital in
Rizhao, China
2. Age: from 0.5 to 5.5 years of age
3. Sex (men/women): 52/43
4. Number of participants randomised: 95
5. T/C: 48/47
Interventions I. Treatment group
1. Jingfang mixture
1.1 Ingredients and dosage
• Qianghuo (Rhizoma seu Radix notopterygii)
• Duhuo (Radix angelicae pubescentis)
• Qianhu (Radix peucedani)
• Zhiqiao (Fructus aurantii)
• Fuling (Poria)
• Gancao(Radix glycyrrhizae)
• Fangfeng(Radix saposhnikovia)
• Jingjie(Herba schizonepetae)
• Jiegen (Radix platycodi)
• Chuangxiong (Rhizoma chuanxiong)
• Did not provide dosage of the ingredients
1.2 Administration
• Topical use twice daily
1.3 Duration of treatment
• 2 weeks
1.4 Follow up
• Did not state
II. Control group
2. Hydrocortisone butyrate cream
2.1 Ingredients and dosage
• Hydrocortisone butyrate, did not state dosage
2.2 Administration
• Topical use twice daily
2.3 Duration of treatment
• 2 weeks
2.4 Follow up
• Did not state
- Topical use of Vitamin E cream for both groups
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Outcomes 1. Percentage of reduction of total EASI score
2. Effectiveness rate
3. Adverse events
Assessments were conducted at baseline, day 3, week 1, week 7, and at the end of the 2-week treatment period,
respectively
Notes 1. Effectiveness rate = ((pre-treatment score of EASI - post-treatment score of EASI)/pre-treatment score of EASI) *
100%
2. We contacted the corresponding trial investigator for further information (such as the randomisation method,
whether the study was a prospective design, etc). We received no reply
Shi 2012
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from a women’s and children’s hospital in Guangzhou, China
2. Age: from 5 to 25 years of age
3. Sex (men/women): 45/66
4. Number of participants randomised: 110
5. T/C: 54/56
Interventions I. Treatment group
1. Chinese herbal decoction
1.1 Ingredients and dosage
• Huangqi (Radix astragali) 15 g
• Baizhu (Rhizoma atractylodis macrocephalae) 10 g
• Yiyiren (Semen coicis) 10 g
• Beishashen (Radix glehniae) 15 g
• Fangfeng(Radix saposhnikovia) 15 g
• Fuling (Poria) 10 g
• Gancao(Radix glycyrrhizae) 6 g
1.2 Administration
• 1 pack of herbs cooked with water and the decoction drank twice daily
1.3 Duration of treatment
• 3 weeks
1.4 Follow up
• Did not state
II. Control group
2. Cetirizine tablet
2.1 Ingredients and dosage
• Desloratadine 10 mg
2.2 Administration
• Once daily oral ingestion
2.3 Duration of treatment
• 3 weeks
2.4 Follow up
• Did not state
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Outcomes 1. Percentage of reduction of total SASSAD score
2. Effectiveness rate
3. QoL
4. Serum CD3+CD4+T cells and CD3+CD8+T cells, immunoglobulin A (IgA), immunoglobulin G (IgG), im-
munoglobulin M (IgM), and IgE
Assessments were conducted at baseline and at the end of the 3-week treatment period, respectively
Notes 1. Effectiveness rate = ((pre-treatment score of SASSAD - post-treatment score of SASSAD)/pre-treatment score of
SASSAD) * 100%
2. We contacted the corresponding trial investigator for further information (such as why there was discrepancy in
the number of participants and sum of the genders, and randomisation method, diagnostic criteria, report of adverse
events, and data on QoL). We received no reply
Tian 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient department of a general hospital in Shenyang, China
2. Age: from 39 days to 20 months old
3. Sex (men/women): 28/22
4. Number of participants randomised: 60
5. T/C: 30/30
Interventions I. Treatment group
a. Oral ingestion
1. Qushi Zhiyang formula with individualised modifications
1.1 Ingredients and dosage
• Shigao(Gypsum fibrosum) 10 g
• Fuling (Poria) 10 g
• Yiyiren (Semen coicis) 15 g
• Yinchen (Herba artemisiae scopariae) 15 g
• Danzhuye (Herba lophatheri) 8 g
• Gancao(Radix glycyrrhizae) 6 g
• Mudanpi (Cortex moutan) 10 g
• Lianqiao (Fructus forsythiae) 10 g
• Jinyinhua (Flos lonicerae) 10 g
• Yejuhua (Flos chrysanthemi indici) 15 g
• Baixianpi (Cortex dictamni) 10 g
• Danggui (Radix angelicae sinensis) 10 g
• Huashi (Talcum) 10 g
1.2 Administration
• The formula was decocted twice to produce a total of 100 ml of herbal liquid. Oral ingestion of the herbal
liquid was 3 times daily
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• 8 weeks after the end of treatment
b. Topical application
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• Decocted the formula above for the third time, external use of the herbal liquid twice daily
II. Control group
a. Oral ingestion
2. Chlorpheniramine tablet, diphenhydramine syrup, antibiotics, vitamin E, and vitamin C
2.1 Ingredients and dosage
• Chlorpheniramine tablet 0.35 mg per day
• Did not provide dosage of diphenhydramine syrup, vitamin E, and vitamin C, did not provide ingredient of
antibiotics
2.2 Administration
• Oral ingestion of chlorpheniramine tablet 3 times daily
• Did not provide administration of diphenhydramine syrup, antibiotics, and vitamins
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• 8 weeks after the end of treatment
b. Topical application
2. Hydrocortisone butyrate cream
2.1 Ingredients and dosage
• 0.1% hydrocortisone butyrate cream (dosage not provided)
2.2 Administration
• Once to 3 times daily
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• 8 weeks after the end of treatment
Outcomes 1. Effectiveness rate assessed at the end of the 8-week treatment period
Notes We contacted the corresponding trial investigator for further information (such as the randomisation method, a
report of adverse events, and whether the study was a prospective design). We received no reply
Xu 2012
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from the inpatient paediatric department of a Chinese medicine hospital
in Zhangzhou, China
2. Age: from 35 days to 2 years of age
3. Sex (men/women): 56/48
4. Number of participants randomised: 104
5. T/C: 53/51
Interventions I. Treatment group
1. Kouqiang Xiaoyan powder
1.1 Ingredients and dosage
• Qingdai (Indigo naturalis)
• Bingpian (Borneolum syntheticum)
• Did not provide dosage
1.2 Administration
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• Topical use twice daily
1.3 Duration of treatment
• 2 weeks
1.4 Follow up
• Did not state
II. Control group
2. Triamcinolone acetonide acetate cream
2.1 Ingredients and dosage
• Triamcinolone acetonide acetate
• Did not provide dosage
2.2 Administration
• Topical use twice daily
2.3 Duration of treatment
• 2 weeks
2.4 Follow up
• Did not state
Outcomes 1. Effectiveness rate
2. Adverse events
Assessed at the end of the 2-week treatment period
Notes We contacted the corresponding trial investigator for further information (such as the randomisation method, a
report of adverse events, and whether the study was a prospective design). We received no reply
Yang 2012
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient dermatology department of aChinesemedicine teaching
hospital in Harbin, China
2. Age: did not state age range
3. Sex (men/women): 45/39
4. Number of participants randomised: 84
5. T/C: 42/42
Interventions I. Treatment group
1. Shirun Shaoshang ointment
1.1 Ingredients and dosage
• Huanglian (Coptis chinensis)
• Huangqin (Radix scutellariae)
• Huangbai (Cortex phellodendri)
• Dilong (Pheretima)
• Yingsuqiao (Pericarpium papaveris)
• Mayou (Oleum sesami)
• Did not provide dosage
1.2 Administration
• Topical use 3 times daily
1.3 Duration of treatment
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Yang 2012 (Continued)
• 4 weeks
1.4 Follow up
• Did not state
II. Control group
2. Zinc oxide ointment (15%)
2.1 Ingredients and dosage
• Zinc oxide 3 g
2.2 Administration
• Topical use 3 times daily
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
Outcomes 1. Effectiveness rate assessed at the end of the 4-week treatment period
Notes We contacted the corresponding trial investigator for further information (such as the randomisationmethod, whether
the study was a prospective design, and the safety issues of the interventions). We received no reply
Zhao 2011
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient dermatology department of a Chinese medicine hospital
in Beijing, China
2. Age: from 12 to 41 years of age
3. Sex (men/women): 51/71
4. Number of participants randomised: 122
5. T/C: 62/60
Interventions I. Treatment group
a. Oral ingestion
1. No. 1 Longmu formula for subgroups with “retention of wind dampness on the skin”
1.1 Ingredients and dosage
No. 1 Longmu formula:
• Longgu (Os draconis) 30 g
• Muli (Concha ostreae) 30 g
• Fuling (Poria) 30 g
• Danzhuye (Herba lophatheri) 15 g
No. 2 Longmu formula for subgroups with “blood deficiency with dryness wind”:
• Longgu (Os draconis) 30 g
• Muli (Concha ostreae) 30 g
• Gushuibu (Rhizoma drynariae) 10 g
• Difuzi (Fructus kochiae) 30 g
1.2 Administration
• The decocted formula produced 150 ml of herbal liquid. Oral ingestion of the herbal liquid was twice daily
1.3 Duration of treatment
• 8 weeks
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Zhao 2011 (Continued)
1.4 Follow up
• Did not state
b. Topical application
• Decocted the above formula for the second time, external use of the herbal liquid twice daily
II. Control group
a. Oral ingestion
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine (dosage not provided)
2.2 Administration
• Once daily
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• Did not state
b. Topical application
2. Hydrocortisone butyrate cream
2.1 Ingredients and dosage
• 0.1% Hydrocortisone butyrate cream (dosage not provided)
2.2 Administration
• Twice daily
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• Did not state
- Silicone creams were used externally for both groups
Outcomes 1. Skin lesion score
2. Severity of itching score
3. SCORAD
4. DLQI
5. Adverse events
Assessments were conducted at baseline; weeks 1, 2, and 4; and at the end of the 8-week treatment period
6. Complete blood cell count (CBC), urine analysis, liver and kidney function
Assessments were conducted at baseline and at the end of the 8-week treatment period
Notes 1. The trial investigators claimed that they included only those who were diagnosed with AD and identified as
“retention of wind dampness on the skin” or “blood deficiency with dryness wind” in Chinese medicine
2. We contacted the corresponding trial investigator for further information (such as the randomisation method,
data on the scores for the outcome measures, etc). We received no reply
3. The trial was funded by Science and Technology National Suppport Scheme - Research on Chinese medicine for
common diseases, China
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Zheng 2012
Methods This was a randomised, controlled, parallel clinical trial
Participants 1. Setting: The trial recruited participants from an outpatient and inpatient department of a Chinese medicine
hospital in Zhongshan, China
2. Age: did not state
3. Sex (men/women): 58/43
4. Number of participants randomised: 101
5. T/C: 50/51
Interventions I. Treatment group
1. Bupi Qufeng granules
1.1 Ingredients and dosage
• Dangshen (Radix salviae miltiorrhizae) 20 g
• Huangqi (Radix astragali) 20 g
• Baizhu (Rhizoma atractylodis macrocephalae) 10 g
• Fuling (Poria) 10 g
• Fangfeng(Radix saposhnikovia) 10 g
• Baijili (Fructus tribuli terrestris) 15 g
• Zhigancao (Gancao)(Radix glycyrrhizae) 10 g
• Chantui(Periostracum cicdae) 10 g
1.2 Administration
• 10 grams (6 grams for 3 to 11 year-olds) 2 times daily oral ingestion
1.3 Duration of treatment
• 4 weeks
1.4 Follow up
• Did not state
II. Control group
2. Loratadine tablet
2.1 Ingredients and dosage
• Loratadine 10 mg/tablet
2.2 Administration
• 1 tablet daily oral ingestion
2.3 Duration of treatment
• 4 weeks
2.4 Follow up
• Did not state
- Topical application of CHM cream was used in both groups
Outcomes 1. Effectiveness rate
2. Reduction of total SASSAD score
3. Reduction of itching score (measured by participant-rated score, scale unknown)
4. Adverse events
5. Full counts of blood, routine tests of urine and stool, fecal occult blood
6. Liver and renal function tests
Outcome 1 was measured at the end of the trial
Outcomes 2 to 4 were assessed at baseline, at 2 weeks, and at the end of the 4-week treatment period
Outcomes 5 and 6 were assessed before and after the treatment period, respectively
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Zheng 2012 (Continued)
Notes 1. The trial investigator claimed that they only included those who were diagnosed with AD and identified as “spleen
deficiency” in Chinese medicine
2. Effectiveness rate = ((pre-treatment score of SASSAD - post-treatment score of SASSAD)/pre-treatment score of
SASSAD) * 100%
3. We contacted the corresponding trial investigator for further information (such as the randomisation method, the
age range of the participants, whether the study was a prospective design, etc). We received no reply
4. The trial was funded by Science and Technology Program, Science and Technology Bureau, Zhongshan, China
AD: Atopic dermatitis
DLQI: Dermatology Life Quality Index
EASI: Eczema Area and Severity Index
SASSAD: Six Area, Six Sign Atopic Dermatitis severity score
SCORAD: Severity Scoring of Atopic Dermatitis
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-TRC-08000156
Trial name or title The clincal trial of the traditional Chinese formula of Hilling and Clearing Away Heart-fire (HCAH) for
atopic dermatitis
Methods This is a randomised, non-blind, controlled, 3-arm parallel, multicentre clinical trial
Participants 1. Setting: The trial recruited participants from3Chinese medicine teaching hospitals and 2 teaching hospitals
in Guangzhou, Chengdu, Nanjing, Haikou, and Luzhou, China
2. Age: from 7 to 25 years of age
3. Sex (men/women): -
4. Target number of participants for randomisation: 249
Interventions I. Treatment group
a. Oral ingestion
1. Peitu Qingxin formula
1.1 Ingredients and dosage
• Taizishen
• Dengxincao, etc
• Did not state other ingredients and dosage
1.2 Administration
• Did not state
1.3 Duration of treatment
• 12 weeks
1.4 Follow up
• Did not state
b. Topical application
• External use with 4 Chinese herbs
• Did not provide ingredients and dosage
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ChiCTR-TRC-08000156 (Continued)
II. Control group A
a. Oral ingestion
2. Cyproheptadine tablet
2.1 Ingredients and dosage
• Cyproheptadine
2.2 Administration
• 0.25 mg/kg/day
2.3 Duration of treatment
• 12 weeks
2.4 Follow up
• Did not state
b. Topical application
• Mometasone furoate cream twice daily, zinc oxide oil, and 3% boric acid solution
III. Control group B
• Oral ingestion of Peitu Qingxin formula only
Outcomes 1. SCORAD
2. DLQI
3. Index of curative effect
Did not state assessment points
Starting date 1st October 2008
Contact information Dr Xiumei Mo, Department of Dermatology, Guangdong Provincial Hospital, No.111 Dade Road,
Guangzhou, Guangdong, China 510120
Email: moxiumeilsamay@163.com
Notes 1. The trial has been registered on http://www.chictr.org/cn. Registration number: ChiCTR-TRC-08000156
2. The trial was completed, and the report of the trial has not been published
3. We contacted the corresponding investigator on 12 December 2011, who indicated that no protocol of
the trial has been published
4. The trial was funded by the ’11.5 Key Projects’, the Ministry of Science and Technique, China
5. We contacted the corresponding investigator again on 17 September 2012 for the publication status of the
trial. The corresponding investigator replied that the report of the trial has not been published yet
6. We contacted the corresponding investigator again on 21 June 2013 for the publication status of the trial
as we found a title and abstract of a PhD thesis with a report of a clinical trial published by the corresponding
investigator in 2012. We assumed the trial reported in the PhD thesis was the one started in 2008, but we
were unable to retrieve the full text of the report for further assessment. We have received no reply
ChiCTR-TRC-09000562
Trial name or title Clinical trial of Bu Shen Yi Qi Fang on treating atopic dermatitis in deficiency of Kidney Yang and Qi
Methods This is a randomised, double-blind, placebo-controlled, parallel, multicentre clinical trial
Participants 1. Setting: Participants will be recruited from 3 teaching hospitals in Shanghai, Nanjing, and Chengdu, China
2. Age: from 18 to 70 years of age
3. Sex (men/women): -
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ChiCTR-TRC-09000562 (Continued)
4. Target number of participants for randomisation: 320
Interventions I. Treatment group
1. Bu Shen Yi Qi Fang formula
1.1 Ingredients and dosage
• Did not state
1.2 Administration
• Did not state
1.3 Duration of treatment
• Did not state
1.4 Follow up
• Did not state
II. Control group
2. Placebo
2.1 Ingredients and dosage
• Did not state
2.2 Administration
• Did not state
2.3 Duration of treatment
• Did not state
2.4 Follow up
• Did not state
- Desloratadine tablet will be used for 2 groups
Outcomes 1. Traditional Chinese medicine symptom scores
2. Severity of itching score measured by VAS
3. Numbers of sleep disturbance by skin itching
4. DLQI
5. SCORAD
6. Full blood counts, routine tests of urine, liver and renal function tests, electrocardiogram
7. Serum IgE, IFN-γ , TNF-α, IL-4, IL-6, IL-10, TGF-β, c-reactive protein (CRP), CORT, adrenocorti-
cotrophin (ACTH)
Did not state assessment points
Starting date Not started yet
Contact information Dr. Liu Runhong, Lab of integrative medicine for Lung inflammation and cancer, Number 12 of Middle Wu
Lu Mu Qi Lu, Shanghai, China 200040
Email: liurunhong@163.com
Notes 1. The trial has been registered on http://www.chictr.org/cn. Registration number: ChiCTR-TRC-09000562
2. We contacted the corresponding investigator on 30 January 2012 and received no reply
3. The trial was funded by Ministry of Science and Technology, China
4. We contacted the corresponding investigator again on 17 September 2012 for the publication status of the
trial and received no reply
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ChiCTR-TRC-12003174
Trial name or title Effectiveness of PeiTu QingXin (PTQX) Granules adds on usual care to reduce the accumulated relapse of
the atopic dermatitis in children: a protocol for a multi-center, double-blind, randomized controlled trial
Methods This is a randomised, double-blind, placebo-controlled, parallel, multicentre clinical trial
Participants 1. Setting: Participants will be recruited from 4 Chinese medicine teaching hospitals and 5 general hospitals
in Guangzhou, Xi’an, Haikou, Nanjing, Beijing, Hangzhou, Shanghai, and Zhengzhou, China
2. Age: from 2 to 12 years of age
3. Sex (men/women): -
4. Target number of participants for randomisation: 380
Interventions I. Treatment group
1. Oral ingestion of Peitu Qingxin formula (CHM granules)
1.1 Ingredients and dosage
• Did not state ingredients and dosage
1.2 Administration
• Did not state
1.3 Duration of treatment
• Did not state
1.4 Follow up
• Did not state
II. Control group
2. Placebo
2.1 Ingredients and dosage
• Did not state
2.2 Administration
• Did not state
2.3 Duration of treatment
• Did not state
2.4 Follow up
• Did not state
- Conventional medicines will be provided in both groups
Outcomes 1. The starting time of a relapse
2. SCORAD
3. The Dermatitis Family Impact Questionnaire
4. Total usage of topical fluticasone propionate cream
Did not state assessment points
Starting date 1 March 2013
Contact information Dr Chi Liu, Department of Dermatology, Second Affiliated Hospital of Guangzhou University of Chinese
Medicine. No.111 Dade Road, Guangzhou, Guangdong, China 510120
Email: ich008@163.com
Notes 1. The trial has been registered on http://www.chictr.org/cn. Registration number: ChiCTR-TRC-12003174
2. The trial has been funded by the State Administration of Traditional Chinese Medicine, China
3. We contacted the corresponding investigator on 17 June 2013 for details of interventions. We received no
reply
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ISRCTN26218532
Trial name or title A clinical study of Hwangryunhaedoktang in adult atopic dermatitis: a randomised, double-blind, placebo-
controlled, multicenter trial
Methods This is a randomised, double-blind, placebo-controlled, parallel, multicentre clinical trial
Participants 1. Setting: The trial recruited participants from South Korea
2. Age: more than 19 years of age
3. Sex (men/women): -
4. Target number of participants for randomisation: 100
Interventions I. Treatment group
1. Hwangryunhaedoktang extracted granules
1.1 Ingredients and dosage
• Powdered extract of Huangqin (Scutellaria baicalensis) 334.00 mg as Baicalin equal to 1.67 g of raw
herb
• Zhizi (Gardenia jasminoides) 1.67 g
• Huanglian (Coptis chinensis) 116.20 mg as Berberine 0.83 g
• Huangbai (Phellodendron amurense) 19.92 mg as Berberine 0.83 g
1.2 Administration
• 5 grams of the herbs, 3 times daily
1.3 Duration of treatment
• 8 weeks
1.4 Follow up
• 2 weeks after the treatment period
II. Control group
2. Placebo
2.1 Ingredients and dosage
• Mixing 3.489 g of lactose, 1.495 g of starch, and 0.016 g of pigments
2.2 Administration
• 5 grams 3 times daily
2.3 Duration of treatment
• 8 weeks
2.4 Follow up
• 2 weeks after the treatment period
Outcomes 1. SCORAD
Measured at treatment period (treatment initiation; 2, 4, and 8 weeks after the first medication)
2. Complete blood cell count (CBC), erythrocyte sedimentation rate (ESR), blood chemistry, urine analysis
3. Chest-PA film
Measured at baseline and 8 weeks after first medication
4. Vital signs
Measured at baseline and treatment period (treatment initiation; 2, 4, and 8 weeks after the first medication)
5. Total IgE, eosinophil count
Measured at treatment initiation and 4 and 8 weeks after the first medication
6. EuroQol 5-Dimension (EQ-5D)
7. Health Utilities Index Mark 3 (HUI-3)
8. DLQI
Measured at treatment initiation and 8 weeks after first medication
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ISRCTN26218532 (Continued)
Starting date 21 June 2010
Contact information Dr Namkwen Kim Wonkwang University Oriental Medical Center 1126-1 Sanbon-dong, Gunpo, Korea,
South 435-040
Email: drkim@wonkwang.ac.kr
Notes 1. The trial has been registered on http://www.controlled-trials.com/ISRCTN26218532. The protocol of the
trial was published in 2011
2. The trial was completed, and a report of the trial has not been identified via electronic searches
3. We contacted the corresponding investigator on 30 January 2012 and received no reply
4. The trial was funded by Korea Health Industry Development Institute (KHIDI) (South Korea) - The
Traditional Korean Medicine Research and Development Project
5. We contacted the corresponding investigator again on 17 September 2012 for the publication status of the
trial and received no reply
DLQI: Dermatology Life Quality Index
SCORAD: Severity Scoring of Atopic Dermatitis
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D A T A A N D A N A L Y S E S
Comparison 1. CHM versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total effectiveness rate (number
of participants recovered and
significantly improved)
2 85 Risk Ratio (IV, Random, 95% CI) 2.09 [1.32, 3.32]
2 Itching VAS 2 94 Std. Mean Difference (IV, Random, 95% CI) -1.53 [-2.64, -0.41]
3 Overall severity score 4 239 Std. Mean Difference (IV, Random, 95% CI) -0.88 [-1.67, -0.09]
4 Overall severity score (short-term
improvement)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 QoL 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 QoL (short-term improvement) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Adverse events 2 129 Risk Ratio (IV, Random, 95% CI) 0.71 [0.06, 8.67]
8 Adverse events in one study 1 Risk Ratio (Fixed, 95% CI) Totals not selected
Comparison 2. CHM versus drugs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total effectiveness rate (number
of participants recovered and
significantly improved) with
subgroup analysis
21 1868 Risk Ratio (IV, Random, 95% CI) 1.43 [1.27, 1.61]
1.1 Individualised treatment 7 567 Risk Ratio (IV, Random, 95% CI) 1.50 [1.30, 1.74]
1.2 Non-individualised
treatment
14 1301 Risk Ratio (IV, Random, 95% CI) 1.37 [1.17, 1.60]
2 Total effectiveness rate
(long-term improvement)
2 276 Risk Ratio (IV, Random, 95% CI) 1.52 [1.11, 2.08]
3 Itching VAS 7 465 Std. Mean Difference (IV, Random, 95% CI) -0.83 [-1.43, -0.22]
4 Overall severity score 15 1062 Std. Mean Difference (IV, Random, 95% CI) -0.97 [-1.23, -0.71]
5 Overall severity score (long-term
improvement)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Adverse events 15 1396 Risk Ratio (IV, Random, 95% CI) 0.44 [0.32, 0.61]
7 Total effectiveness rate with
posthoc subgroup analysis
21 1868 Risk Ratio (IV, Random, 95% CI) 1.43 [1.27, 1.61]
7.1 CHM versus topical
steroid
6 671 Risk Ratio (IV, Random, 95% CI) 1.18 [0.99, 1.40]
7.2 CHM versus
antihistamines
12 906 Risk Ratio (IV, Random, 95% CI) 1.58 [1.37, 1.82]
7.3 CHM versus other agents 3 291 Risk Ratio (IV, Random, 95% CI) 1.58 [1.31, 1.90]
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Comparison 3. Combination of oral and topical CHM versus same oral CHM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total effectiveness rate (number
of participants recovered and
significantly improved)
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Total effectiveness rate
(long-term improvement)
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Itching VAS 1 Mean Difference (Fixed, 95% CI) Totals not selected
4 Skin lesion score 1 Mean Difference (Fixed, 95% CI) Totals not selected
5 Overall severity score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 QoL 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Adverse events 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 CHM versus placebo, Outcome 1 Total effectiveness rate (number of
participants recovered and significantly improved).
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 1 Total effectiveness rate (number of participants recovered and significantly improved)
Study or subgroup CHM Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chao 2003 25/30 12/30 97.8 % 2.08 [ 1.31, 3.32 ]
Sun 2009 1/14 0/11 2.2 % 2.40 [ 0.11, 53.77 ]
Total (95% CI) 44 41 100.0 % 2.09 [ 1.32, 3.32 ]
Total events: 26 (CHM), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.13 (P = 0.0017)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours CHM
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Analysis 1.2. Comparison 1 CHM versus placebo, Outcome 2 Itching VAS.
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 2 Itching VAS
Study or subgroup CHM Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cheng 2010 (1) 46 -1.3 (0.7407) 23 -0.2 (1.4815) 57.7 % -1.04 [ -1.57, -0.51 ]
Sun 2009 14 4.13 (1.64) 11 7.81 (1.6) 42.3 % -2.19 [ -3.22, -1.16 ]
Total (95% CI) 60 34 100.0 % -1.53 [ -2.64, -0.41 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 3.78, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours CHM Favours placebo
(1) Cheng 2010 study reported improvement of VAS score
Analysis 1.3. Comparison 1 CHM versus placebo, Outcome 3 Overall severity score.
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 3 Overall severity score
Study or subgroup CHM Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chao 2003 30 1.8 (2.57) 30 5.7 (3.97) 25.8 % -1.15 [ -1.70, -0.60 ]
Cheng 2010 46 -79.1 (56.29) 23 -13.5 (50.37) 25.9 % -1.19 [ -1.73, -0.65 ]
Hon 2007 42 49.7 (20) 43 46.9 (22) 27.1 % 0.13 [ -0.29, 0.56 ]
Sun 2009 14 15.86 (6.86) 11 26.51 (7.24) 21.3 % -1.47 [ -2.37, -0.56 ]
Total (95% CI) 132 107 100.0 % -0.88 [ -1.67, -0.09 ]
Heterogeneity: Tau2 = 0.56; Chi2 = 23.12, df = 3 (P = 0.00004); I2 =87%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours CHM Favours placebo
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Analysis 1.4. Comparison 1 CHM versus placebo, Outcome 4 Overall severity score (short-term
improvement).
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 4 Overall severity score (short-term improvement)
Study or subgroup CHM Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hon 2007 42 50 (20.8) 43 46.6 (22) 3.40 [ -5.70, 12.50 ]
-100 -50 0 50 100
Favours CHM Favours placebo
Analysis 1.5. Comparison 1 CHM versus placebo, Outcome 5 QoL.
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 5 QoL
Study or subgroup CHM Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hon 2007 42 7.6 (5.2) 43 10.1 (5.5) -2.50 [ -4.77, -0.23 ]
-4 -2 0 2 4
Favours CHM Favours placebo
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Analysis 1.6. Comparison 1 CHM versus placebo, Outcome 6 QoL (short-term improvement).
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 6 QoL (short-term improvement)
Study or subgroup CHM Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hon 2007 42 7.4 (5.4) 43 8.7 (5) -1.30 [ -3.51, 0.91 ]
-50 -25 0 25 50
Favours CHM Favours placebo
Analysis 1.7. Comparison 1 CHM versus placebo, Outcome 7 Adverse events.
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 7 Adverse events
Study or subgroup CHM Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chao 2003 0/30 2/30 50.0 % 0.20 [ 0.01, 4.00 ]
Cheng 2010 (1) 2/46 0/23 50.0 % 2.55 [ 0.13, 51.09 ]
Total (95% CI) 76 53 100.0 % 0.71 [ 0.06, 8.67 ]
Total events: 2 (CHM), 2 (Placebo)
Heterogeneity: Tau2 = 0.91; Chi2 = 1.39, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours CHM Favours placebo
(1) one patient had transient elevation of aspartateCheng 2010 report one case with AST transiently increased,but did not state which group the patient was assessed.
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Analysis 1.8. Comparison 1 CHM versus placebo, Outcome 8 Adverse events in one study.
Review: Chinese herbal medicine for atopic eczema
Comparison: 1 CHM versus placebo
Outcome: 8 Adverse events in one study
Study or subgroup log [Risk Ratio] Risk Ratio Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Hon 2007 0.571 (0.1824) 1.77 [ 1.24, 2.53 ]
0.01 0.1 1 10 100
Favours CHM Favours placebo
Analysis 2.1. Comparison 2 CHM versus drugs, Outcome 1 Total effectiveness rate (number of participants
recovered and significantly improved) with subgroup analysis.
Review: Chinese herbal medicine for atopic eczema
Comparison: 2 CHM versus drugs
Outcome: 1 Total effectiveness rate (number of participants recovered and significantly improved) with subgroup analysis
Study or subgroup CHM Drugs Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Individualised treatment
Cao 2009 31/32 16/24 5.7 % 1.45 [ 1.09, 1.94 ]
Liu 2005 82/94 64/94 7.5 % 1.28 [ 1.09, 1.50 ]
Luo 2010 33/34 18/28 5.8 % 1.51 [ 1.14, 2.00 ]
Ma 2010 24/42 13/40 3.3 % 1.76 [ 1.05, 2.95 ]
Xue 2011 25/33 12/30 3.6 % 1.89 [ 1.17, 3.06 ]
Yang 2009 18/30 7/30 2.1 % 2.57 [ 1.26, 5.24 ]
Zhang 2011 17/30 7/26 2.1 % 2.10 [ 1.04, 4.27 ]
Subtotal (95% CI) 295 272 30.2 % 1.50 [ 1.30, 1.74 ]
Total events: 230 (CHM), 137 (Drugs)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.69, df = 6 (P = 0.26); I2 =22%
0.1 0.2 0.5 1 2 5 10
Favours drugs Favours CHM
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(. . . Continued)
Study or subgroup CHM Drugs Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 5.40 (P < 0.00001)
2 Non-individualised treatment
Chao 2003 25/30 26/30 6.8 % 0.96 [ 0.78, 1.19 ]
Chen 2011 39/50 43/50 7.2 % 0.91 [ 0.75, 1.09 ]
Gong 2010 19/28 13/28 3.7 % 1.46 [ 0.91, 2.34 ]
Huang 2010 79/98 68/97 7.5 % 1.15 [ 0.98, 1.35 ]
Lang 2007 25/33 16/31 4.5 % 1.47 [ 0.99, 2.17 ]
Tian 2005 39/58 27/42 5.7 % 1.05 [ 0.78, 1.40 ]
Wang 2008 23/35 13/30 3.7 % 1.52 [ 0.94, 2.44 ]
Xiao 2011 14/30 7/30 1.9 % 2.00 [ 0.94, 4.25 ]
Yang 2007 27/32 14/32 4.2 % 1.93 [ 1.27, 2.94 ]
Yu 1999 72/120 29/100 5.1 % 2.07 [ 1.47, 2.91 ]
Zhang 2005 14/15 7/15 3.0 % 2.00 [ 1.15, 3.49 ]
Zhang 2009 31/36 16/25 5.3 % 1.35 [ 0.98, 1.86 ]
Zhou 2011 69/89 40/87 6.2 % 1.69 [ 1.31, 2.17 ]
Zou 2011 28/30 13/20 5.1 % 1.44 [ 1.03, 2.01 ]
Subtotal (95% CI) 684 617 69.8 % 1.37 [ 1.17, 1.60 ]
Total events: 504 (CHM), 332 (Drugs)
Heterogeneity: Tau2 = 0.05; Chi2 = 44.46, df = 13 (P = 0.00003); I2 =71%
Test for overall effect: Z = 4.00 (P = 0.000063)
Total (95% CI) 979 889 100.0 % 1.43 [ 1.27, 1.61 ]
Total events: 734 (CHM), 469 (Drugs)
Heterogeneity: Tau2 = 0.04; Chi2 = 56.87, df = 20 (P = 0.00002); I2 =65%
Test for overall effect: Z = 5.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
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Analysis 2.2. Comparison 2 CHM versus drugs, Outcome 2 Total effectiveness rate (long-term
improvement).
Review: Chinese herbal medicine for atopic eczema
Comparison: 2 CHM versus drugs
Outcome: 2 Total effectiveness rate (long-term improvement)
Study or subgroup CHM Drugs Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Gong 2010 22/28 17/28 49.7 % 1.29 [ 0.91, 1.85 ]
Yu 1999 62/120 29/100 50.3 % 1.78 [ 1.25, 2.53 ]
Total (95% CI) 148 128 100.0 % 1.52 [ 1.11, 2.08 ]
Total events: 84 (CHM), 46 (Drugs)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours drugs Favours CHM
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Analysis 2.3. Comparison 2 CHM versus drugs, Outcome 3 Itching VAS.
Review: Chinese herbal medicine for atopic eczema
Comparison: 2 CHM versus drugs
Outcome: 3 Itching VAS
Study or subgroup CHM Drugs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chen 2011 50 0.4 (0.5) 50 0.3 (0.5) 15.2 % 0.20 [ -0.19, 0.59 ]
Jin 2007 32 4.42 (2.21) 30 5.74 (1.78) 14.5 % -0.65 [ -1.16, -0.14 ]
Lang 2007 33 1.45 (0.56) 31 1.85 (0.69) 14.6 % -0.63 [ -1.13, -0.13 ]
Ma 2010 42 2 (1.1) 40 2.7 (1.5) 14.9 % -0.53 [ -0.97, -0.09 ]
Xue 2011 33 1.53 (0.64) 30 3.55 (0.71) 13.1 % -2.96 [ -3.69, -2.23 ]
Yang 2007 32 4.47 (2.14) 32 5.75 (1.71) 14.6 % -0.65 [ -1.16, -0.15 ]
Zhang 2005 15 1.8 (0.9) 15 2.9 (1.6) 13.0 % -0.82 [ -1.57, -0.07 ]
Total (95% CI) 237 228 100.0 % -0.83 [ -1.43, -0.22 ]
Heterogeneity: Tau2 = 0.59; Chi2 = 56.79, df = 6 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 2.4. Comparison 2 CHM versus drugs, Outcome 4 Overall severity score.
Review: Chinese herbal medicine for atopic eczema
Comparison: 2 CHM versus drugs
Outcome: 4 Overall severity score
Study or subgroup CHM Drugs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cao 2009 (1) 32 -91.37 (15.19) 24 -70.82 (19.1) 6.4 % -1.19 [ -1.77, -0.62 ]
Chao 2003 (2) 30 1.8 (2.57) 30 1.6 (2.33) 6.9 % 0.08 [ -0.43, 0.59 ]
Chen 2011 (3) 50 0.3 (0.4) 50 0.3 (0.5) 7.6 % 0.0 [ -0.39, 0.39 ]
Gong 2010 28 17.46 (9.13) 28 26.85 (8.72) 6.5 % -1.04 [ -1.60, -0.48 ]
Huang 2010 98 0.2 (0.29) 97 0.56 (0.4) 8.2 % -1.03 [ -1.33, -0.73 ]
Jin 2007 32 41.11 (12.4) 30 54.33 (12.15) 6.7 % -1.06 [ -1.60, -0.53 ]
Lang 2007 33 0.97 (0.66) 31 1.86 (0.67) 6.6 % -1.32 [ -1.87, -0.78 ]
Luo 2010 (4) 34 -90.96 (15.31) 28 -69.99 (18.43) 6.6 % -1.23 [ -1.78, -0.69 ]
Ma 2010 42 7.4 (3.3) 40 9.6 (4.1) 7.3 % -0.59 [ -1.03, -0.14 ]
Xiao 2008 26 15.88 (8.2) 26 23.34 (9.25) 6.4 % -0.84 [ -1.41, -0.27 ]
Xiao 2011 30 32.62 (9.41) 30 47.58 (11.14) 6.4 % -1.43 [ -2.00, -0.86 ]
Xue 2011 33 17.22 (5.17) 30 27.52 (9.55) 6.6 % -1.34 [ -1.89, -0.79 ]
Yang 2007 32 39.56 (12.29) 32 54.34 (12.22) 6.7 % -1.19 [ -1.73, -0.66 ]
Zhang 2005 (5) 15 -76.63 (13.37) 15 -60.52 (13.62) 5.1 % -1.16 [ -1.94, -0.38 ]
Zhang 2011 30 30.24 (9.52) 26 45.24 (9.26) 6.2 % -1.57 [ -2.18, -0.97 ]
Total (95% CI) 545 517 100.0 % -0.97 [ -1.23, -0.71 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 54.73, df = 14 (P<0.00001); I2 =74%
Test for overall effect: Z = 7.30 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours CHM Favours drugs
(1) Cao 2009’s study expressed the data measured at the endpoint as percentage of reduction of total SASSAD score.
(2) Chao 2003 study used self-developed score
(3) Chen 2011 study used self-developed score
(4) Lou 2010’s study expressed the data measured at the endpoint as percentage of reduction of total SASSAD score.
(5) Zhang 2005’s study expressed the data measured at the endpoint as percentage of reduction of total SASSAD score.
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Analysis 2.5. Comparison 2 CHM versus drugs, Outcome 5 Overall severity score (long-term improvement).
Review: Chinese herbal medicine for atopic eczema
Comparison: 2 CHM versus drugs
Outcome: 5 Overall severity score (long-term improvement)
Study or subgroup CHM Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Xiao 2008 26 18.92 (9.18) 26 27.42 (8.86) -8.50 [ -13.40, -3.60 ]
-100 -50 0 50 100
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Analysis 2.6. Comparison 2 CHM versus drugs, Outcome 6 Adverse events.
Review: Chinese herbal medicine for atopic eczema
Comparison: 2 CHM versus drugs
Outcome: 6 Adverse events
Study or subgroup CHM Drugs Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chao 2003 0/30 2/30 1.2 % 0.20 [ 0.01, 4.00 ]
Chen 2011 0/50 6/50 1.3 % 0.08 [ 0.00, 1.33 ]
Gong 2010 0/28 11/28 1.4 % 0.04 [ 0.00, 0.70 ]
Huang 2010 0/98 5/97 1.3 % 0.09 [ 0.01, 1.61 ]
Lang 2007 3/33 5/31 5.8 % 0.56 [ 0.15, 2.16 ]
Liu 2005 19/94 36/94 46.2 % 0.53 [ 0.33, 0.85 ]
Ma 2010 5/42 6/40 8.6 % 0.79 [ 0.26, 2.40 ]
Tian 2005 0/58 5/42 1.3 % 0.07 [ 0.00, 1.17 ]
Wang 2008 1/35 4/30 2.3 % 0.21 [ 0.03, 1.81 ]
Xiao 2008 2/26 3/26 3.6 % 0.67 [ 0.12, 3.67 ]
0.005 0.1 1 10 200
Favours CHM Favours drugs
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(. . . Continued)
Study or subgroup CHM Drugs Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Xiao 2011 0/30 3/30 1.2 % 0.14 [ 0.01, 2.65 ]
Yang 2007 1/32 1/32 1.4 % 1.00 [ 0.07, 15.30 ]
Yang 2009 6/30 19/30 17.9 % 0.32 [ 0.15, 0.68 ]
Yu 1999 3/120 3/100 4.2 % 0.83 [ 0.17, 4.04 ]
Zhang 2005 1/15 3/15 2.3 % 0.33 [ 0.04, 2.85 ]
Total (95% CI) 721 675 100.0 % 0.44 [ 0.32, 0.61 ]
Total events: 41 (CHM), 112 (Drugs)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.98, df = 14 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 4.97 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours CHM Favours drugs
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Analysis 2.7. Comparison 2 CHM versus drugs, Outcome 7 Total effectiveness rate with posthoc subgroup
analysis.
Review: Chinese herbal medicine for atopic eczema
Comparison: 2 CHM versus drugs
Outcome: 7 Total effectiveness rate with posthoc subgroup analysis
Study or subgroup Favours drugs Drugs Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 CHM versus topical steroid
Chao 2003 25/30 26/30 6.8 % 0.96 [ 0.78, 1.19 ]
Chen 2011 39/50 43/50 7.2 % 0.91 [ 0.75, 1.09 ]
Huang 2010 79/98 68/97 7.5 % 1.15 [ 0.98, 1.35 ]
Lang 2007 25/33 16/31 4.5 % 1.47 [ 0.99, 2.17 ]
Liu 2005 82/94 64/94 7.5 % 1.28 [ 1.09, 1.50 ]
Yang 2007 27/32 14/32 4.2 % 1.93 [ 1.27, 2.94 ]
Subtotal (95% CI) 337 334 37.5 % 1.18 [ 0.99, 1.40 ]
Total events: 277 (Favours drugs), 231 (Drugs)
Heterogeneity: Tau2 = 0.03; Chi2 = 18.02, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 1.84 (P = 0.065)
2 CHM versus antihistamines
Cao 2009 31/32 16/24 5.7 % 1.45 [ 1.09, 1.94 ]
Gong 2010 19/28 13/28 3.7 % 1.46 [ 0.91, 2.34 ]
Luo 2010 33/34 18/28 5.8 % 1.51 [ 1.14, 2.00 ]
Ma 2010 24/42 13/40 3.3 % 1.76 [ 1.05, 2.95 ]
Tian 2005 39/58 27/42 5.7 % 1.05 [ 0.78, 1.40 ]
Xiao 2011 14/30 7/30 1.9 % 2.00 [ 0.94, 4.25 ]
Xue 2011 25/33 12/30 3.6 % 1.89 [ 1.17, 3.06 ]
Yang 2009 18/30 7/30 2.1 % 2.57 [ 1.26, 5.24 ]
Yu 1999 72/120 29/100 5.1 % 2.07 [ 1.47, 2.91 ]
Zhang 2005 14/15 7/15 3.0 % 2.00 [ 1.15, 3.49 ]
Zhang 2009 31/36 16/25 5.3 % 1.35 [ 0.98, 1.86 ]
Zhang 2011 17/30 7/26 2.1 % 2.10 [ 1.04, 4.27 ]
Subtotal (95% CI) 488 418 47.5 % 1.58 [ 1.37, 1.82 ]
Total events: 337 (Favours drugs), 172 (Drugs)
Heterogeneity: Tau2 = 0.02; Chi2 = 15.74, df = 11 (P = 0.15); I2 =30%
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(Continued . . . )
119Chinese herbal medicine for atopic eczema (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Study or subgroup Favours drugs Drugs Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 6.22 (P < 0.00001)
3 CHM versus other agents
Wang 2008 23/35 13/30 3.7 % 1.52 [ 0.94, 2.44 ]
Zhou 2011 69/89 40/87 6.2 % 1.69 [ 1.31, 2.17 ]
Zou 2011 28/30 13/20 5.1 % 1.44 [ 1.03, 2.01 ]
Subtotal (95% CI) 154 137 15.0 % 1.58 [ 1.31, 1.90 ]
Total events: 120 (Favours drugs), 66 (Drugs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 4.81 (P < 0.00001)
Total (95% CI) 979 889 100.0 % 1.43 [ 1.27, 1.61 ]
Total events: 734 (Favours drugs), 469 (Drugs)
Heterogeneity: Tau2 = 0.04; Chi2 = 56.87, df = 20 (P = 0.00002); I2 =65%
Test for overall effect: Z = 5.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.80, df = 2 (P = 0.02), I2 =74%
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Analysis 3.1. Comparison 3 Combination of oral and topical CHM versus same oral CHM, Outcome 1 Total
effectiveness rate (number of participants recovered and significantly improved).
Review: Chinese herbal medicine for atopic eczema
Comparison: 3 Combination of oral and topical CHM versus same oral CHM
Outcome: 1 Total effectiveness rate (number of participants recovered and significantly improved)
Study or subgroup CHM (combination) CHM (oral) Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Rao 2010 9/10 8/10 1.13 [ 0.78, 1.63 ]
0.005 0.1 1 10 200
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Analysis 3.2. Comparison 3 Combination of oral and topical CHM versus same oral CHM, Outcome 2 Total
effectiveness rate (long-term improvement).
Review: Chinese herbal medicine for atopic eczema
Comparison: 3 Combination of oral and topical CHM versus same oral CHM
Outcome: 2 Total effectiveness rate (long-term improvement)
Study or subgroup CHM (combination) CHM (oral) Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Rao 2010 9/10 9/10 1.00 [ 0.75, 1.34 ]
0.01 0.1 1 10 100
Favours CHM (oral) Favours CHM (combination)
Analysis 3.3. Comparison 3 Combination of oral and topical CHM versus same oral CHM, Outcome 3
Itching VAS.
Review: Chinese herbal medicine for atopic eczema
Comparison: 3 Combination of oral and topical CHM versus same oral CHM
Outcome: 3 Itching VAS
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2010 -1.05 (0.3559) -1.05 [ -1.75, -0.35 ]
-4 -2 0 2 4
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Analysis 3.4. Comparison 3 Combination of oral and topical CHM versus same oral CHM, Outcome 4 Skin
lesion score.
Review: Chinese herbal medicine for atopic eczema
Comparison: 3 Combination of oral and topical CHM versus same oral CHM
Outcome: 4 Skin lesion score
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2010 -1.59 (0.678) -1.59 [ -2.92, -0.26 ]
-4 -2 0 2 4
Favours CHM (combination) Favours CHM (oral)
Analysis 3.5. Comparison 3 Combination of oral and topical CHM versus same oral CHM, Outcome 5
Overall severity score.
Review: Chinese herbal medicine for atopic eczema
Comparison: 3 Combination of oral and topical CHM versus same oral CHM
Outcome: 5 Overall severity score
Study or subgroup CHM (combination) CHM (oral)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rao 2010 10 17.59 (3.46) 10 21.02 (4.62) -3.43 [ -7.01, 0.15 ]
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Analysis 3.6. Comparison 3 Combination of oral and topical CHM versus same oral CHM, Outcome 6 QoL.
Review: Chinese herbal medicine for atopic eczema
Comparison: 3 Combination of oral and topical CHM versus same oral CHM
Outcome: 6 QoL
Study or subgroup CHM (combination) CHM (oral)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rao 2010 10 6.7 (3.65) 10 5.8 (4.9) 0.90 [ -2.89, 4.69 ]
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Analysis 3.7. Comparison 3 Combination of oral and topical CHM versus same oral CHM, Outcome 7
Adverse events.
Review: Chinese herbal medicine for atopic eczema
Comparison: 3 Combination of oral and topical CHM versus same oral CHM
Outcome: 7 Adverse events
Study or subgroup CHM (combination) CHM (oral) Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Rao 2010 1/10 1/10 1.00 [ 0.07, 13.87 ]
0.01 0.1 1 10 100
Favours CHM (oral) Favours CHM (combination)
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A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library) search strategy
#1 MeSH descriptor Eczema explode all trees
#2 MeSH descriptor Dermatitis, Atopic explode all trees
#3 MeSH descriptor Dermatitis explode all trees
#4 eczema or dermatitis or “besnier* prurigo”
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Medicine, Chinese Traditional explode all trees
#7 MeSH descriptor Drugs, Chinese Herbal explode all trees
#8 MeSH descriptor Plants, Medicinal explode all trees
#9 MeSH descriptor Medicine, Traditional explode all trees
#10 MeSH descriptor Plant Extracts explode all trees
#11 MeSH descriptor Phytotherapy explode all trees
#12 (phytopharmaceutic*)
#13 (herb*)
#14 (traditional or herbal) and (therap* or medicine*)
#15 “aconite root” or camelia or cayenne or “chinese cucumber” or “chrysanthemum flower*” or “cocklebur fruit” or “cow dipper” or
“croton seed” or ginger or ginkgo or ginseng or “goji berry” or “horny goat weed” or rhubarb or “thunder vine” or “strychnine tree” or
“sweet wormwood” or “willow bark”
#16 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17 (#5 AND #16)
Appendix 2. MEDLINE (OVID) search strategy
1. exp Eczema/ or eczema.mp.
2. atopic dermatitis.mp. or exp Dermatitis, Atopic/
3. exp Dermatitis/ or dermatitis.mp.
4. Besnier$ prurigo.mp.
5. or/1-4
6. exp drugs, chinese herbal/ or exp medicine, chinese traditional/
7. exp Plants, Medicinal/
8. exp Medicine, Traditional/
9. exp Plant Extracts/
10. exp Phytotherapy/
11. phytopharmaceutic$.mp.
12. herb$.mp.
13. traditional medicine$.mp.
14. traditional therap$.mp.
15. herbal medicine$.mp.
16. herbal therap$.mp.
17. aconite root.mp.
18. camelia.mp.
19. cayenne.mp.
20. chinese cucumber.mp.
21. chrysanthemum flower$.mp.
22. cocklebur fruit.mp.
23. cow dipper.mp.
24. croton seed.mp. or exp Croton/
25. ginger.mp. or exp Ginger/
26. ginkgo.mp. or exp Ginkgo biloba/
27. ginseng.mp. or exp Panax/
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28. goji berry.mp.
29. horny goat weed.mp.
30. rhubarb.mp. or exp Rheum/
31. thunder vine.mp.
32. strychnine tree.mp.
33. sweet wormwood.mp.
34. willow bark.mp.
35. randomized controlled trial.pt.
36. controlled clinical trial.pt.
37. randomized.ab.
38. placebo.ab.
39. clinical trials as topic.sh.
40. randomly.ab.
41. trial.ti.
42. 35 or 36 or 37 or 38 or 39 or 40 or 41
43. (animals not (human and animals)).sh.
44. 42 not 43
45. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31 or 32 or 33 or 34
46. 5 and 44 and 45
Appendix 3. EMBASE (OVID) search strategy
1. eczema.ti,ab. or *eczema/
2. exp *DERMATITIS/ or dermatitis.ti,ab.
3. atopic dermatitis.ti,ab. or *atopic dermatitis/
4. Besnier$ prurigo.ti,ab.
5. or/1-4
6. exp oriental medicine/ or exp medicinal plant/ or exp Chinese medicine/ or exp traditional medicine/ or exp Chinese drug/
7. exp herb/ or exp Chinese herb/
8. exp herbal medicine/
9. (herb or herbs).mp. or herbal.ti,ab.
10. exp plant medicinal product/ or exp plant extract/
11. exp phytotherapy/
12. phytopharmaceutic$.ti,ab.
13. traditional medicine$.ti,ab.
14. traditional therap$.ti,ab.
15. herbal medicine$.ti,ab.
16. herbal therap$.ti,ab.
17. aconite root.ti,ab.
18. camelia.ti,ab.
19. cayenne.ti,ab.
20. chinese cucumber.ti,ab.
21. chrysanthemum flower$.ti,ab.
22. cocklebur fruit.ti,ab.
23. cow dipper.ti,ab.
24. croton seed.ti,ab.
25. ginger.ti,ab.
26. ginkgo.ti,ab.
27. ginseng.ti,ab.
28. goji berry.ti,ab.
29. horny goat weed.ti,ab.
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30. rhubarb.ti,ab.
31. thunder vine.ti,ab.
32. strychnine tree.ti,ab.
33. sweet wormwood.ti,ab.
34. willow bark.ti,ab.
35. random$.mp.
36. factorial$.mp.
37. (crossover$ or cross-over$).mp.
38. placebo$.mp. or PLACEBO/
39. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
40. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
41. (assign$ or allocat$).mp.
42. volunteer$.mp. or VOLUNTEER/
43. Crossover Procedure/
44. Double Blind Procedure/
45. Randomized Controlled Trial/
46. Single Blind Procedure/
47. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46
48. or/6-34
49. 5 and 47 and 48
Appendix 4. AMED (OVID) search strategy
1. exp Eczema/ or eczema.mp.
2. dermatitis.mp.
3. Dermatitis/ or exp Dermatitis atopic/
4. besnier$ prurigo.mp.
5. or/1-4
6. exp Drugs chinese herbal/ or exp Traditional medicine chinese/
7. exp Plant extracts/ or exp Herbs/ or exp Herbal drugs/ or exp Plants medicinal/
8. exp Traditional medicine/
9. exp Herbalism/
10. exp Phytotherapy/
11. phytopharmaceutic$.mp.
12. traditional medicine$.mp.
13. traditional therap$.mp.
14. herbal medicine$.mp.
15. herbal therap$.mp.
16. aconite root.mp.
17. camelia.mp.
18. cayenne.mp.
19. chinese cucumber.mp.
20. chrysanthemum flower$.mp.
21. cocklebur fruit.mp.
22. cow dipper.mp.
23. croton seed.mp.
24. ginger.mp.
25. ginkgo.mp. or exp Ginkgo biloba/
26. ginseng.mp. or exp Panax ginseng/
27. goji berry.mp.
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28. horny goat weed.mp.
29. rhubarb.mp.
30. thunder vine.mp.
31. strychnine tree.mp.
32. sweet wormwood.mp.
33. willow bark.mp.
34. (plant$1 or herb$).mp. [mp=abstract, heading words, title]
35. randomized controlled trial$/
36. random allocation/
37. double blind method/
38. single blind method.mp.
39. exp Clinical trials/
40. (clin$ adj25 trial$).mp. [mp=abstract, heading words, title]
41. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$ or dummy)).mp. [mp=abstract, heading words, title]
42. (placebo$ or random$).mp. [mp=abstract, heading words, title]
43. research design/ or clinical trials/ or comparative study/ or double blind method/ or random allocation/
44. prospective studies.mp.
45. cross over studies.mp.
46. Follow up studies/
47. control$.mp.
48. (multicent$ or multi-cent$).mp. [mp=abstract, heading words, title]
49. ((stud or design$) adj25 (factorial or prospective or intervention or crossver or cross-over or quasi-experiment$)).mp. [mp=abstract,
heading words, title]
50. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49
51. or/6-34
52. 5 and 50 and 51
Appendix 5. LILACS search strategy
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Words] and chinese or
herb$ or traditional [Words] and eczema or dermatitis [Words]
Appendix 6. CINAHL (EBSCO) search strategy
S1 (MM “Eczema”) OR (MM “Dermatitis, Atopic”)
S2 (MH “Medicine, Chinese Traditional”) OR (MH “Drugs, Chinese Herbal”)
S3 TI (Chinese and (herb* or medicin* or traditional or plant*))
S4 AB (Chinese and (herb* or medicin* or traditional or plant*))
S5 S2 or S3 or S4
S6 TI eczema or dermatitis
S7 S1 or S6
S8 S5 and S7
S9 (MH “Clinical Trials+”)
S10 PT clinical trial
S11 TX (clinic* n1 trial*)
S12 (MH “Random Assignment”)
S13 TX random* allocat*
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S14 TX placebo*
S15 (MH “Placebos”)
S16 (MH “Quantitative Studies”)
S17 TX allocat* random*
S18 “randomi#ed control* trial*”
S19 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S20 S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19
S21 S8 and S20
Appendix 7. Chinese database CQVIP search strategy
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”,
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”,
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”,
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”,
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”,
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”,
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”
“(Keyword˙C= )*((Keyword˙C=( )+Title˙C=( )))”
Appendix 8. Chinese database CNKI search strategy
( between (1979,2011)) (( ( = ( ) = ( ))) =
( )) ( )
( between (2011, 2012)) (( ( = ( ) = ( ))) =
( )) ( )
( between (2012-09-14, 2013-06-12)) (( ( = ( ) = ( )))
= ( )) ( )
( between (1979,2011)) (( ( = ( ) = ( ))) =
( )) ( )
( between (2011, 2012)) (( ( = ( ) = ( ))) =
( )) ( )
( between (2012-09-14, 2013-06-12)) (( ( = ( ) = ( )))
= ( )) ( )
( between (1979,2011)) (( ( = ( ) = ( ))) =
( )) ( )
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( between (2011, 2012)) (( ( = ( ) = ( ))) =
( )) ( )
( between (2012-09-14, 2013-06-12)) (( ( = ( ) = ( ))) =
( )) ( )
Appendix 9. Chinese database Wanfang data search strategy
title: keyword: date:1982-2013
title: keyword: date:1982-2013
title: keyword: date:1982-2013
title: keyword: date:1982-2013
title: date:1982-2013
title: keyword: date:1982-2013
title: keyword: date:1982-2013
Appendix 10. List of contacted Chinese medicine dermatologists or experts
Professor Rudi Ai, Professor Dacan Chen, Dr Chi Jing Liu, Professor Chuanjian Lu, Dr Xiumei Mo.
H I S T O R Y
Protocol first published: Issue 8, 2010
Review first published: Issue 9, 2013
Date Event Description
24 June 2013 New citation required and conclusions have changed We did not include the four studies that were in the previ-
ous version of this review. We included 28 newly identified
studies and rewrote the full review
C O N T R I B U T I O N S O F A U T H O R S
SG was the contact person with the editorial base.
SG co-ordinated contributions from the co-authors and wrote the final draft of the review.
SG and AWY screened papers against eligibility criteria.
SG and AWY obtained data on ongoing and unpublished studies.
HCW, WZ, CCX, and CGL appraised the quality of papers.
SG and AWY extracted data for the review and sought additional information about papers.
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SG and AWY entered data into RevMan.
SG, AWY, HCW, WZ, CCX, and CGL analysed and interpreted data.
SG, AWY, HCW, WZ, CCX, and CGL worked on the methods sections.
SG, AWY, HCW, and WZ drafted the clinical sections of the background and responded to the clinical comments of the referees.
SG, AWY, HCW, and WZ responded to the methodology and statistics comments of the referees.
CP was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes are relevant to
consumers.
SG is the guarantor of the update.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the
Department of Health, UK.
D E C L A R A T I O N S O F I N T E R E S T
Kam-Lun Ellis Hon, who peer-reviewed this review as a clinical referee, was also the Principal Investigator in the following included
study:
Hon KL, Leung TF, Ng PC, LamMCA, KamWYC,Wong KY, et al. Efficacy and tolerability of a Chinese herbal medicine concoction
for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. British Journal of Dermatology 2007;157(2):
357-63. [MEDLINE: 17501956]
S O U R C E S O F S U P P O R T
Internal sources
• Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Australia.
External sources
• Centre of Evidence Based Dermatology, Nottingham University, UK.
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added “in children and adults” under the heading of ’Objectives’ to define the participants in this review.
In the Methods section under ’Type of interventions’, we found in the protocol that the words “or formula” were missing and CHM
had been listed as one of the control interventions, which was inappropriate. We changed the wording to: “Oral ingestion and topical
applications of a single Chinese medicinal herb or formula, manufactured or clinician self-designed Chinese medicinal formulae, (a
clinician self-designed formula is usually composed of different types of Chinese herbs prescribed by a Chinese medicine practitioner
who determines the selection of herbs based on a patient’s condition) compared to the following control interventions: placebo, no
intervention, and active controls, including acupuncture or conventional medicines.”
To make the meaning of the statement more precise, in the Methods section under ’Measures of treatment effect’ and then the
subheading ’Studies with multiple treatment groups’, we rephrased the wording to: “For studies with more than two interventions, we
selected the comparison group that met the inclusion criteria.”
To reflect the actual process of the review, in the Methods section under ’Data collection and analysis’ and then the subheading ’Data
synthesis’, we deleted the following sentence: “In the presence of substantial heterogeneity that cannot be explained, we would not
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undertake statistical pooling.” We replaced it with, “We performed the meta-analyses irrespective of the level of heterogeneity for the
purpose of explanation of potential inconsistency across the included studies. When substantial heterogeneity was found (I² statistic
greater than 50%), then we explored the sources of such heterogeneity by rechecking the data, and by subgroup analysis based on
clinical and methodological diversity factors.”
We performed a posthoc subgroup analysis to further investigate heterogeneity across the included studies where Western medications
were used as comparators.
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